



National Comprehensive  
Cancer Network®

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)

# Colorectal Cancer Screening

Version 1.2024 — February 27, 2024

**NCCN.org**

NCCN Guidelines for Patients® available at [www.nccn.org/patients](http://www.nccn.org/patients)

**Continue**



# NCCN Guidelines Version 1.2024 Colorectal Cancer Screening

[NCCN Guidelines Index](#)  
[Table of Contents](#)  
[Discussion](#)

**\*Reid M. Ness, MD, MPH/Chair** ☒  
Vanderbilt-Ingram Cancer Center

**\*Xavier Llor, MD, PhD/Vice Chair** ☒ ☐  
Yale Cancer Center/  
Smilow Cancer Hospital

**Mohammad Ali Abbass, MD, MPH** ¶  
Robert H. Lurie Comprehensive Cancer  
Center of Northwestern University

**Shrinivas Bishu, MD** ☒  
University of Michigan Rogel Cancer Center

**Christopher T. Chen, MD** †  
Stanford Cancer Institute

**Gregory Cooper, MD** ☒  
Case Comprehensive Cancer Center/  
University Hospitals Seidman Cancer  
Center and Cleveland Clinic Taussig  
Cancer Institute

**Dayna S. Early, MD** ☒  
Siteman Cancer Center at Barnes-  
Jewish Hospital and Washington  
University School of Medicine

**Mark Friedman, MD** ☒  
Moffitt Cancer Center

**David Fudman, MD** ☒  
UT Southwestern Simmons  
Comprehensive Cancer Center

**Francis M. Giardiello, MD, MBA** ☒  
The Sidney Kimmel Comprehensive  
Cancer Center at Johns Hopkins

**Kathryn Glaser, PhD, MA** «  
Roswell Park Comprehensive Cancer Center

**Surya Gurudu, MD** ☒  
Mayo Clinic Comprehensive Cancer Center

**Michael Hall, MD, MS** †  
Fox Chase Cancer Center

**Lyen C. Huang, MD, MPH** ¶  
Huntsman Cancer Institute  
at the University of Utah

**Rachel Issaka, MD, MAS** ☒  
Fred Hutchinson Cancer Center

**Bryson Katona, MD, PhD** ☒  
Abramson Cancer Center  
at the University of Pennsylvania

**Trilokesh Kidambi, MD** ☒  
City of Hope National Medical Center

**Audrey J. Lazenby, MD** ≠  
Fred & Pamela Buffett Cancer Center

**Jennifer Maratt, MD, MS** ☒  
Indiana University Melvin and Bren Simon  
Comprehensive Cancer Center

**Arnold J. Markowitz, MD** ☒  
Memorial Sloan Kettering Cancer Center

**Joseph Marsano, MD** ☒  
UC Davis Comprehensive Cancer Center

**Folasade P. May, MD, PhD, MPhil** † ☒  
UCLA Jonsson Comprehensive Cancer Center

**Robert J. Mayer, MD** † ☐  
Dana-Farber/Brigham and Women's  
Cancer Center | Mass General Cancer Center

**Kinga Orlortegui, MD** ¶  
The UChicago Medicine  
Comprehensive Cancer Center

**Swati Patel, MD, MS** ☒  
University of Colorado Cancer Center

**Shajan Peter, MD** ☒  
O'Neal Comprehensive  
Cancer Center at UAB

**Laura D. Porter, MD** ¥  
Independent Patient Advocate

**Mehnaz Shafi, MD** ☒  
The University of Texas  
MD Anderson Cancer Center

**Peter P. Stanich, MD** ☒  
The Ohio State University Comprehensive  
Cancer Center - James Cancer Hospital  
and Solove Research Institute

**Jonathan Terdiman, MD** ☒  
UCSF Helen Diller Family  
Comprehensive Cancer Center

**Peter Vu, MD** †  
UC San Diego Moores Cancer Center

**Jennifer M. Weiss, MD, MS** ☒  
University of Wisconsin  
Carbone Cancer Center

**Elizabeth Wood, MD** ¶  
St. Jude Children's Research Hospital/The  
University of Tennessee Health Science Center

## **NCCN**

**Carly J. Cassara, MSc**  
**Susan Darlow, PhD**

☒ Gastroenterology	¶ Surgery/Surgical oncology
☐ Internal medicine	* Discussion Writing Committee Member
« Medical anthropology	¥ Patient advocacy
† Medical oncology	
≠ Pathology	

[NCCN Guidelines Panel Disclosures](#)

**Continue**



# NCCN Guidelines Version 1.2024

## Colorectal Cancer Screening

[NCCN Guidelines Index](#)  
[Table of Contents](#)  
[Discussion](#)

[NCCN Colorectal Cancer Screening Panel Members](#)  
[Summary of the Guidelines Updates](#)

[Primary and Secondary Prevention of Colorectal Cancer \(CSCR-PREV\)](#)  
[Risk Assessment for Colorectal Cancer \(CSCR-1\)](#)

Average Risk  
[Average Risk \(CSCR-3\)](#)

Increased Risk  
[Personal History of Polyp Found at Colonoscopy \(CSCR-4\)](#)  
[Management of Large Colorectal Polyps \(CSCR-6\)](#)  
[Diagnosis of Colorectal Cancer \(CSCR-7\)](#)  
[Increased Risk Based on Personal History of Inflammatory Bowel Disease \(CSCR-8\)](#)  
[Increased Risk Based on Personal History of Cystic Fibrosis \(CSCR-11\)](#)  
[Increased Risk Based on Positive Family History \(CSCR-12\)](#)  
[Increased Risk Based on Personal History of Childhood, Adolescent, and Young Adult Cancer \(CSCR-13\)](#)  
[Glossary of Terms Commonly Used in NCCN Guidelines for Colorectal Cancer Screening \(CSCR-GLOS\)](#)  
[Screening Modality and Schedule \(CSCR-A\)](#)

For High-Risk Colorectal Cancer Syndromes,  
see [NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal](#)

For Principles of Cancer Risk Assessment and Counseling,  
see [NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic](#)

[Abbreviations \(ABBR-1\)](#)

**Clinical Trials:** NCCN believes that the best management for any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

Find an NCCN Member Institution:  
<https://www.nccn.org/home/member-institutions>.

**NCCN Categories of Evidence and Consensus:** All recommendations are category 2A unless otherwise indicated.

See [NCCN Categories of Evidence and Consensus](#).

The NCCN Guidelines® are a statement of evidence and consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult the NCCN Guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The National Comprehensive Cancer Network® (NCCN®) makes no representations or warranties of any kind regarding their content, use or application and disclaims any responsibility for their application or use in any way. The NCCN Guidelines are copyrighted by National Comprehensive Cancer Network®. All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN. ©2024.

**Terminologies in all NCCN Guidelines are being actively modified to advance the goals of equity, inclusion, and representation.**

**Updates in Version 1.2024 of the NCCN Guidelines for Colorectal Cancer Screening from Version 1.2023 include:**

### [CSCR-PREV 1 of 2](#)

- Lifestyle/dietary factors associated with increased CRC risk, bullet 6 added: While supplemental calcium, vitamin D, and folate use have all been linked to a decreased risk of conventional adenomas, some evidence suggests that these agents may increase the risk of serrated polyps.
- Aspirin
  - ▶ ~~Bullet 1 modified: There is substantial evidence about the protective effect of aspirin for CRC development when taken for at least 5–10 years. Evidence is unclear whether aspirin use reduces the risk of CRC incidence or mortality when employed for primary prevention.~~
  - ▶ Bullet 2 added: Aspirin use has been associated with improved CRC-specific survival and overall survival when employed for secondary prevention.
  - ▶ ~~Bullet 3 modified: There is also substantial evidence supporting use of aspirin for chemoprevention for CRC in LS (a hereditary CRC syndrome) evidence supporting the use of aspirin for CRC chemoprevention in patients with Lynch syndrome (LS) (a hereditary CRC syndrome). See NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal.~~
  - ▶ Sub-bullet removed: The U.S. Preventive Services Task Force (USPSTF) recommends considering initiating low-dose aspirin (81 mg) for individuals ages 40–59 with a  $\geq 10\%$  10-year cardiovascular risk for the purpose of lowering cardiovascular risk, but evidence indicates that the net benefit of aspirin use in this group is small. The USPSTF reports that evidence is unclear whether aspirin use reduces the risk of CRC incidence or mortality.
  - ▶ Sub-bullet removed: In patients with an estimated cardiovascular risk of  $\geq 10\%$ , shared decision-making should occur that takes into account the risk of bleeding, life expectancy, and long-term adherence.
  - ▶ Sub-bullet removed: Regarding secondary prevention, aspirin use has been associated with improved CRC-specific survival and overall survival.

### [CSCR-PREV 2 of 2](#)

- References added
  - ▶ He X, Wu K, Ogino S, et al. Association between risk factors for colorectal cancer and risk of serrated polyps and conventional adenomas. *Gastroenterology* 2018;155:355-373.e18.
  - ▶ Crockett SD, Barry EL, Mott LA, et al. Calcium and vitamin D supplementation and increased risk of serrated polyps: results from a randomised clinical trial. *Gut* 2019;68:475-486.
- Reference removed: U.S. Preventive Services Task Force. Final Recommendation Statement: Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Preventive Medication. 2022. Available at: <https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/aspirin-to-prevent-cardiovascular-disease-preventivemedication>.

### [CSCR-1](#)

- Average risk
  - ▶ Bullet 1 modified: Age  $\geq 45$ –75 years
  - ▶ Bullet 4 modified: No personal history of high-risk CRC genetic syndromes (*list of syndromes on CSCR-2*)
  - ▶ Bullet 8 modified: Negative family history for CRC in first-, second-, or third-degree relatives

### [CSCR-1A](#)

- Footnotes modified
  - ▶ ~~b: CRC screening is recommended in adults aged 45–75 years who might have a life expectancy of  $\geq 10$  years. The decision to screen between ages 76–85 years should be individualized and include a discussion of the risks and benefits based on comorbidity status and estimated life expectancy.~~

**Note: All recommendations are category 2A unless otherwise indicated.**

**Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.**

[Continued](#)

**UPDATES**

### Updates in Version 1.2024 of the NCCN Guidelines for Colorectal Cancer Screening from Version 1.2023 include:

Eligible individuals who have not been previously screened are most likely to benefit in this age group. *CRC screening is recommended in adults aged 45–75 years who might have a life expectancy of  $\geq 10$  years. The decision to screen between ages 76–85 years should be individualized and include a discussion of the risks and benefits based on comorbidity status and estimated life expectancy. Eligible individuals who have not been previously screened are most likely to benefit in this age group.* (Also for CSCR-3A)

#### [CSCR-2](#)

- Evaluation of alarm symptoms in patients <45 years: Half of the patients who present with early-onset CRC (<50 years of age) are <45 years of age and many have signs or symptoms of CRC such as iron deficiency anemia, rectal bleeding, or a change in bowel habits. Individuals with these symptoms warrant prompt evaluation with a colonoscopy regardless of age. *All patients, regardless of age, who present with symptoms associated with CRC, including but not limited to rectal bleeding, iron deficiency anemia, diarrhea, abdominal pain, or weight loss should undergo a prompt tailored evaluation for both gastrointestinal (GI) and non-GI causes. In most unexplained cases, an anorectal exam and colonoscopy should be considered. Patients with rectal bleeding initially attributed to hemorrhoids that does not resolve with treatment should be considered for colonoscopy.* The majority of early-onset CRCs appears to be sporadic. Nonetheless, the possibility of an inherited cancer syndrome should be investigated given the higher incidence of inherited CRC syndromes in younger compared to older patients.
- High-risk genetic syndromes with predisposition to CRC *Hereditary CRC syndromes*
  - ▶ Bullet added: Other pathogenic variants
- Footnote h added: Fritz CD, et al. J Natl Cancer Inst 2023;115:909

#### [CSCR-3A](#)

- Footnotes modified:
  - ▶ m: For patients who cannot undergo colonoscopy or have had incomplete colonoscopy, capsule colonoscopy can be considered (Rex DK, et al. Gastroenterology 2015;148:948-957).
  - ▶ q: If the colonoscopy is negative after a FIT or mt-sDNA and no symptoms are present, there is no need for further tests prior to the next recommended screening interval. *If the colonoscopy is negative after a FIT or mt-sDNA, no symptoms are present, and the colonoscopy was a high quality examination, patients can return to average-risk screening intervals beginning at 10 years after the colonoscopy. This interval could be modified based on the presence of symptoms or signs or additional CRC risk factors such as family history.*
- Footnote v added: If polypectomy is unable to be performed, the patient should be referred to a provider or endoscopist who can perform endoscopy with polypectomy.

#### [CSCR-5](#)

- Footnote x modified: Consider *germline genetic* testing for 10–19 cumulative adenomas if other factors suggest the possibility of a polyposis/CRC syndrome such as age of onset or family or personal history of CRC. Ten or fewer polyps in the setting of a strong family history or younger age (<40 years) may sometimes be associated with an inherited polyposis syndrome.

#### [CSCR-7](#)

- Footnotes modified
  - ▶ kk: The panel recommends universal screening of all CRC tumors to maximize sensitivity for MMR deficiency and/or LS, and to inform prognosis and care processes in patients with and/or without LS.
  - ▶ mm: Consider multigene panel test for all individuals with a diagnosis of CRC <50 years, regardless of MMR status. Germline multigene testing for

**Note: All recommendations are category 2A unless otherwise indicated.**

**Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.**

[Continued](#)

**UPDATES**

### Updates in Version 1.2024 of the NCCN Guidelines for Colorectal Cancer Screening from Version 1.2023 include:

evaluation of LS and other hereditary cancer syndromes is recommended for individuals with CRC <50 years of age. See NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal.

#### [CSCR-8](#)

- Surveillance Modality and Schedule
  - ▶ Colonoscopy, sub-sub-bullet 1 modified: ~~Additional extensive sampling~~ *Targeted biopsies of any mucosal abnormality strictures and masses*
  - ▶ Bullet 2 modified: Chromoendoscopy (dye spray or high-definition virtual) *with*
  - ▶ Chromoendoscopy, sub-bullet modified: ~~Targeted biopsies, including extensive sampling of strictures or masses. of any mucosal abnormality~~
- Footnotes modified:
  - ▶ nn: Risk factors for dysplasia include Crohn's colitis historically involving more than 1/3 of the colon, ulcerative colitis; extensive colitis; colonic stricture; PSC; family history of CRC, especially age <50 y; personal history of dysplasia; and severe long-standing inflammation. Confirmation by an expert GI pathologist is desirable. For patients with proctitis, who have little or no increased risk for CRC compared with the population at large, *consider 5-year follow-up or average-risk follow-up...*
  - ▶ oo: Endoscopy should be performed during quiescent disease. Targeted biopsies improve detection of dysplasia, and should be considered for surveillance colonoscopies in patients with ulcerative colitis ~~where expertise is available...~~
  - ▶ pp: ~~If using SD-WLE, performing colonoscopy in conjunction with chromoendoscopy is recommended.~~ If HD-WLE or chromoendoscopy is not available, refer to institutions with expertise in these modalities.

#### [CSCR-9](#)

- Invisible dysplasia, column 2 modified: ~~Confirmed by gastrointestinal (GI) pathologist~~ *Reviewed by GI pathologist*
- Invisible dysplasia, dysplasia confirmed, follow-up
  - ▶ Bullet removed: Referral to IBD expert
  - ▶ Bullet 1 modified: Assess with chromoendoscopy if not already performed *or refer to endoscopist with expertise in chromoendoscopy*
- Non-resectable polypoid lesion or mass, follow-up
  - ▶ Bullet 1 added: Refer to endoscopist with expertise in advanced resection techniques
  - ▶ Bullet 2 modified: Consider referral *to a surgeon with expertise in IBD or therapeutic endoscopy expert with expertise in large/complex polyp resection and/or a surgeon with expertise in IBD for resection.*
- Resectable lesion, complete endoscopic resection, higher risk follow up
  - ▶ Column 1, sub-bullet 2 modified:  $\geq 1$  cm low-grade dysplasia
  - ▶ Column 2, bullet 2 modified: In dysplastic lesions with low-grade dysplasia  $\geq 2$  cm, high-grade dysplasia, or piecemeal resection, colonoscopy follow-up within 3–6 mo
- Resectable lesion, incomplete endoscopic resection
  - ▶ Bullet removed: Referral to center with expertise in IBD management
  - ▶ Bullet removed: Consider assessment with chromoendoscopy if not already performed
  - ▶ Bullet added: Refer to endoscopist with expertise in advanced resection techniques

#### [CSCR-9A](#)

- Reference added: Gordon H, et al. J Crohns Colitis 2023;17:827-854.

**Note: All recommendations are category 2A unless otherwise indicated.**

**Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.**

[Continued](#)

**UPDATES**

### Updates in Version 1.2024 of the NCCN Guidelines for Colorectal Cancer Screening from Version 1.2023 include:

#### [CSCR-10](#)

- Colon stricture, non-traversable stricture, follow-up modified: Consider referral to an IBD or therapeutic endoscopy expert with expertise in large/complex polyp resection and/or a surgeon with expertise in IBD for resection *a center with expertise in management of IBD-associated colonic strictures*.
- Footnote yy modified: UK, Australian, and European GI societies position statements recommend risk-stratified surveillance with increased surveillance interval to 3–5 years in lower risk patients. Shergill AK, et al. *Gastrointest Endosc Clin N Am* 2014;24:469-481. Magro F, et al. *J Crohns Colitis* 2017;11:649-670. Gordon H, et al. *J Crohns Colitis* 2023;17:827-854.; Lamb CA, et al. *Gut* 2019;68:s1-s106.

#### [CSCR-12](#)

- ≥1 first-degree relative with CRC at any age, screening modified: Colonoscopy beginning at age 40 y or 10 y before earliest diagnosis of CRC whichever is first

#### [CSCR-13](#)

- Risk Status, Individual meets the following criteria for therapy-associated polyposis
  - ▶ Sub-bullet 2 modified: History of systemic therapy and/or radiotherapy for a childhood or young adult cancer, specifically ~~abdominopelvic~~ radiotherapy and/or ~~alkylating~~ chemotherapy
- History of chemotherapy, surveillance modality and schedule modified: Colonoscopy starting at 35 or 10 years after age of chemotherapy, (whichever occurs first last) and continue every 5 years
- No history of chemotherapy, surveillance modality and schedule modified: Average-risk screening guidelines starting at age 45 ~~and continue every 10y~~
- Footnotes
  - ▶ III modified: ~~Multi-gene testing should include all polyposis and colorectal cancer genes (Stanich P, et al. *Clin Gastroenterol Hepatol* 2019;17:2008-2015)~~ *Germline multigene panel testing should include at minimum the following CRC risk-associated genes: APC, MUTYH, MLH1, MSH2, MSH6, PMS2, EPCAM, BMPR1A, SMAD4, PTEN, STK11, and TP53.* Pathogenic variants associated with adenomatous polyposis include, but are not limited to, monoallelic pathogenic variants in APC, GREM1, POLE, POLD1, and AXIN2, and biallelic pathogenic variants in MUTYH, NTHL1, and MSH3.
  - ▶ Footnote ppp added: Initiate colonoscopy no later than age 45.

#### [CSCR-A 1 of 6](#)

- Bullet 2 modified: CRC screening should be performed as part of a population-based program that includes a systematic method for: 1) identifying those who are eligible for and wish to undergo screening; 2) risk stratification and administration of the screening tests at agreed upon intervals; 3) shared decision-making with patients regarding the choice of screening method; 4) standardized reporting of the results; and 5) follow-up of those with a positive test. *Assuring timely colonoscopy completion for individuals with a positive stool-based test or an imaging abnormality on CTC is critical for these screening approaches to be successful. Thus, a robust mechanism to ensure prompt and nearly complete adherence with colonoscopy completion should be established.* The program should also include a systematic method for the arranging of repeat screening and surveillance.

#### [CSCR-A 3 of 6](#)

- Final sub-bullet added: The use of artificial intelligence (AI) in colonoscopy is rapidly evolving. Future studies should help determine the specific tools and uses of AI for CRC screening.

#### [CSCR-A 5 of 6](#)

- FIT/mt stool DNA-based testing, bullet 8 modified: If the colonoscopy is negative after a *positive* FIT or mt-sDNA and no additional symptoms are present, there is no need for further tests prior to the next recommended screening interval.

**Note: All recommendations are category 2A unless otherwise indicated.**

**Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.**

### PRIMARY AND SECONDARY PREVENTION OF COLORECTAL CANCER

Certain lifestyle modifications are associated with a reduced risk of colorectal cancer (CRC) and can be an important adjunct to screening for CRC prevention. For risk assessment for individuals at average risk of disease, [CSCR-1](#).

Lifestyle/dietary factors associated with reduced CRC risk/recurrence:

- **Physical activity:** Regular physical activity (ie, occupational, recreational, transportation) has been associated with decreased CRC risk.<sup>1</sup>
- **Fruits and vegetables:** A diet high in fruits and vegetables has been associated with decreased CRC risk in some studies.<sup>2,3</sup>
- **Dietary supplements:** In general, nutrients should be obtained from natural food sources rather than solely from dietary supplements.<sup>1</sup>
- **Smoking cessation:** Smoking cessation counseling is strongly recommended. See [NCCN Guidelines for Smoking Cessation](#).

Lifestyle/dietary factors associated with increased CRC risk:

- **Smoking:** Long-term cigarette smoking is associated with increased CRC incidence and mortality.<sup>4,5</sup> Risk reduction is seen with early smoking cessation.<sup>5</sup>
- **Red meat and processed meat:** Long-term consumption is associated with increased CRC risk.<sup>1,6</sup>
- **Moderate to heavy alcohol consumption:** This level of consumption is associated with increased CRC risk.<sup>1,7,8</sup>
- **Obesity:** Obesity is associated with an increased risk for CRC.<sup>1,9,10,11</sup>
- **Vitamin D:** Low levels of vitamin D have been associated with increased CRC risk.<sup>12</sup>
- **While supplemental calcium, vitamin D, and folate use have all been linked to a decreased risk of conventional adenomas, some evidence suggests that these agents may increase the risk of serrated polyps.**<sup>13,14</sup>

Aspirin:

- Evidence is unclear whether aspirin use reduces the risk of CRC incidence or mortality when employed for primary prevention.<sup>15</sup>
- Aspirin use has been associated with improved CRC-specific survival and overall survival when employed for secondary prevention.<sup>16</sup>
- There is evidence supporting the use of aspirin for CRC chemoprevention in patients with Lynch syndrome (LS) (a hereditary CRC syndrome).<sup>17</sup> See [NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal](#).

Please also see relevant sections in:

- [NCCN Guidelines for Colon Cancer](#) - Principles of Survivorship
- [NCCN Guidelines for Survivorship](#)

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



### REFERENCES

- <sup>1</sup> World Cancer Research Fund/American Institute for Cancer Research. Diet, Nutrition, Physical Activity and Cancer: a Global Perspective. Continuous Update Project Expert Report. 2018. Available at: <https://www.wcrf.org/dietandcancer>. This comprehensive report analyzed 99 studies comprising greater than 29 million adults with over 247,000 cases of CRC.
- <sup>2</sup> Koushik A, Hunter DJ, Spiegelman D, et al. Fruits, vegetables, and colon cancer risk in a pooled analysis of 14 cohort studies. *J Natl Cancer Inst* 2007;99:1471-1483.
- <sup>3</sup> Michels KB, Edward G, Joshipura KJ, et al. Prospective study of fruit and vegetable consumption and incidence of colon and rectal cancers. *J Natl Cancer Inst* 2000;92:1740-1752.
- <sup>4</sup> Hannan LM, Jacobs EJ, Thun MJ. The association between cigarette smoking and risk of colorectal cancer in a large prospective cohort from the United States. *Cancer Epidemiol Biomarkers Prev* 2009;18:3362-3367.
- <sup>5</sup> Chao A, Thun MJ, Jacobs EJ, et al. Cigarette smoking and colorectal cancer mortality in the cancer prevention study II. *J Natl Cancer Inst* 2000;92:1888-1896.
- <sup>6</sup> Bouvard V, Loomis D, Guyton KZ, et al. Carcinogenicity of consumption of red and processed meat. *Lancet Oncol* 2015;16:1599-1600.
- <sup>7</sup> LoConte NK, Brewster AM, Kaur JS, et al. Alcohol and cancer: A statement of the American Society of Clinical Oncology. *J Clin Oncol* 2018;36:83-93.
- <sup>8</sup> Fedirko V, Tramacere I, Bagnardi V, et al. Alcohol drinking and colorectal cancer risk: an overall and dose-response meta-analysis of published studies. *Ann Oncol* 2011;22:1958-1972.
- <sup>9</sup> Ligibel JA, Alfano CM, Courneya KS, et al. American Society of Clinical Oncology position statement on obesity and cancer. *J Clin Oncol* 2014;32:3568-3574.
- <sup>10</sup> Karahalios A, English DR, Simpson JA. Weight change and risk of colorectal cancer: a systematic review and meta-analysis. *Am J Epidemiol* 2015;181:832-845.
- <sup>11</sup> Lauby-Secretan B, Scoccianti C, Loomis D, et al. Body fatness and cancer--viewpoint of the IARC Working Group. *N Engl J Med* 2016;375:794-798.
- <sup>12</sup> IARC. Vitamin D and Cancer. IARC Working Group Report Volume 5, International Agency for research on Cancer. Lyon: 2008. Available at: <https://publications.iarcfr/Book-And-Report-Series/Iarc-Working-Group-Reports/Vitamin-D-And-Cancer-2008>.
- <sup>13</sup> He X, Wu K, Ogino S, et al. Association between risk factors for colorectal cancer and risk of serrated polyps and conventional adenomas. *Gastroenterology* 2018; 155:355-373.e18.
- <sup>14</sup> Crockett SD, Barry EL, Mott LA, et al. Calcium and vitamin D supplementation and increased risk of serrated polyps: results from a randomised clinical trial. *Gut* 2019;68:475-486.
- <sup>15</sup> Guirguis-Blake JM, Evans CV, Perdue LA, et al. Aspirin use to prevent cardiovascular disease and colorectal cancer: Updated evidence report and systematic review for the US Preventive Services Task Force. *JAMA* 2022;327:1585-1597.
- <sup>16</sup> Bains SJ, Mahic M, Myklebust TA, et al. Aspirin as secondary prevention in patients with colorectal cancer: An unselected population-based study. *J Clin Oncol* 2016;34:2501-2508.
- <sup>17</sup> Burn J, Sheth H, Elliott F, et al. Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial. *Lancet* 2020;395:1855-1863.

**Note: All recommendations are category 2A unless otherwise indicated.**

**Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.**

### RISK ASSESSMENT FOR COLORECTAL CANCER

#### Average risk:

- Age 45–75 years<sup>a,b</sup>
- No personal history of adenoma or sessile serrated polyp/sessile serrated lesion (SSP/SSL)<sup>c</sup> or CRC
- No personal history of inflammatory bowel disease (IBD)
- No personal history of high-risk CRC genetic syndromes (list of syndromes on [CSCR-2](#))
- No personal history of cystic fibrosis
- No personal history of childhood cancer
- Negative family history for confirmed advanced adenoma (ie, high-grade dysplasia, ≥1 cm, villous or tubulovillous histology) or an advanced SSP/SSL<sup>c,d</sup> (≥1 cm, any dysplasia) in first-degree relatives<sup>e</sup>
- Negative family history for CRC<sup>f</sup>

→ [Average-Risk Screening and Evaluation \(CSCR-3\)](#)

#### Increased risk:

- Personal history
  - ▶ Adenoma or SSP/SSL<sup>c</sup> → [Follow-up of Clinical Findings: Polyp Found at Colonoscopy \(CSCR-4\)](#)
  - ▶ CRC → [Diagnosis of Colorectal Cancer \(CSCR-7\)](#)
  - ▶ IBD (ulcerative colitis, Crohn’s colitis) → [Increased Risk Screening Based on Personal History of Inflammatory Bowel Disease \(CSCR-8\)](#)
  - ▶ Cystic fibrosis → [Increased Risk Based on Personal History of Cystic Fibrosis \(CSCR-11\)](#)
- Positive family history → [Increased Risk Based on Positive Family History \(CSCR-12\)](#)
- Personal history of childhood, adolescent, and young adult cancer (including individuals who meet criteria for therapy-associated polyposis) → [Increased Risk Based on Personal History of Childhood, Adolescent, and Young Adult Cancer \(CSCR-13\)](#)

For individuals at average risk, the choice of a particular screening modality should include a conversation with the patient concerning their preference and availability. For individuals at increased risk, colonoscopy is the preferred method.

[Footnotes on CSCR-1A](#)

Note: All recommendations are category 2A unless otherwise indicated.  
 Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

### FOOTNOTES FOR [CSCR-1](#)

- <sup>a</sup> The panel has reviewed existing data for beginning screening of individuals at age <50 years who are of average risk. Based on their assessment, the panel agrees that the data are stronger to support beginning screening at 50 years, but acknowledges that lower-level evidence supports a benefit for screening earlier. When initiating screening for all eligible individuals, the panel recommends a discussion of potential harms/risks and benefits, and the consideration of all recommended CRC screening options. Ladabaum U, et al. *Gastroenterology* 2019;157:137-148. Knudsen AB, et al. *JAMA* 2021;325:1998-2011.
- <sup>b</sup> CRC screening is recommended in adults aged 45–75 years who might have a life expectancy of ≥10 years. The decision to screen between ages 76–85 years should be individualized and include a discussion of the risks and benefits based on comorbidity status and estimated life expectancy. Eligible individuals who have not been previously screened are most likely to benefit in this age group.
- <sup>c</sup> The terms sessile serrated polyp, sessile serrated lesion, SSP/SSL, and sessile serrated adenoma are synonymous; SSPs/SSLs are a type of serrated polyp that are not dysplastic but they can develop foci of dysplasia and are then termed SSP/SSL with dysplasia (SSP/SSL-d). These guidelines will use “SSP/SSL” for SSPs/SSLs without dysplasia and “SSP/SSL-d” for SSPs/SSLs with dysplasia. In general SSPs/SSLs are managed like tubular adenomas and SSP/SSL-d with any grade dysplasia are managed like high-risk adenomas but may need even more frequent surveillance. Classification systems for serrated lesions are evolving, and a recent proposal by WHO suggests using the term sessile serrated lesion (WHO Classification of Tumours Editorial Board. *Digestive System Tumours: IARC Lyon, France; 2019:162-169*). See [CSCR-GLOS 1 of 7](#).
- <sup>d</sup> Advanced SSPs/SSLs are generally considered to have a comparable cancer risk and are managed similarly to advanced adenomas, rather than high-risk adenomas, a definition that includes multiplicity.
- <sup>e</sup> Ochs-Balcom HM, et al. *Cancer Epidemiol* 2021;73:101973.
- <sup>f</sup> While current risk estimates for a family history of CRC in only second- and third-degree relatives may not be sufficiently elevated to recommend increased screening (Taylor DP, et al. *Gastroenterology* 2010;138:877-885; Taylor DP, et al. *Genet Med* 2011;13:385-391; Samadder NJ, et al. *Gastroenterology* 2014;147:814-821; Tian Y, et al. *BMJ* 2019;364:1803), there are some data showing that having a second- and, to a lesser degree, a third-degree relative with early-onset (<50 years old) CRC increases risk of both CRC and early-onset CRC (Ochs-Balcom HM. *Cancer Epidemiol* 2021;73:101973). Some combinations of affected first-, second-, and third-degree relatives may increase risk sufficiently to alter screening guidelines. If there are multiple distant relatives affected, consider evaluation for an inherited CRC syndrome in the family.

**Note: All recommendations are category 2A unless otherwise indicated.**

**Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.**

### RISK ASSESSMENT FOR COLORECTAL CANCER (CONT.)

#### Evaluation of alarm symptoms in patients <45 years:

- Half of the patients who present with early-onset CRC (<50 years of age) are <45 years of age.<sup>g,h</sup> All patients, regardless of age, who present with symptoms potentially associated with CRC, including but not limited to rectal bleeding, iron deficiency anemia, abdominal pain, or weight loss should undergo a prompt tailored evaluation for both gastrointestinal (GI) and non-GI causes. In most unexplained cases, an anorectal exam and colonoscopy should be considered. Patients with rectal bleeding initially attributed to hemorrhoids that does not resolve with treatment should also be considered for colonoscopy.

#### Hereditary CRC syndromes:

- LS (hereditary nonpolyposis CRC [HNPCC])
- Polyposis syndromes
  - ▶ Classical familial adenomatous polyposis
  - ▶ Attenuated familial adenomatous polyposis
  - ▶ *MUTYH*-associated polyposis
  - ▶ Peutz-Jeghers syndrome
  - ▶ Juvenile polyposis syndrome
  - ▶ Serrated polyposis syndrome (rarely inherited)
- Other pathogenic variants
- Cowden syndrome/*PTEN* hamartoma tumor syndrome
- Li-Fraumeni syndrome

[NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal](#)


[NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic](#)

<sup>g</sup> Stoffel EM, et al. Gastroenterology 2020;158:341-353.

<sup>h</sup> Fritz CD, et al. J Natl Cancer Inst 2023;115:909.

**Note: All recommendations are category 2A unless otherwise indicated.**

**Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.**



[Footnotes on CSCR-3A](#)

**Note:** All recommendations are category 2A unless otherwise indicated.  
**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.


### FOOTNOTES FOR [CSCR-3](#)

- <sup>a</sup> The panel has reviewed existing data for beginning screening of individuals at age <50 years who are of average risk. Based on their assessment, the panel agrees that the data are stronger to support beginning screening at 50 years, but acknowledges that lower-level evidence supports a benefit for screening earlier. When initiating screening for all eligible individuals, the panel recommends a discussion of potential harms/risks and benefits, and the consideration of all recommended CRC screening options. Ladabaum U, et al. *Gastroenterology* 2019;157:137-148. Knudsen AB, et al. *JAMA* 2021;325:1998-2011.
- <sup>b</sup> CRC screening is recommended in adults aged 45–75 years who might have a life expectancy of ≥10 years. The decision to screen between ages 76–85 years should be individualized and include a discussion of the risks and benefits based on comorbidity status and estimated life expectancy. Eligible individuals who have not been previously screened are most likely to benefit in this age group.
- <sup>d</sup> Advanced SSPs/SSLs are generally considered to have a comparable cancer risk and are managed similarly to advanced adenomas, rather than high-risk adenomas, a definition that includes multiplicity.
- <sup>i</sup> For details on classification, see footnote b on [CSCR-1A](#). For definitions of commonly used terms, see [CSRC-GLOS 1 of 7](#).
- <sup>j</sup> Screening should be individualized and include a discussion of the risks and benefits of each modality. See [Screening Modality and Schedule \(CSCR-A\)](#).
- <sup>k</sup> A blood test that detects circulating methylated SEPT9 DNA has been FDA-approved for CRC screening for those who refuse other screening modalities. Based on current data, the panel concludes that the interval for repeating testing is unknown/unclear. The panel will continue to review this strategy and monitor data as they emerge.
- <sup>l</sup> If colonoscopy is incomplete or the preparation is suboptimal, colonoscopy should be repeated as soon as possible and no later than 1 year after the index procedure (Johnson DA, et al. *Gastroenterology* 2014;147:903-924).
- <sup>m</sup> For patients who have had incomplete colonoscopy, capsule colonoscopy can be considered (Rex DK, et al. *Gastroenterology* 2015;148:948-957).
- <sup>n</sup> Based on recent evidence, FIT has been shown to have superior sensitivity to guaiac-based tests. However, guaiac-based testing has been shown to reduce mortality from CRC and high-sensitivity fecal occult blood test (FOBT) is a reasonable alternative if an immunochemical test cannot be used (Rabeneck L, et al. *Can J Gastroenterol* 2012;26:131-147; Scholefield JH, et al. *Gut* 2012;61:1036-1040).
- <sup>o</sup> The term “polyp” refers to both polyp and nonpolypoid (flat) lesions.
- <sup>p</sup> When a screening stool-based test is positive, a colonoscopy is recommended for further evaluation. Recommendations for an appropriate time frame for follow-up colonoscopy in this population lack a strong evidence base, but a large observational study and a meta-analysis reported significantly higher risks for CRC and advanced-stage disease when follow-up occurred 10 months or later with a trend towards increased cancer risk observed as early as 6 months after an abnormal result (Corley DA, et al. *JAMA* 2017;317:1631-1641; Forbes N, et al. *Clin Gastro Hepatol* 2020;19:1344-1354).
- <sup>q</sup> If the colonoscopy is negative after a FIT or mt-sDNA, no symptoms are present, and the colonoscopy was a high-quality examination, patients can return to average-risk screening intervals beginning at 10 years after the colonoscopy. This interval could be modified based on the presence of symptoms or signs or additional CRC risk factors such as family history.
- <sup>r</sup> If >20 serrated polyps are found at colonoscopy, consider a diagnosis of serrated polyposis syndrome ([NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal](#)). There are conflicting data to suggest that hyperplastic polyp(s) (<1 cm) proximal to the sigmoid colon pose an increased risk and whether they should be managed differently. Li D, et al. *Gastroenterology* 2020;159:502-511; Anderson JA, et al. *Gastrointest Endosc* 2020;92:387-393.
- <sup>s</sup> There are limited data to support whether individuals with hyperplastic polyps ≥1 cm in size represent an increased risk group. Several analyses suggest that many of the larger polyps classified as hyperplastic in the past were reclassified as SSPs/SSLs when reviewed by experts. For this reason, it is reasonable to follow patients with hyperplastic polyps ≥1 cm in size similarly to patients with SSPs/SSLs, particularly if they have not been reviewed by an expert gastrointestinal (GI) pathologist. Anderson JA, et al. *Gastrointest Endosc* 2020;92:387-393.
- <sup>t</sup> Data on optimal frequency, polyp size leading to colonoscopy referral, and protocol for evaluation of extracolonic lesions are evolving. The [American College of Radiology](#) has recommended that reporting of polyps ≤5 mm in size is not necessary. If polyp(s) of this size are reported, a decision to refer for colonoscopy with polypectomy versus surveillance CTC should be individualized. Zalis ME, et al. *Radiology* 2005;236:3-9; Tutein Nolthenius CJ, et al. *Am J Gastroenterol* 2015;110:1682-1690; Pickhardt PJ, et al. *Lancet Oncol* 2013;14:711-720.
- <sup>u</sup> There are alternative strategies that have been recommended with flexible sigmoidoscopy, including flexible sigmoidoscopy every 10 years with annual FIT or considering longer interval flexible sigmoidoscopy without FIT (Knudsen AB, et al. *AMA* 2016;315:2595-2609).
- <sup>v</sup> If polypectomy is unable to be performed, the patient should be referred to a provider who can perform endoscopy with polypectomy.

**Note: All recommendations are category 2A unless otherwise indicated.**

**Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.**

### PERSONAL HISTORY OF POLYP FOUND AT COLONOSCOPY<sup>s</sup>



**Note:** All recommendations are category 2A unless otherwise indicated.  
**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

[Footnotes on CSCR-5](#)

### FOOTNOTES FOR [CSCR-4](#)

<sup>i</sup> For details on classification, see footnote b on [CSCR-1A](#). For definitions of commonly used terms, see [CSRC-GLOS 1 of 7](#).

<sup>j</sup> Screening should be individualized and include a discussion of the risks and benefits of each modality. See [Screening Modality and Schedule \(CSCR-A\)](#).

<sup>s</sup> There are limited data to support whether individuals with hyperplastic polyps  $\geq 1$  cm in size represent an increased risk group. Several analyses suggest that many of the larger polyps classified as hyperplastic in the past were reclassified as SSPs/SSLs when reviewed by experts. For this reason, it is reasonable to follow patients with hyperplastic polyps  $\geq 1$  cm in size similarly to patients with SSPs/SSLs, particularly if they have not been reviewed by an expert GI pathologist. Anderson JA, et al. *Gastrointest Endosc* 2020;92:387-393.

<sup>w</sup> Surveillance colonoscopy is recommended in adults aged 45–75 years with a history of adenomas. Surveillance of individuals between ages 76–85 years should be individualized and include a discussion of risks and benefits of continued colonoscopy based on comorbidity status, estimated life expectancy, and findings on the last or the most recent colonoscopy.

<sup>x</sup> Consider germline genetic testing for 10–19 cumulative adenomas if other factors suggest the possibility of a polyposis/CRC syndrome such as age of onset or family or personal history of CRC. Ten or fewer polyps in the setting of a strong family history or younger age (<40 years) may sometimes be associated with an inherited polyposis syndrome.

<sup>y</sup> Surveillance intervals assume complete resection, adequate bowel preparation, and complete examination.

<sup>z</sup> Available data suggest that individuals with low-risk adenomas or SSPs/SSLs may not have an increased risk of metachronous advanced colorectal neoplasia compared to the general population (Cottet V, et al. *Gut* 2012;61:1180-1186; He X, et al. *Gastroenterol* 2019;158:852-861). Any recommendation for a shorter interval should include a discussion with the individual based on an assessment of individual risk, including age, family history, comorbidity, and the results of previous colonoscopies. Dube C, et al. *Am J Gastroenterol* 2017;112:1790-1801; Click B, et al. *JAMA* 2018;319:2021-2031; Lieberman D, et al. *Gastroenterology* 2020;158:862-874; Lee J, et al. *Gastroenterology* 2020;158:884-894.e5.

<sup>aa</sup> If genetic testing is negative or if evaluation it is not performed, repeat colonoscopy within 1–3 years. Frequency of surveillance may be modified based on factors such as age at which patient met cumulative adenoma threshold or total number of adenomas at most recent colonoscopy, with more frequent surveillance favored for younger age at meeting threshold or higher adenoma burden at last colonoscopy.

**Note: All recommendations are category 2A unless otherwise indicated.**


**Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.**



### MANAGEMENT OF LARGE COLORECTAL POLYPS<sup>cc</sup>

#### CLINICAL FINDINGS

#### FOLLOW-UP OF CLINICAL FINDINGS



**Note:** All recommendations are category 2A unless otherwise indicated.  
**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

[Footnotes on CSCR-6A](#)


### FOOTNOTES FOR [CSCR-6](#)

- <sup>bb</sup> Consider a referral to a center of expertise for large polyp management. For sessile polyps or laterally spreading lesions (LSLs)  $\geq 20$  mm size, recommend endoscopic tattoo placement for future lesion identification.
- <sup>cc</sup> Wang R, et al. Surg Endosc 2016;30:1530-1533; Hayashi N, et al. Gastrointest Endosc 2013;78:625-632; Li M, et al. World J Gastroenterol 2014;20:12649-12656; Ishiguro A, et al. Gastrointest Endosc 1999;50:329-333; Belderbos TD, et al. Endoscopy 2014;46:388-402; Tate DJ, et al. Gastrointest Endosc 2017;85:647-656. e6; The Paris endoscopic classification of superficial neoplastic lesions: esophagus, stomach, and colon: November 30 to December 1, 2002. Gastrointest Endosc 2003;58:S3-S43.
- <sup>dd</sup> Paris subtype 0–1p lesions.
- <sup>ee</sup> Paris subtype 0–1s lesions.
- <sup>ff</sup> Paris subtype 0–IIa, 0–IIb, 0–IIc, and 0–III lesions. The panel recommends consideration of referral to a center of expertise for management of these lesions.
- <sup>gg</sup> Histology may include adenoma, SSP/SSL, hyperplastic polyp, or TSA.
- <sup>hh</sup> High-risk features suggestive of submucosal invasion include NICE classification type 3, Kudo classification type V (VN and VI), and non-lifting sign.
- <sup>ii</sup> Unfavorable risk factors for laterally spreading tumor (LST) recurrence include LST size  $\geq 40$  mm, intraprocedural bleeding requiring endoscopic control, high-grade dysplasia, and macroscopic tissue ablation performed.
- <sup>jj</sup> Consider follow-up  $< 3$  years when polyp(s) is  $> 2$  cm or confidence of complete en bloc resection is low.

**Note: All recommendations are category 2A unless otherwise indicated.**

**Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.**

### DIAGNOSIS OF COLORECTAL CANCER



<sup>kk</sup> The panel recommends universal screening of all CRC tumors to maximize sensitivity for MMR deficiency and/or LS, and to inform prognosis and care processes in patients with or without LS. The panel recommends tumor testing with immunohistochemistry (IHC) and/or microsatellite instability (MSI) be used as the primary approach for pathology-lab-based universal screening and to guide treatment decisions.


<sup>ll</sup> See pros and cons of screening for LS using colonoscopy-based biopsies versus a surgical resection specimen. See [NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal](#).

<sup>mm</sup> Germline multigene testing for evaluation of LS and other hereditary cancer syndromes is recommended for individuals with CRC <50 years of age. See [NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal](#).

**Note: All recommendations are category 2A unless otherwise indicated.**

**Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.**

### INCREASED RISK BASED ON PERSONAL HISTORY OF INFLAMMATORY BOWEL DISEASE



<sup>nn</sup> Risk factors for dysplasia include Crohn's colitis historically involving more than 1/3 of the colon; ulcerative colitis; extensive colitis; colonic stricture; PSC; family history of CRC, especially age <50 y; personal history of dysplasia; and severe long-standing inflammation. Confirmation by an expert GI pathologist is desirable. For patients with proctitis, who have little or no increased risk for CRC compared with the population at large, consider 5-year follow-up or average-risk follow-up. Lutgens M, et al. Clin Gastroenterol Hepatol 2015;13:148-154. Beaugerie L, et al. Gastroenterology 2013;145:166-175. Murthy SK, et al. Gastroenterology 2021;161:1043-1051.e4.

<sup>oo</sup> Endoscopy should be performed during quiescent disease. Targeted biopsies improve detection of dysplasia, and should be considered for surveillance colonoscopies in patients with ulcerative colitis. High-definition colonoscopes are suggested. If using standard-definition colonoscopes, non-targeted biopsies in 4 quadrants every 10 cm should be performed and dye spray chromoendoscopy is recommended. Murthy Y, et al. Gastrointest Endosc 2013;77:351-359. Picco MF, et al. Inflamm Bowel Dis 2013;19:1913-1920. Laine L, et al. Gastrointest Endosc 2015;81:489-501.

<sup>pp</sup> If HD-WLE or chromoendoscopy is not available, refer to institutions with expertise in these modalities.


<sup>qq</sup> If PSC is present, annual surveillance colonoscopies should be started independent of the individual's time since symptom onset or colonoscopic findings and instead should be initiated at time of PSC diagnosis. Family history of CRC is another important risk factor for developing CRC in patients with IBD, and such individuals may benefit from earlier initiation of colonoscopic surveillance. Samadder NJ, et al. Clin Gastroenterol Hepatol 2019;17:1807-1813. Shergill AK, et al. Gastrointest Endosc Clin N Am 2014;24:469-481.

**Note:** All recommendations are category 2A unless otherwise indicated.  
**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

### INCREASED RISK BASED ON PERSONAL HISTORY OF INFLAMMATORY BOWEL DISEASE

#### EVALUATION OF SURVEILLANCE FINDINGS

#### FOLLOW-UP OF CLINICAL FINDINGS



**Note:** All recommendations are category 2A unless otherwise indicated.  
**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

[Footnotes and References on CSCR-9A](#)

### FOOTNOTES

<sup>rr</sup> Consider utilizing Paris classification to describe lesion. Lesions should be described as polypoid ( $\geq 2.5$  mm tall), nonpolypoid ( $< 2.5$  mm), or invisible. All polypoid and nonpolypoid lesions should be completely resected.

<sup>ss</sup> Patients with ulcerative colitis develop sporadic colorectal adenomas at the same rate as the general population. Lesions that appear endoscopically and histologically similar to a sporadic adenoma or SSP/SSL and without invasive carcinoma in the polyp can be treated safely by polypectomy. Some lesions may require EMR (endoscopic mucosal resection) or ESD (endoscopic submucosal dissection) techniques for complete resection. Confirmation of all polyp histology and dysplasia by an expert GI pathologist is desirable.

<sup>tt</sup> Following endoscopic resection of visible lesions, biopsy of surrounding mucosa is not routinely necessary, but should be considered if there is any doubt regarding the completeness of resection. Murthy SK, et al. *Gastroenterology* 2021;161:1043-1051.e4; Lahiff C, et al. *Gastrointest Endosc* 2018;88:782-783; Cleveland NK, et al. *Gastrointest Endosc* 2018;87:1304-1309; Ten Hove JR, et al. *Clin Gastroenterol Hepatol* 2017;15:222-228.e222.

<sup>uu</sup> In patients with endoscopically invisible dysplasia, the recommendation for referral to an endoscopist with IBD expertise for chromoendoscopy is consensus-based as data to support its use in this setting are limited.

<sup>vv</sup> A surgical consult may include a discussion about surveillance and colectomy based on multiple factors including other visible dysplastic lesions in the same segment, histology, and a discussion with the patient about risks and benefits of each approach. Laine L, et al. *Gastroenterology* 2015;148:639-651.

### REFERENCES

<sup>1</sup> Gordon H, et al. *J Crohns Colitis* 2023;17:827-854.


**Note: All recommendations are category 2A unless otherwise indicated.**

**Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.**

### INCREASED RISK BASED ON PERSONAL HISTORY OF INFLAMMATORY BOWEL DISEASE

#### EVALUATION OF SURVEILLANCE FINDINGS

#### FOLLOW-UP OF CLINICAL FINDINGS



<sup>ww</sup> Consider surgery in patients with symptomatic or non-traversable strictures as there is risk of underlying cancer, particularly in patients with long-standing IBD.

<sup>xx</sup> The literature describes a wide range of prevalence of dysplasia or cancer in colitis-associated colonic strictures, with rates up to 7% in Crohn's disease, and reported rates between 2% and 90% in ulcerative colitis. Among strictures with negative surveillance biopsies, reported rates of dysplasia or cancer in follow-up range from 2%–6% in Crohn's disease and 7.5%–27% in ulcerative colitis. Fumery M, et al. J Crohns Colitis 2021;15:1766-1773.


<sup>vv</sup> A surgical consult may include a discussion about surveillance and colectomy based on multiple factors including other visible dysplastic lesions in the same segment, histology, and a discussion with the patient about risks and benefits of each approach. Laine L, et al. Gastroenterology 2015;148:639-651.

<sup>yy</sup> UK, Australian, and European GI societies position statements recommend risk-stratified surveillance with increased surveillance interval to 3–5 years in lower risk patients. Shergill AK, et al. Gastrointest Endosc Clin N Am 2014;24:469-481. Gordon H, et al. J Crohns Colitis 2023;17:827-854; Lamb CA, et al. Gut 2019;68:s1-s106.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

### INCREASED RISK BASED ON PERSONAL HISTORY OF CYSTIC FIBROSIS<sup>aaa</sup>



<sup>zz</sup> Patient should undergo cystic fibrosis-specific intensive bowel preparation.

<sup>aaa</sup> Hadjiliadis D, et al. Gastroenterology 2018;154:736-745; Matson AG, et al. BMC Gastroenterol 2019;19:89.

<sup>bbb</sup> Alternative screening tests could be considered but data on their efficacy in cystic fibrosis are limited.

**Note: All recommendations are category 2A unless otherwise indicated.**

**Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.**




### INCREASED RISK BASED ON POSITIVE FAMILY HISTORY

(Not meeting criteria for consideration of a hereditary cancer syndrome or appropriate testing for a hereditary cancer syndrome non-diagnostic or not done)<sup>ccc</sup>

#### FAMILY HISTORY CRITERIA

#### SCREENING<sup>fff</sup>



<sup>ccc</sup> If a patient meets the criteria for an inherited colorectal syndrome, see Assessment for Hereditary CRC Syndrome (HRS-1) in the [NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal](#).

<sup>ddd</sup> While current risk estimates for a family history of CRC in only second- and third-degree relatives may not be sufficiently elevated to recommend increased screening (Taylor DP, et al. *Gastroenterology* 2010;138:877-885; Taylor DP, et al. *Genet Med* 2011;13:385-391; Samadder NJ, et al. *Gastroenterology* 2014;147:814-821; Tian Y, et al. *BMJ* 2019;364:1803), there are some data showing that having a second- and, to a lesser degree, a third-degree relative with early-onset (<50 years old) CRC increases risk of both CRC and early-onset CRC (Ochs-Balcom HM. *Cancer Epidemiol* 2021;73:101973). Some combinations of affected first-, second-, and third-degree relatives may increase risk sufficiently to alter screening guidelines. If there are multiple distant relatives affected, consider evaluation for an inherited colorectal syndrome in the family.

<sup>eee</sup> It is important for endoscopists to add specific recommendations to endoscopy reports for first-degree relatives (ie, siblings, parents, children) or alternatively generate a letter meant to be shared with first-degree relatives to increase adherence when this applies. Examples of patient letters can be found at [National Colorectal Cancer Roundtable. Cottet V, et al. \*Gastroenterology\* 2007;133:1086-1092; Ng S, et al. \*Gastroenterology\* 2016;150:608-616](#).

<sup>fff</sup> Colonoscopy intervals may be further modified based on personal and family history as well as on individual preferences. Factors that modify age to begin screening and colonoscopy intervals include: age of individual undergoing screening; specifics of the family history, including number and age of onset of all affected relatives, whether relatives had an inciting cause such as IBD; size of family; completeness of the family history; participation in screening; and colonoscopy findings in family members. See [Discussion](#).

<sup>ggg</sup> Multiple (2 or more) negative colonoscopies may support stepwise lengthening in the colonoscopy interval.

<sup>hhh</sup> Samadder NJ, et al. *Am J Gastroenterol* 2017;112:1439-1447.


<sup>iii</sup> Advanced SSPs/SSLs are generally considered to have a comparable cancer risk and are managed similarly to advanced adenomas. While there are limited data concerning the specific risk of CRC in first-degree relatives of individuals with advanced serrated polyps, it is reasonable to follow the same recommendations used for first-degree relatives of those with advanced adenomas. Cottet V, et al. *Gastroenterology* 2007;133:1086-1092; Ng S, et al. *Gastroenterology* 2016;150:608-616.

<sup>jjj</sup> Cottet V, et al. *Gastroenterology* 2007;133:1086-1092; Ng SC, et al. *Gastroenterology* 2016;150:608-616.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

### INCREASED RISK BASED ON PERSONAL HISTORY OF CHILDHOOD, ADOLESCENT, AND YOUNG ADULT CANCER



<sup>kkk</sup> The adolescent and young adult (AYA) oncology patient is defined as an individual aged 15–39 years of age at the time of initial cancer diagnosis. This definition is based on the National Cancer Institute (NCI) Progress Review Group recommendations for a national agenda to advance AYA oncology. See [NCCN Guidelines for Adolescent and Young Adult \(AYA\) Oncology](#).

<sup>lll</sup> Germline multigene panel testing should include at minimum the following CRC risk-associated genes: *APC*, *MUTYH*, *MLH1*, *MSH2*, *MSH6*, *PMS2*, *EPCAM*, *BMPR1A*, *SMAD4*, *PTEN*, *STK11*, and *TP53*. Pathogenic variants associated with adenomatous polyposis include, but are not limited to, monoallelic pathogenic variants in *APC*, *GREM1*, *POLE*, *POLD1*, and *AXIN2*, and biallelic pathogenic variants in *MUTYH*, *NTHL1*, and *MSH3*.

<sup>mmm</sup> Biller L, et al. *Cancer Prev Res* 2020;13:291-298.

<sup>nnn</sup> Children's Oncology Group Long-Term Follow-up Guidelines for survivors of childhood, adolescent, and young adult cancers – Version 5.0-October 2018.

<sup>ooo</sup> Therapy-associated polyposis is an acquired phenotype that presents years after exposure to chemotherapy and/or radiotherapy.

<sup>ppp</sup> Initiate colonoscopy no later than age 45.

**Note: All recommendations are category 2A unless otherwise indicated.**  
**Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.**

### SCREENING MODALITY AND SCHEDULE

- Screening of individuals at average risk reduces CRC incidence by detecting and removing precancerous polyps, and reduces CRC mortality by detecting cancer at an early, curable stage.
- CRC screening should be performed as part of a population-based program that includes a systematic method for: 1) identifying those who are eligible for and wish to undergo screening; 2) risk stratification and administration of the screening tests at agreed upon intervals; 3) shared decision-making with patients regarding the choice of screening method; 4) standardized reporting of the results; and 5) follow-up of those with a positive test. Assuring timely colonoscopy completion for individuals with a positive stool-based test or an imaging abnormality on CTC is critical for these screening approaches to be successful. Thus, a robust mechanism to ensure prompt and nearly complete adherence with colonoscopy completion should be established. The program should also include a systematic method for the arranging of repeat screening and surveillance.
- Organized screening programs that provide direct outreach to patients and clinic-focused interventions have been shown to increase CRC screening rates, reduce mortality, and minimize disparities by race/ethnicity.<sup>1</sup> Examples of evidence-based interventions to increase CRC screening rates include mailed stool test outreach, patient navigation, patient education and reminders, and clinician-directed feedback and alerts.<sup>2</sup>
- Screening rates improve when programs offer different screening test options to ensure that testing characteristics are aligned with patient preferences.<sup>3</sup>

<sup>1</sup> Levin TR, et al. Gastroenterology 2018;155:1383-1391; Mehta SJ, et al. J Gen Intern Med 2016;31:1323-1330; Sumit SK, et al. Prev Med 2020;141:106242.

<sup>2</sup> Sumit SK, et al. Prev Med 2020;141:106242.

<sup>3</sup> Inadomi JM, et al. Arch Intern Med 2012;172:575-582; Mehta SJ, et al. JAMA Netw Open 2019;2:e1910305.

**Note: All recommendations are category 2A unless otherwise indicated.**

**Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.**

[Continued](#)

**CSCR-A**  
**1 OF 6**



# NCCN Guidelines Version 1.2024 Colorectal Cancer Screening

[NCCN Guidelines Index](#)  
[Table of Contents](#)  
[Discussion](#)

## SCREENING MODALITY AND SCHEDULE

Screening Test*	Recommended Testing Interval**	Sensitivity <sup>5</sup>		Specificity <sup>5</sup>	
		Colon Cancer		Colon Cancer	
Colonoscopy	Every 10 years	94.7% <sup>4</sup>	89%–95% (≥10 mm adenomas) 75%–93% (≥6 mm adenomas)	—	89% (≥10 mm adenomas) 94% (≥6 mm adenomas)
Flexible sigmoidoscopy***	Every 5–10 years	58%–75% <sup>6</sup>	72%–86% <sup>6</sup>	—	92% <sup>7</sup>
CT colonography	Every 5 years	86%–100%	89% (≥10 mm adenomas) 86% (≥6 mm adenomas)	—	94% (≥10 mm adenomas) 88% (≥6 mm adenomas)
High-sensitivity guaiac-based test	Annually	50%–75%	7%–21% (advanced neoplasia) 6%–17% (advanced adenoma)	96%–98%	96%–99% (advanced neoplasia) 96%–99% (advanced adenoma)
Quantitative FIT (using OC-Sensor)	Annually	74%	25% (advanced neoplasia) 23% (advanced adenoma)	94%	96% (advanced neoplasia) 96% (advanced adenoma)
Quantitative FIT (using OC-Light)	Annually	81%	27% (advanced neoplasia) 28% (advanced adenoma)	93%	95% (advanced neoplasia) 94% (advanced adenoma)
mt-sDNA test****	Every 3 years	93%	47% (advanced neoplasia) 43% (advanced adenoma)	85%	89% (advanced neoplasia) 89% (advanced adenoma)

\* A blood test that detects circulating methylated SEPT9 DNA has been FDA-approved for CRC screening for those who refuse other screening modalities. Based on current data, the panel concludes that the interval for repeating testing is unknown/unclear. The panel will continue to review this strategy and monitor data as they emerge.

\*\* Frequency based upon normal (negative) results.

\*\*\* Data for the sensitivity and specificity of flexible sigmoidoscopy are for the entire colon and are based on the completion of colonoscopy for those found to have a distal colon lesion on flexible sigmoidoscopy.

\*\*\*\* Optimal FIT thresholds will vary across screening programs, taking into consideration available colonoscopy resources to investigate abnormal results, including false-positive tests.

<sup>4</sup> Pickhardt PJ, Hasan C, Halligan S, Marmo R. Colorectal cancer: CT colonography and colonoscopy for detection--systematic review and meta-analysis. *Radiology* 2011;259:393-405.

<sup>5</sup> Lin JS, Perdue LA, Henrikson NB, et al. Screening for colorectal cancer: Updated evidence report and systematic review for the US Preventive Services Task Force. *JAMA* 2021;325:1978-1998.

<sup>6</sup> Whitlock EP, Lin JS, Liles E, et al. Screening for colorectal cancer: A targeted, updated systematic review for the U.S. Preventive services task force. *Ann Intern Med* 2008;149:638-658.

<sup>7</sup> Zauber AG, Lansdorp-Vogelaar I, Knudsen AB, et al. Evaluating test strategies for colorectal cancer screening: A decision analysis for the U.S. Preventive Services Task Force. *Ann Intern Med* 2008;149:659-669.

**Note: All recommendations are category 2A unless otherwise indicated.**

**Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.**

[Continued](#)

**CSCR-A  
2 OF 6**

### SCREENING MODALITY AND SCHEDULE

#### Colonoscopy

- In the United States, colonoscopy is the most commonly employed CRC screening test for populations at average and high risk. There are multiple options; however, the choice of modality for individuals at average risk should include consideration of patient preferences and availability.
- Caveats for the 10-year interval:
  - ▶ A 10-year interval is appropriate for those who had a complete procedure with an adequate bowel prep.
  - ▶ Repeating within 1 year may be indicated based on the quality and completeness of the colonoscopy. In addition, individual risk factors and physician judgment should be included in the interval determination.
  - ▶ The number and characteristics of polyps as well as family history and medical assessment should influence judgment regarding the interval between colonoscopies.
  - ▶ Colonoscopy has limitations and may not detect all cancers and polyps.<sup>8</sup>
- Colonoscopy bowel preparation<sup>9</sup>
  - ▶ To determine preparation quality, a preliminary assessment should often be made in the rectosigmoid colon. If an inadequate preparation would interfere with the detection of polyps >5 mm, colonoscopy should be repeated within 1 year but preferably as soon as possible. Alternatively, additional bowel cleaning can be attempted for the colonoscopy to proceed that day.
  - ▶ In cases where colonoscopy is complete to the cecum but the preparation is ultimately considered inadequate, colonoscopy should be repeated within 1 year. A more aggressive preparation regimen should be recommended in these cases. When advanced neoplasia is detected and prep was inadequate, an interval shorter than 1 year is indicated.
- Accumulating data suggest that there is substantial variability in the quality, and by extension, the clinical effectiveness of colonoscopy. A number of quality indicators have been examined. Quality indicators for colonoscopy are an important part of the fidelity of findings. Improving the overall impact of screening colonoscopy requires a programmatic approach that addresses quality issues at several levels. These colonoscopy quality indicators may include:
  - ▶ Cecal intubation rates
  - ▶ Withdrawal time
  - ▶ Appropriate intervals between endoscopic studies based on family and personal history, and number and histologic type of polyps on last colonoscopy
  - ▶ Minor and major complication rates
  - ▶ Pre-procedure medical evaluation
  - ▶ Appropriate prep instructions<sup>9</sup>
    - ◊ Split-dose prep has been shown to be superior and is typically recommended.
    - ◊ Preferred timing of the second dose of split-dose preparation:
      - Start 4–6 hours before colonoscopy
      - End at least 2 hours before colonoscopy
    - ◊ Same-day, morning-only preparation is an acceptable alternative to split-dose preparation, especially in patients scheduled for afternoon procedures.
  - ▶ [Adenoma detection rate](#)
  - ▶ The use of artificial intelligence (AI) in colonoscopy is rapidly evolving. Future studies should help determine the specific tools and uses of AI for CRC screening.

<sup>8</sup> Singh S, Singh PP, Murad MH, et al. Prevalence, risk factors, and outcomes of interval colorectal cancers: a systematic review and meta-analysis. *Am J Gastroenterol* 2014;109:1375-1389.

<sup>9</sup> Johnson D, Barkun AN, Cohen LB, et. al. Optimizing adequacy of bowel cleansing for colonoscopy: recommendations from the US multi-society task force on colorectal cancer. *Gastroenterology* 2014;147:903-924.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

[Continued](#)

**CSCR-A**  
**3 OF 6**

### SCREENING MODALITY AND SCHEDULE

#### Colonoscopy (Continued)

- **Standardized colonoscopy reports that contain, at a minimum:<sup>10</sup>**
  - ▶ Patient demographic, clinical factors including comorbidities, adenoma and cancer history, and GI family history
  - ▶ Procedure indications
  - ▶ Endoscopic findings, including polyp number, size, location, and method of excision
  - ▶ Photographic documentation of endoscopic landmarks, including the ileocecal valve, the appendiceal orifice, and retroflexed view of rectum if intact/technically feasible
  - ▶ Estimate of quality of bowel preparation
  - ▶ Documentation of follow-up planning, including pathology results
  - ▶ Sedation administered
  - ▶ Written communication of the findings and plans to the patient and referring physician is encouraged

#### Stool-based screening

- This modality should only be employed for screening in individuals of average risk unless colonoscopy cannot be safely employed.
- If colonoscopy is used as the screening modality in a patient at average risk, then additional interval stool-based testing is not indicated.
- If a stool-based screening test is positive, colonoscopy should be recommended. Recommendations for an appropriate time frame for follow-up colonoscopy in this population lack a strong evidence base, but a large observational study reported significantly higher risks for CRC and advanced-stage disease when follow-up occurred 10 months or later, with a trend towards increased cancer risk observed as early as 6 months after an abnormal result. Thus, we recommend that follow-up colonoscopy is completed ideally within 6 to 10 months after an abnormal stool-based test.<sup>12</sup>
- High-sensitivity, guaiac-based, nonrehydrated<sup>11</sup> screening requires 3 successive stool specimens annually (not via digital rectal examination [DRE]), a prescribed diet, and coordination by a health care provider.

<sup>10</sup> Lieberman D, Nadel M, Smith R, et al. Standardized colonoscopy reporting and data system: report of the Quality Assurance Task Group of the National Colorectal Cancer Roundtable. *Gastrointest Endosc* 2007;65:757-766.

<sup>11</sup> There are category 1 data that regular (not high-sensitivity) guaiac-based FOBT and flexible sigmoidoscopy reduce mortality from colorectal cancer. Mandel JS, et al. *N Engl J Med* 1993;328:1365-1371. Kronborg O, et al. *Lancet* 1996;348:1467-1471. Atkin WS, et al. *Lancet* 2010;375:1624-1633; Schoen RE, et al. *N Engl J Med* 2012;366:2345-2357; Nishihara R, et al. *N Engl J Med*; 2013;369:1095-1105.

<sup>12</sup> Corley DA, et al. *JAMA* 2017;317:1631-1641; Forbes N, et al. *Clin Gastro Hepatol* 2020;19:1344-135.

**Note: All recommendations are category 2A unless otherwise indicated.**

**Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.**

**Continued**

**CSCR-A  
4 OF 6**

### SCREENING MODALITY AND SCHEDULE

#### FIT/mt-sDNA-based testing

- This modality is only FDA approved for individuals of average risk.
- Non-randomized studies have demonstrated that FIT is more sensitive than guaiac-based testing<sup>13,14,15</sup> and also reduces mortality.<sup>16,17</sup>
- Both detect human globin.
- A prescribed diet is not required.
- Optimal FIT thresholds will vary across screening programs, taking into consideration available colonoscopy resources to investigate abnormal results, including false-positive tests.
- Many brands of FIT require only a single stool sample annually.
- mt-sDNA is suggested to be performed every 3 years.
- If the colonoscopy is negative after a positive FIT or mt-sDNA and no additional symptoms are present, there is no need for further tests prior to the next recommended screening interval.

#### Flexible sigmoidoscopy<sup>11</sup>

- Recommended every 5–10 years for average-risk screening

<sup>11</sup> There are category 1 data that regular (not high-sensitivity) guaiac-based FOBT and flexible sigmoidoscopy reduce mortality from colorectal cancer. Mandel JS, Bond JH, Church TR, et al. N Engl J Med 1993;328:1365-1371. Kronborg O, Fenger C, Olsen J, et al. Lancet 1996;348:1467-1471. Atkin WS, Edwards R, Kralj-Hans I, et al. Lancet 2010;375:1624-1633; Schoen RE, Pinsky PF, Weissfeld JL, et al. N Engl J Med 2012;366:2345-2357; Nishihara R, Wu K, Lochhead P, et al. N Engl J Med; 2013;369:1095-1105.

<sup>13</sup> Imperiale TF. Noninvasive screening tests for colorectal cancer. Dig Dis 2012;30:16-26.

<sup>14</sup> Park D, Ryu S, Kim Y, et al. Comparison of guaiac-based and quantitative immunochemical fecal occult blood testing in a population at average risk undergoing colorectal cancer screening. Am J Gastroenterol 2010;105:2017-2025.

<sup>15</sup> Parra-Blanco A, Gimeno-García A, Quintero E, et al. Diagnostic accuracy of immunochemical versus guaiac faecal occult blood tests for colorectal cancer screening. J Gastroenterol 2010;45:703-712.

<sup>16</sup> Chiu HM, Chen SL, Yen AM, et al. Effectiveness of fecal immunochemical testing in reducing colorectal cancer mortality from the One Million Taiwanese Screening Program. Cancer 2015;121:3221-3229.

<sup>17</sup> Giorgi Rossi P, Vicentini M, Sacchetti C, et al. Impact of screening program on incidence of colorectal cancer: A cohort study in Italy. Am J Gastroenterol 2015;110:1359-1366.

**Note: All recommendations are category 2A unless otherwise indicated.**

**Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.**

[Continued](#)

**CSCR-A**  
**5 OF 6**

### SCREENING MODALITY AND SCHEDULE

#### Radiographic

##### CTC<sup>18,19</sup>

- **Accuracy**
  - ▶ **≥10-mm lesions can be identified by CTC with an accuracy similar to colonoscopy.**
  - ▶ **Lesions 6–9 mm can be identified with an acceptable accuracy that is less than that identified for colonoscopy.**
  - ▶ **Lesions ≤5 mm cannot be identified with acceptable accuracy.**
- **Follow-up of identified lesions**
  - ▶ **Data on optimal frequency, polyp size leading to colonoscopy referral, and protocol for evaluation of extracolonic lesions are evolving. The ACR has recommended that reporting of polyps ≤5 mm in size is not necessary. If polyp(s) of this size are reported, the decision to refer for colonoscopy with polypectomy versus surveillance CTC should be individualized.**
  - ▶ **If 1 or 2 lesions that are 6–9 mm are found, then CTC surveillance in 3 years or colonoscopy is recommended.<sup>20,21,22</sup>**
  - ▶ **If ≥3 lesions that are 6–9 mm or any lesion ≥10 mm are found, then colonoscopy is recommended.**
- **The recommended performance interval of every 5 years was originally based on barium enema; however, it has been supported with more recent data.<sup>23</sup>**
- **All visualized extracolonic findings should be described and recommendations should be provided as to appropriate follow-up (including no follow-up).**
- **The future cancer risk related to undergoing a single CTC is unknown but likely very low. No empiric data have shown increased risk at levels below an exposure of 100 mSv.<sup>24</sup>**
- **CTC interpretation should be accomplished only by those trained according to the American Gastroenterological Association<sup>18</sup> or American College of Radiology (ACR)<sup>19</sup> guidelines.**
- **Procedure quality should be tracked and assured using current ACR practice guidelines for patient preparation, image acquisition, study interpretation, and reporting.**

#### mSEPT9 blood test

- **A blood test that detects circulating methylated SEPT9 DNA has been FDA-approved for CRC screening for those who refuse other screening modalities. Based on current data, the panel concludes that the interval for repeating testing is unknown/unclear. The panel will continue to review this strategy and monitor data as they emerge.**

<sup>18</sup> [American Gastroenterological Association CT Colonography Standards](#). Cash BD, Rockey DC, Brill JV. AGA standards for gastroenterologists for performing and interpreting diagnostic computed tomography colonography: 2011 update. *Gastroenterology* 2011;141:2240-2266.

<sup>19</sup> [American College of Radiology Practice Guideline for the Performance of Computed Tomography \(CT\) Colonography in Adults](#).

<sup>20</sup> Zalis ME, Barish MA, Choi JR, et al; Working Group on Virtual Colonoscopy. CT colonography reporting and data system: a consensus proposal. *Radiology* 2005;236:3-9.

<sup>21</sup> Tutein Nolthenius CJ, Boellaard TN, de Haan MC, et al. Evolution of screen-detected small (6-9 mm) polyps after a 3-year surveillance interval: assessment of growth with CT colonography compared with histopathology. *Am J Gastroenterol* 2015;110:1682-1690.

<sup>22</sup> Pickhardt PJ, Kim DH, Pooler BD, et al. Assessment of volumetric growth rates of small colorectal polyps with CT colonography: a longitudinal study of natural history. *Lancet Oncol* 2013;14:711-720.

<sup>23</sup> Pickhardt PJ, Pooler BD, Mbah I, Weiss JM, Kim DH. Colorectal findings at repeat CT colonography screening after initial CT colonography screening negative for polyps larger than 5 mm. *Radiology* 2017;282:139-148.

<sup>24</sup> Health Physics Society. Radiation Risk in Perspective. Position Statement. May 2017.

**Note: All recommendations are category 2A unless otherwise indicated.**

**Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.**



### GLOSSARY OF TERMS COMMONLY USED IN NCCN GUIDELINES FOR COLORECTAL CANCER SCREENING

Term	Abbreviation (if applicable)	Definition
<b>General Terms</b>		
<b>Colorectal cancer</b>	<b>CRC</b>	<b>Cancer that occurs in the colon or rectum</b>
<b>Crohn's disease</b>	<b>CD</b>	<b>Chronic inflammatory disorder that may affect the entire GI tract<sup>1</sup></b>
<b>Inflammatory bowel disease</b>	<b>IBD</b>	<b>Comprised of ulcerative colitis or Crohn's disease<sup>2</sup></b>
<b>Mismatch repair</b>	<b>MMR</b>	<b>Molecular pathway that targets replication errors missed during DNA replication<sup>3</sup></b>
<b>Mismatch repair deficiency</b>	<b>dMMR</b>	<b>Form of genetic instability in CRC characterized by loss of function genetic mutations in the mismatch repair pathway<sup>4</sup></b>
<b>Primary sclerosing cholangitis</b>	<b>PSC</b>	<b>Chronic cholestatic disease characterized by fibroinflammatory fibrosis of the biliary tree; is a risk factor for CRC<sup>2,5</sup></b>
<b>Ulcerative colitis</b>	<b>UC</b>	<b>Chronic inflammatory disorder of the colon<sup>6</sup></b>
<b>Screening/Surveillance Modalities</b>		
<b>Chromoendoscopy</b>		<b>Image-enhanced endoscopic procedure using dye or optical technologies<sup>7</sup></b>
<b>Colonoscopy</b>		<b>Structural endoscopic examination of the entire colon</b>
<b>Computed tomography colonography</b>	<b>CTC</b>	<b>Also known as virtual colonoscopy; involves helical computed tomographic scanning of the colon after cathartic preparation and colonic distension<sup>8</sup></b>
<b>Fecal immunochemical test</b>	<b>FIT</b>	<b>Fecal-based CRC screening test that measures amount of human hemoglobin in stool using antibodies against globin moiety of human hemoglobin<sup>9</sup></b>
<b>Flexible sigmoidoscopy</b>		<b>Structural endoscopic examination of the distal portion of the colon<sup>10</sup></b>
<b>High-definition white light endoscopy</b>	<b>HD-WLE</b>	<b>Endoscopy procedure that uses high-definition imaging system without optical filters<sup>11</sup></b>

**Note: All recommendations are category 2A unless otherwise indicated.**

**Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.**

[Continued](#)  
[References](#)

**CSCR-GLOS**  
**1 OF 7**

### GLOSSARY OF TERMS COMMONLY USED IN NCCN GUIDELINES FOR COLORECTAL CANCER SCREENING

Term	Abbreviation (if applicable)	Definition
Multitargeted stool DNA	mt-sDNA	Stool DNA-based CRC screening test, which includes quantitative molecular assays for <i>KRAS</i> mutations, aberrant <i>NDRG4</i> and <i>BMP3</i> methylation, and $\beta$ -actin, plus a hemoglobin immunoassay <sup>12</sup>
Polypectomy		Procedure used to remove visually detectable polypoid tissue in the colon <sup>13</sup>
Histology		
Adenoma		Noninvasive neoplastic lesion of the columnar epithelium <sup>14</sup>
Advanced adenoma		Adenoma that is $\geq 1$ cm or has villous/tubulovillous histology or high-grade dysplasia
Non-advanced adenoma		Adenoma that is $< 1$ cm and has tubular histology
Tubular adenoma		Tubular adenomas are comprised mostly of tubular glands and have $< 25\%$ villous features <sup>15</sup>
Villous adenoma		High-risk feature; a polyp/adenoma with $> 75\%$ villous structures (long finger-like or leaf-like projections on surface) <sup>15</sup>
Tubulovillous adenoma		High-risk feature; a polyp/adenoma with $25\% - 75\%$ villous histology <sup>15</sup>
Low-risk adenomas		1–2 nonadvanced polyps/adenomas $< 10$ mm in size <sup>13</sup>
High-risk adenomas		Advanced adenoma or $\geq 3$ non-advanced adenomas <sup>13</sup>
Traditional serrated adenomas	TSAs	Polyps with complex villous growth pattern; ectopic crypt formation is a unique feature that leads to mucosal protrusions; <sup>16,17</sup> are associated with high-risk polyp recurrence <sup>18</sup>
Dysplasia		<ul style="list-style-type: none"> <li>In sporadic CRC, a dysplastic precursor or preinvasive lesion is an adenomatous polyp, which is a single discrete focus of neoplasia that is managed by polypectomy<sup>19</sup></li> <li>In long-standing cases of IBD, dysplasia may be polypoid or flat, localized, diffuse or multifocal, and once detected marks the entire colon as being at increased risk<sup>19</sup></li> </ul>
High-grade dysplasia		High-risk feature; refers to the distribution of nuclei within the cells; in high-grade dysplasia, nuclei are stratified haphazardly between the basal and apical halves of the cells <sup>19</sup>

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

[Continued](#)  
[References](#)

CSCR-GLOS  
2 OF 7

### GLOSSARY OF TERMS COMMONLY USED IN NCCN GUIDELINES FOR COLORECTAL CANCER SCREENING

Term	Abbreviation (if applicable)	Definition
Invisible dysplasia		Dysplasia diagnosed on pathology but not described on endoscopy; <sup>20</sup> identified on random/non-targeted biopsies of colon mucosa without a visible lesion <sup>21</sup>
Hyperplastic polyps	HPs	Hyperplastic polyps are serrated polyps with normal crypt architecture and proliferative characteristics <sup>22,23</sup>
Sessile serrated polyp/sessile serrated lesion	SSP/SSL	Synonymous with sessile serrated adenoma; <sup>24</sup> SSPs/SSLs are a type of serrated polyp that is not dysplastic or does not contain foci of dysplasia; sessile lesions are attached to the mucosa without a stalk
Sessile serrated polyp/sessile serrated lesion with dysplasia	SSP/SSL-d	SSP/SSL with dysplasia
Low-risk SSP/SSL		1–2 SSPs/SSLs <10 mm in size; no dysplasia
High-risk SSP/SSL		SSP/SSL ≥1 cm and/or containing dysplasia and/or ≥3 low-risk SSPs/SSLs
Sessile colorectal polyps		Paris subtype 0–1s lesion <sup>14</sup>
Non-pedunculated polyps		Sessile and non-polypoid lesions; <sup>25</sup> lesion not attached to mucosa by stalk, and base and top of lesion have the same diameter <sup>24</sup>
Pedunculated polyps		Paris subtype 0–1p lesion; <sup>14</sup> lesion attached to the mucosa by a stalk and the base of lesion is narrow <sup>21,24</sup>
Polypoid lesion		Lesion protruding from the mucosa into the lumen ≥2.5 mm <sup>21</sup>
Nonpolypoid lesion		Paris subtype 0–IIa, 0–IIb, and 0–IIc lesions; <sup>14</sup> lesion with little (<2.5 mm) or no protrusion above the mucosa; <sup>21</sup> includes superficial elevated, flat, and depressed <sup>24</sup> <ul style="list-style-type: none"> <li>• Superficial elevated (0–IIa) lesions: include height &lt;2.5 mm above normal mucosa; sometimes defined as height &lt; one-half of the lesion diameter<sup>24</sup></li> <li>• Flat (0–IIb) lesions: those without any protrusion above mucosa<sup>24</sup></li> <li>• Depressed (0–IIc) lesions: those with base that is lower than the normal mucosa<sup>24</sup></li> </ul>
Lateral spreading lesion		Laterally growing superficial neoplasm (instead of upward or downward growth) ≥10 mm in size; <sup>24</sup> may be used to further classify non-pedunculated lesions <sup>25</sup>

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

[Continued](#)  
[References](#)

CSCR-GLOS  
3 OF 7

### GLOSSARY OF TERMS COMMONLY USED IN NCCN GUIDELINES FOR COLORECTAL CANCER SCREENING

Term	Abbreviation (if applicable)	Definition
<b>Surgical Procedures</b>		
Endoscopic mucosal resection	EMR	Technique involving injecting solution into submucosal space to separate mucosal lesion from underlying muscularis propria; lesion can then be removed by snare <sup>24</sup>
Endoscopic submucosal dissection	ESD	Technique involving lifting by submucosal injectant and using ESD knife to create incision around lesion's perimeter and to dissect through expanded submucosal layer for en bloc resection <sup>24</sup>
Piecemeal resection		Removal of colorectal lesions or polyps in multiple pieces, which makes it hard to assess for resection margins and may prevent accurate histologic diagnosis <sup>24</sup>
En bloc resection		Removal of colorectal lesions or polyps in one piece <sup>24,26</sup>
Ileocectomy		Removal of the terminal ileum and the appendix and cecum <sup>27</sup>
Right hemicolectomy		Removal of the right colon and proximal transverse colon with ligation of the ileocolic artery and the right branch of the middle colic artery
Extended right hemicolectomy		Removal of the right colon and transverse colon with ligation of the ileocolic artery and the middle colic artery
Transverse colectomy		Removal of the transverse colon by ligation of the middle colic artery <sup>28</sup>
Left hemicolectomy		Removal of the splenic flexure, descending colon, and the sigmoid colon (if indicated) with ligation of the left colic artery or inferior mesenteric artery; may require ligation of the left branch or middle colic artery
Sigmoid colectomy		Removal of the sigmoid colon to the rectosigmoid junction or upper rectum with ligation of the inferior mesenteric artery or the superior rectal branch
Subtotal colectomy		Removal of most but not all of the colon (eg, right colon, transverse colon and descending colon with ligation of the ileocolic, middle colic, and left colic artery) <sup>29</sup>
Total colectomy		Removal of the whole colon down to the upper rectum, with ligation of the ileocolic, middle colic, and inferior mesenteric artery

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

[Continued](#)  
[References](#)

**CSCR-GLOS**  
**4 OF 7**

### GLOSSARY OF TERMS COMMONLY USED IN NCCN GUIDELINES FOR COLORECTAL CANCER SCREENING

Term	Abbreviation (if applicable)	Definition
<b>Surgical Procedures</b>		
<b>Low anterior resection</b>	<b>LAR</b>	Removal of the sigmoid colon, some or all of the rectum, and a total or tumor-specific mesorectal excision with ligation of the inferior mesenteric artery or the superior rectal branch <sup>30</sup>
<b>Abdominoperineal resection</b>	<b>APR</b>	Removal of the sigmoid colon, rectum, and anus with ligation of the inferior mesenteric artery or the superior rectal branch <sup>31</sup>
<b>Total proctocolectomy</b>		Removal of the entire colon and rectum, with or without preservation of the anal canal

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

[References](#)

**CSCR-GLOS**  
**5 OF 7**

### GLOSSARY OF TERMS COMMONLY USED IN NCCN GUIDELINES FOR COLORECTAL CANCER SCREENING REFERENCES

- <sup>1</sup> Van Assche G, Dignass A, Panes J, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. *J Crohns Colitis* 2010;4:7-27.
- <sup>2</sup> Magro F, Langner C, Driessen A, et al. European consensus on the histopathology of inflammatory bowel disease. *J Crohns Colitis* 2013;7:827-851.
- <sup>3</sup> Modrich P. Methyl-directed DNA mismatch correction. *J Biol Chem* 1989;264:6597-6600.
- <sup>4</sup> Poulogiannis G, Frayling IM, Arends MJ. DNA mismatch repair deficiency in sporadic colorectal cancer and Lynch syndrome. *Histopathology* 2010;56:167-179.
- <sup>5</sup> Broome U, Lofberg R, Veress B, Eriksson LS. Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. *Hepatology* 1995;22:1404-1408.
- <sup>6</sup> Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. *Gastroenterology* 2011;140:1785-1794.
- <sup>7</sup> Buchner AM. The role of chromoendoscopy in evaluating colorectal dysplasia. *Gastroenterol Hepatol (N Y)* 2017;13:336-347.
- <sup>8</sup> Cotton PB, Durkalski VL, Pineau BC, et al. Computed tomographic colonography (virtual colonoscopy): a multicenter comparison with standard colonoscopy for detection of colorectal neoplasia. *JAMA* 2004;291:1713-1719.
- <sup>9</sup> Robertson DJ, Lee JK, Boland CR, et al. Recommendations on fecal immunochemical testing to screen for colorectal neoplasia: A consensus statement by the US Multi-Society Task Force on Colorectal Cancer. *Gastroenterology* 2017;152:1217-1237.e3.
- <sup>10</sup> Holme O, Schoen RE, Senore C, et al. Effectiveness of flexible sigmoidoscopy screening in men and women and different age groups: pooled analysis of randomised trials. *BMJ* 2017;356:i6673.
- <sup>11</sup> Buchner AM, Shahid MW, Heckman MG, et al. High-definition colonoscopy detects colorectal polyps at a higher rate than standard white-light colonoscopy. *Clin Gastroenterol Hepatol* 2010;8:364-370.
- <sup>12</sup> Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. *N Engl J Med* 2014;370:1287-1297.
- <sup>13</sup> Gupta S, Lieberman D, Anderson JC, et al. Recommendations for follow-up after colonoscopy and polypectomy: A consensus update by the US Multi-Society Task Force on Colorectal Cancer. *Am J Gastroenterol* 2020;115:415-434.
- <sup>14</sup> The Paris endoscopic classification of superficial neoplastic lesions: esophagus, stomach, and colon: November 30 to December 1, 2002. *Gastrointest Endosc* 2003;58:S3-43.
- <sup>15</sup> Taherian M, Lotfollahzadeh S, Daneshpajouhnejad P, Arora K. Tubular Adenoma. *StatPearls*. Treasure Island (FL): StatPearls Publishing Copyright © 2020, StatPearls Publishing LLC.; 2020.
- <sup>16</sup> McCarthy AJ, Serra S, Chetty R. Traditional serrated adenoma: an overview of pathology and emphasis on molecular pathogenesis. *BMJ Open Gastroenterol* 2019;6:e000317.
- <sup>17</sup> Torlakovic EE, Gomez JD, Driman DK, et al. Sessile serrated adenoma (SSA) vs. traditional serrated adenoma (TSA). *Am J Surg Pathol* 2008;32:21-29.
- <sup>18</sup> Yoon JY, Kim HT, Hong SP, et al. High-risk metachronous polyps are more frequent in patients with traditional serrated adenomas than in patients with conventional adenomas: a multicenter prospective study. *Gastrointest Endosc* 2015;82:1087-1093.e3.
- <sup>19</sup> Itzkowitz SH, Harpaz N. Diagnosis and management of dysplasia in patients with inflammatory bowel diseases. *Gastroenterology* 2004;126:1634-1648.
- <sup>20</sup> Rubin DT, Rothe JA, Hetzel JT, et al. Are dysplasia and colorectal cancer endoscopically visible in patients with ulcerative colitis? *Gastrointest Endosc* 2007;65:998-1004.
- <sup>21</sup> Kaltenbach T, Sandborn WJ. Endoscopy in inflammatory bowel disease: advances in dysplasia detection and management. *Gastrointest Endosc* 2017;86:962-971.
- <sup>22</sup> WHO Classification of Tumors Editorial Board. *Digestive System Tumours: IARC Lyon, France; 2019:162-169.*
- <sup>23</sup> Rex DK, Ahnen DJ, Baron JA, et al. Serrated lesions of the colorectum: review and recommendations from an expert panel. *Am J Gastroenterol* 2012;107:1315-1329; quiz 1314, 1330.

**Note: All recommendations are category 2A unless otherwise indicated.**

**Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.**

[Continued](#)

**CSCR-GLOS**  
**6 OF 7**

### GLOSSARY OF TERMS COMMONLY USED IN NCCN GUIDELINES FOR COLORECTAL CANCER SCREENING REFERENCES (CONTINUED)

- <sup>24</sup> Kaltenbach T, Anderson JC, Burke CA, et al. Endoscopic removal of colorectal lesions-recommendations by the US Multi-Society Task Force on Colorectal Cancer. *Gastroenterology* 2020;158:1095-1129.
- <sup>25</sup> Rutter MD, Chattree A, Barbour JA, et al. British Society of Gastroenterology/Association of Coloproctologists of Great Britain and Ireland guidelines for the management of large non-pedunculated colorectal polyps. *Gut* 2015;64:1847-1873.
- <sup>26</sup> Fukami N. Large colorectal lesions: Is it possible to stratify the lesions for optimal treatment in the right hands? *Gastrointest Endosc* 2016;83:963-965.
- <sup>27</sup> Kulungowski AM, Acker SN, Hoffenberg EJ, et al. Initial operative treatment of isolated ileal Crohn's disease in adolescents. *Am J Surg* 2015;210:141-145.
- <sup>28</sup> Roy MK, Pipara A, Kumar A. Surgical management of adenocarcinoma of the transverse colon: What should be the extent of resection? *Ann Gastroenterol Surg* 2020;5:24-31.
- <sup>29</sup> Kaser SA, Glauser PM, Kunzli B, et al. Subtotal colectomy for malignant left-sided colon obstruction is associated with a lower anastomotic leak rate than segmental colectomy. *Anticancer Res* 2012;32:3501-3505.
- <sup>30</sup> Caulfield H, Hyman NH. Anastomotic leak after low anterior resection: a spectrum of clinical entities. *JAMA Surg* 2013;148:177-182.
- <sup>31</sup> Perry WB, Connaughton JC. Abdominoperineal resection: how is it done and what are the results? *Clin Colon Rectal Surg* 2007;20:213-220.

**Note: All recommendations are category 2A unless otherwise indicated.**

**Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.**

### ABBREVIATIONS

<b>AI</b>	<b>artificial intelligence</b>
<b>AYA</b>	<b>adolescent and young adult</b>
<b>CRC</b>	<b>colorectal cancer</b>
<b>CTC</b>	<b>computed tomography colonography</b>
<b>DRE</b>	<b>digital rectal examination</b>
<b>dMMR</b>	<b>mismatch repair deficient</b>
<b>EMR</b>	<b>endoscopic mucosal resection</b>
<b>ESD</b>	<b>endoscopic submucosal dissection</b>
<b>FIT</b>	<b>fecal immunochemical test</b>
<b>FOBT</b>	<b>fecal occult blood test</b>
<b>GI</b>	<b>gastrointestinal</b>
<b>HD-WLE</b>	<b>high-definition white light endoscopy</b>
<b>HNPCC</b>	<b>hereditary nonpolyposis colorectal cancer</b>
<b>IBD</b>	<b>irritable bowel disease</b>
<b>IHC</b>	<b>immunohistochemistry</b>
<b>LS</b>	<b>Lynch syndrome</b>
<b>LSL</b>	<b>laterally spreading lesion</b>
<b>MMR</b>	<b>mismatch repair</b>
<b>MSI</b>	<b>microsatellite instability</b>
<b>mt-sDNA</b>	<b>multitargeted stool DNA</b>
<b>PSC</b>	<b>primary sclerosing cholangitis</b>
<b>SSL</b>	<b>sessile serrated lesion</b>
<b>SSP</b>	<b>sessile serrated polyp</b>
<b>TBI</b>	<b>total body irradiation</b>
<b>TSA</b>	<b>traditional serrated adenoma</b>





# NCCN Guidelines Version 1.2024

## Colorectal Cancer Screening

### NCCN Categories of Evidence and Consensus

<b>Category 1</b>	Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.
<b>Category 2A</b>	Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.
<b>Category 2B</b>	Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate.
<b>Category 3</b>	Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate.

All recommendations are category 2A unless otherwise indicated.



# NCCN Guidelines Version 1.2024 Colorectal Cancer Screening

## Discussion

This discussion corresponds to the NCCN Guidelines for Colorectal Cancer Screening. Last updated on 09/30/2022.

## Table of Contents

**Overview** .....MS-2

**Literature Search Criteria and Guidelines Update Methodology**.....MS-2

**Primary and Secondary Prevention of Colorectal Cancer (CSCR-PREV)**.....MS-3

Physical Activity and Diet .....MS-3

Aspirin .....MS-3

Smoking .....MS-4

Alcohol .....MS-5

**Risk Assessment (CSCR-1,2)**.....MS-5

Average Risk .....MS-5

Increased Risk .....MS-6

High-Risk Genetic Syndromes with Predisposition to CRC .....MS-6

**Colorectal Cancer Screening (CSCR-3)**.....MS-6

**Screening Modalities (CSCR-A)**.....MS-7

Structural Screening Tests .....MS-7

Fecal-Based Screening Tests .....MS-13

**Screening of Individuals at Average Risk (CSCR-3)** .....MS-16

Interpretation of Findings .....MS-17

**Screening of Individuals at Increased Risk (CSCR-4)**.....MS-18

Personal History of Polyps Found at Colonoscopy ..... MS-18

Management of Large Colorectal Polyps (CSCR-6) ..... MS-20

Diagnosis of CRC (CSCR-7) ..... MS-20

Personal History of Inflammatory Bowel Disease (CSCR-8)..... MS-21


Evaluation of Surveillance Findings in IBD (CSCR-9, 10)..... MS-22

Increased Risk Based on Personal History of Cystic Fibrosis (CSCR-11) ..... MS-23

Increased Risk Based on Positive Family History (CSCR-12)..... MS-24

Increased Risk Based on Personal History of Childhood, Adolescent, and Young Adult Cancer (CSCR-13) ..... MS-25

**References**..... MS-27





# NCCN Guidelines Version 1.2024

## Colorectal Cancer Screening

### Overview

Colorectal cancer (CRC) is the fourth most frequently diagnosed cancer in the United States. In 2022, an estimated 106,180 new cases of colon cancer and 44,850 new cases of rectal cancer will occur in the United States.<sup>1</sup> During the same year, it is estimated that 52,580 people will die from colon and rectal cancer.<sup>1</sup> Screening of average-risk individuals can reduce CRC mortality by detecting cancer at an early, curable stage and may decrease CRC incidence by detecting and removing precancerous polyps.<sup>2-4</sup> Patients with localized CRC have a 90% relative 5-year survival rate, whereas rates for those with regional and distant disease are 71% and 14%, respectively, demonstrating that earlier diagnosis can have a large impact on survival.<sup>5</sup>

Importantly, the incidence of colon and rectal cancers per 100,000 people decreased from 60.5 in 1976 to 46.4 in 2005.<sup>6</sup> The incidence of CRC continued to trend downward from 54.5 to 38.6 per 100,000 people from 2000 to 2014.<sup>7</sup> Mortality from CRC decreased by almost 35% from 1990 to 2007.<sup>8</sup> Between 2011 and 2017, the 5-year mortality rate from CRC was 45%.<sup>1</sup> These improvements in the incidence of and mortality from CRC over past years are thought, at least in part, to be a result of cancer prevention and earlier diagnosis through screening and better treatment modalities. In fact, modeling suggests that approximately 63% of CRC deaths can be attributed to non-screening.<sup>9</sup> According to the Centers for Disease Control and Prevention (CDC), the screening rate among U.S. adults aged 50 to 75 years has increased from approximately 42% in 2000 to 59% in 2010 and to 68% in 2019.<sup>10,11</sup> The National Colorectal Cancer Roundtable established the goal to increase U.S. CRC screening rates to 80% by 2018, which they estimate could prevent approximately 280,000 new CRC cases and 200,000 CRC deaths through 2030.<sup>12</sup> Conversely, the incidence rates of colon and rectal cancers in adults <50 years of age have been increasing by approximately 2% per year since 2003.<sup>5,13</sup> In general, most CRC cases in adolescent and young adult (AYA) individuals

appear to be sporadic.<sup>14</sup> Causes for this increase in early-onset CRC are unknown and may be attributable to diet and other lifestyle factors.<sup>5</sup>

These NCCN Guidelines for Colorectal Cancer Screening describe various colorectal screening modalities as well as recommended screening schedules for patients at average or increased risk of developing sporadic CRC. They are intended to aid physicians with clinical decision-making regarding CRC screening for patients without defined genetic syndromes. Recommendations regarding the management of inherited syndromes such as Lynch syndrome (also known as hereditary nonpolyposis colorectal cancer, or HNPCC), familial adenomatous polyposis (FAP), *MutY human homolog* (MUTYH)-associated polyposis (MAP), Peutz-Jeghers syndrome (PJS), juvenile polyposis syndrome (JPS), and serrated polyposis syndrome (SPS) are addressed in the [NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal](#).

### Literature Search Criteria and Guidelines Update Methodology

Prior to the update of this version of the NCCN Guidelines for Colorectal Cancer Screening, an electronic search of the PubMed database was performed to obtain key literature in the field of CRC screening since the previous Guidelines update using the following search terms: (colorectal cancer screening) or (colon cancer screening) or (rectal cancer screening) or (colorectal cancer prevention) or (colon cancer prevention) or (rectal cancer prevention) or (colonoscopy) or (fecal occult blood) or (fecal immunochemical testing) or (flexible sigmoidoscopy) or (stool DNA) or (CT colonography) or (inflammatory bowel disease cancer) or (ulcerative colitis cancer) or (Crohn's disease cancer). The PubMed database was chosen because it remains the most widely used resource for medical literature and indexes peer-reviewed biomedical literature.<sup>15</sup>



# NCCN Guidelines Version 1.2024

## Colorectal Cancer Screening

The search results were narrowed by selecting studies in humans published in English. Results were confined to the following article types: Clinical Trial, Phase II; Clinical Trial, Phase III; Clinical Trial, Phase IV; Guideline; Randomized Controlled Trial; Meta-Analysis; Systematic Reviews; and Validation Studies.

The data from key PubMed articles as well as articles from additional sources deemed as relevant to these Guidelines and discussed by the panel have been included in this version of the Discussion section. Recommendations for which high-level evidence is lacking are based on the panel's review of lower-level evidence and expert opinion.

The complete details of the Development and Update of the NCCN Guidelines are available at [www.NCCN.org](http://www.NCCN.org).

### Primary and Secondary Prevention of Colorectal Cancer (CSCR-PREV)

Certain lifestyle modifications are associated with a reduced risk of CRC and can be an important adjunct to CRC screening for prevention.<sup>16</sup>

#### Physical Activity and Diet

A report from the Continuous Update Project (CUP) led by the American Institute for Cancer Research and World Cancer Research Fund International recommends maintaining a healthy weight, being physically active (via recreation, occupation, and/or transportation), and eating a healthy diet, as these measures are strongly associated with decreased colon and/or rectal cancer risk.<sup>17</sup> Other analyses have shown that adherence to guidelines promoting physical activity and a healthy diet are associated with reductions in the incidence of CRC.<sup>18,19</sup> Initiating physical activity during adolescence also appears to lower the risk of developing colorectal adenomas later in life.<sup>20</sup>

In regard to diet and nutrition, the CUP report recommends obtaining nutrients from natural food sources over solely from dietary supplements.<sup>17</sup> Specifically, low levels of vitamin D have been associated with increased CRC risk.<sup>21</sup> Some studies suggest that a diet high in fruits and vegetables is associated with decreased CRC risk.<sup>22,23</sup> In addition, some data suggest that a high body mass index (BMI) is associated with an increased risk for CRC recurrence and mortality, but the data are not consistent.<sup>24-26</sup>

An international panel of experts formed a working group for the International Agency for Research on Cancer (IARC) and assessed more than 800 epidemiologic studies that investigated the association of cancer with the consumption of red and processed meats.<sup>27</sup> Based on their review of the data, the IARC working group determined that the consumption of processed meats is carcinogenic to humans based on sufficient evidence for CRC.<sup>27</sup> Due to limited evidence, consumption of red meat was determined to be “probably carcinogenic” to humans.<sup>27</sup> In contrast, the Nutritional Recommendations (NutriRECS) guidelines panel suggests that adults continue current unprocessed red meat consumption (weak recommendation, low-certainty evidence).<sup>28</sup> Similarly, the panel suggests that adults continue current processed meat consumption (weak recommendation, low-certainty evidence).<sup>28</sup>

#### Aspirin

The U.S. Preventive Services Task Force (USPSTF) conducted a systematic evidence review of trials that assessed the benefits and harms of aspirin in primary cardiovascular disease (CVD) and CRC prevention.<sup>29</sup> The 12 trials (including 1 pilot trial) included in this systematic review compared the effects of low-dose aspirin ( $\leq 100$  mg/day) to placebo or no treatment in adults aged  $\geq 40$  years. For events occurring within trial periods (4 trials,  $n = 86,137$ ), low-dose aspirin had no statistically significant association with CRC incidence at 5 to 10 years of follow-up (odds ratio [OR], 1.07; 95% confidence interval [CI], 0.92–1.24).<sup>29</sup> Based



# NCCN Guidelines Version 1.2024

## Colorectal Cancer Screening

on two trials, aspirin use for 7 to 10 years was associated with a significantly lower risk of CRC mortality only when considering long-term observational follow-up (at 20 years) beyond trial periods (OR, 0.77; 95% CI, 0.61–0.98).<sup>29</sup> The USPSTF recommends that the decision to initiate low-dose aspirin use for the primary prevention of CVD in adults aged 40 to 59 years who have a 10% or greater 10-year CVD risk should be an individual one and recommends against initiating low-dose aspirin use for the primary prevention of CVD in adults aged ≥60 years. However, there is limited trial evidence on benefits for CRC due to differences in duration of aspirin use, timing of outcome measurements, and length of follow-up;<sup>29</sup> therefore, the USPSTF concluded that the evidence is inadequate that low-dose aspirin use reduces CRC incidence or mortality.<sup>30</sup>

An observational, population-based, retrospective cohort study examined the effect of aspirin on patients diagnosed with CRC from 2004 to 2011 in the Cancer Registry of Norway (n = 23,162; 6102 were exposed to aspirin after CRC diagnosis).<sup>31</sup> After a median follow-up time of 3 years, the mortality rate from all causes was lower in patients who were exposed to aspirin (32.9%) versus patients who were not exposed to aspirin (42.3%).<sup>31</sup> In addition, aspirin exposure after CRC diagnosis was independently associated with improved CRC-specific survival (HR, 0.85; 95% CI, 0.79–0.92) and overall survival (OS) (HR, 0.95; 95% CI, 0.90–1.01).<sup>31</sup> A systematic study of 11 randomized controlled trials (RCTs) found that at 3 years, aspirin statistically reduced the risk of colorectal adenomas (relative risk [RR], 0.84; *P* < .05) but not advanced lesions (RR, 0.82; *P* = .10). At 5 years, the risk of advanced lesions was significantly reduced (RR, 0.68; *P* < .05), but not in adenomas (RR, 0.87; *P* = 0.22). Beyond 5 years, aspirin had no effect on the risk of advanced lesions (HR, 0.82; *P* = .07) nor adenomas (HR, 0.99; *P* = .82).<sup>32</sup> A meta-analysis similarly reported a reduced recurrence of adenomas (RR, 0.83; 95% CI, 0.72–0.99; *P* = .006) and reduced mortality of CRC (RR, 0.79; 95% CI, 0.64–0.97; *P* = .02).<sup>33</sup> A cost-effectiveness analysis suggested that the

risk-benefit profile favors the use of very-low-dose aspirin for secondary prevention in individuals with previous advanced colorectal adenomas.<sup>34</sup>

The ASPREE trial randomized subjects aged ≥70 years to either aspirin (n = 9525) or placebo (n = 9589).<sup>35</sup> In contrast, the trial reported that aspirin use was associated with a statistically significant increase in CRC mortality at 4.7 years of follow-up (hazard ratio [HR], 1.77; 95% CI, 1.02–3.06).<sup>35</sup>

### Smoking

Cigarette smoking causes 1 in 5 deaths in the United States every year and is estimated to cause more than 480,000 deaths every year (including the effects of secondhand smoke).<sup>36</sup> The Cancer Prevention Study II (CPS-II) examined the impact of cigarette smoking in relation to CRC mortality in a prospective cohort study of 1,184,657 adults (aged ≥30 years).<sup>37</sup> Multivariate-adjusted CRC mortality rates were highest among patients who smoke, intermediate in patients who formerly smoked, and lowest in patients who never smoked.<sup>37</sup> The multivariate-adjusted RR (95% CI) for patients who currently smoke versus patients who do not smoke was 1.32 (1.16–1.49) among men, and 1.41 (1.26–1.58) among women.<sup>37</sup> Increased risk of CRC was observed after greater than or equal to 20 years of smoking for both men and women, compared to individuals who had never smoked.<sup>37</sup> A subsequent study examined a subgroup of participants from the CPS-II study (n = 184,187).<sup>38</sup> This prospective study assessed the association between cigarette smoking and risk of incident CRC during 13 years of follow-up in which individuals had initiated smoking an average of 44 years before enrollment.<sup>38</sup> The incidence of CRC was significantly higher in patients who currently smoke (HR, 1.27; 95% CI, 1.06–1.52) and those who formerly smoked (HR, 1.23; 95% CI, 1.11–1.36) compared with patients who never smoked.<sup>38</sup> The risk of CRC also decreased with longer time since cessation and earlier age at cessation.<sup>38</sup>



# NCCN Guidelines Version 1.2024

## Colorectal Cancer Screening

### Alcohol

Moderate to heavy alcohol consumption is an established risk factor for several malignancies, including CRC, and is a potentially modifiable risk factor for cancer.<sup>39,40</sup> A meta-analysis of 61 independent studies (27 cohort and 34 case-control studies) examined the association of alcohol intake (light, moderate, or high) and CRC risk.<sup>41</sup> Compared to nondrinkers or occasional drinkers, moderate drinking (>1–4 drinks/day, equivalent to 12.6–49.9 grams of ethanol/day) and heavy drinking (≥4 drinks/day, equivalent to ≥50 grams of ethanol/day) were associated with increased risk for CRC, at 21% and 52%, respectively.<sup>41</sup>

### Risk Assessment (CSCR-1,2)

The NCCN Guidelines for Colorectal Cancer Screening stratify patients into three groups depending on their risk of getting CRC. Colorectal screening is particularly important for African Americans since they have a higher risk of incidence and mortality (see *Increased Risk*, below). Communication with the patient and referring physician of any updated CRC risk assessment and screening plan based on family history, colonoscopy, and pathology findings is highly encouraged.

CRC risk assessment in persons without a known family history is advisable by 40 years of age to determine the appropriate age for initiating screening.

### Average Risk

Individuals at average risk of developing CRC are those: aged ≥45 years; with no personal history of adenoma or sessile serrated polyps (SSPs) or CRC; with inflammatory bowel disease (IBD), high-risk CRC genetic syndromes, or cystic fibrosis (CF); or with a negative family history of CRC or confirmed advanced adenoma (high-grade dysplasia, >1 cm in size, villous or tubulovillous histology, or advanced SSP).

Age consideration may be dependent on race/ethnicity, patient preference, and resources available. Epidemiologic reports suggest that CRC incidence is rising in young adults, with nearly half of patients presenting with early-onset CRC being <45 years of age for unknown reasons.<sup>14,42,43</sup> From 2003 to 2013, there has been a 22% increase in CRC in individuals <50 years.<sup>44</sup> The prevalence of pathogenic germline variants in CRC increases with a decreasing age at diagnosis. Thus, while about 10% of the diagnosed before age 50 will have a pathogenic variant causing Lynch syndrome, this percentage reaches 23% among those diagnosed before the age of 35. However, most young adults diagnosed with CRC have no hereditary syndrome or germline mutation associated with CRC and many patients lack the classical family history as well.<sup>42</sup> Although age and genetic makeup are linked to CRC, the majority of these patients have no family history of the disease; however, inherited cancer syndrome should be ruled out.<sup>14,43</sup> Based on statistical modeling incorporating these data, which predicted potential increased benefit,<sup>45,46</sup> the American Cancer Society (ACS) recommended—as a qualified recommendation—that individuals at average risk of CRC begin screening at age 45 years.<sup>47</sup>

The panel has reviewed these and other existing data for beginning screening of average-risk individuals at <50 years of age. Based on their assessment, the panel agrees that the data are stronger to support beginning screening at 50 years, but acknowledges that lower-level evidence supports a benefit for screening beginning at age 45. When initiating screening for all eligible individuals, the panel recommends a discussion of potential harms/risks and benefits, and the consideration of all recommended CRC screening options. Half of the patients who present with early-onset CRC (<50 years of age) are <45 years of age<sup>42</sup> and many have signs and symptoms of CRC such as iron deficiency anemia, rectal bleeding, or a change in bowel habits. Patients who present with these symptoms regardless of age should undergo a colonoscopy as part of their evaluation unless they recently underwent one.



# NCCN Guidelines Version 1.2024

## Colorectal Cancer Screening

### Increased Risk

Individuals with a personal history of adenomas or SSPs, CRC, IBD (ie, ulcerative colitis, Crohn's colitis), or CF, and those with a positive family history of CRC or advanced adenomatous polyps are considered to be at increased risk of developing CRC. Individuals with diabetes mellitus and those who are obese also have a higher risk,<sup>48,49</sup> although these factors are not considered to affect the screening guidelines. Other factors that influence risk include age, sex, and race.<sup>50</sup>

This increased risk has led some to recommend beginning population CRC screening in African Americans at an earlier age.<sup>51</sup> African Americans have had a disproportionately higher incidence of CRC in the United States for many years. Using a microsimulation model, one study found that differences in screening accounted for 42% of the disparity in CRC incidence and 19% of the disparity in CRC mortality between African Americans and whites.<sup>52</sup> However, mortality from CRC is multifactorial and is related to host factors, tumor biology, environmental exposures, disparities in access to screening, differences in stage at diagnosis, and treatments received. Nevertheless, mortality from CRC has been decreasing in African Americans and whites since 1999.<sup>53</sup> The incidence rate of CRC in African Americans aged 40 to 49 years has not changed between 2000 and 2017 (annual percent change, -0.03; 95% CI, -0.5–0.5). However, the absolute incidence rate (all ages) of CRC still remained higher in African Americans in comparison to other ethnicities.<sup>54</sup> Therefore, based on the available data and emerging evidence, methods to further enhance access to screening in African American and other groups with low screening rates should be endorsed. A meta-analysis reported that the most frequently adopted interventions among African American men were educational materials (39%), stool-based screening kits (14%), and patient navigation (11%). Interventions that were most effective at increasing rates of CRC screening completion were stool-based kits (OR, 9.60; 95%

CI, 2.89–31.82;  $P = .0002$ ) and patient navigation (OR, 2.84; 95% CI, 1.23–6.49;  $P = .01$ ).<sup>55</sup>

### High-Risk Genetic Syndromes with Predisposition to CRC

Individuals with a family history of Lynch syndrome (formerly known as HNPCC) or with a personal or family history of polyposis syndromes are considered to be in the high-risk category (see the [NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal](#)).

### Colorectal Cancer Screening (CSCR-3)

Current technology falls into two broad categories: structural tests and stool/fecal-based tests.<sup>56</sup> There is direct evidence from RCTs (discussed in detail below) that fecal occult blood testing (FOBT) and flexible sigmoidoscopy reduce CRC incidence and mortality by detecting and removing precancerous polyps at an early, curable stage. Colonoscopy is supported by case-control and cohort studies and has the potential ability to prevent CRC (with its associated morbidity) and cancer deaths.

In the United States, colonoscopy is the most commonly employed CRC screening test for average- and high-risk populations. However, multiple options exist, and the choice of modality should include consideration of patient preference and resource availability. In fact, screening completion rates are higher when FOBT is recommended or when a choice of FOBT or colonoscopy is given than when only colonoscopy is recommended (67% or 69% vs. 38%;  $P < .001$  for both).<sup>57</sup> Overall, although some techniques are better established than others, panelists agree that any screening is better than none. Results of a large population-based prospective study in Australia support this supposition; participants who had received screening by FOBT, sigmoidoscopy, or colonoscopy had a 44% lower risk of developing CRC (HR, 0.56; 95% CI, 0.49–0.63) compared with those who had never been screened.<sup>58</sup> A systematic review for the USPSTF similarly reported statistically significant benefits across



# NCCN Guidelines Version 1.2024

## Colorectal Cancer Screening

many forms of CRC screening (flexible sigmoidoscopy, FOBT, colonoscopy, fecal immunochemical test [FIT], CT colonography) when compared to no screening.<sup>59</sup>

CRC screening should be performed as part of a population-based program that includes a systematic method for: 1) identifying those who are eligible for and desire screening; 2) risk stratification and administration of the screening tests at agreed upon intervals; 3) shared decision-making with patients regarding the choice of screening method; 4) standardized reporting of the results; and 5) timely follow-up of those with a positive test. A CRC screening program should include a systematic method for arranging repeat screening and surveillance at appropriate intervals.

Organized screening programs that provide direct outreach to patients and clinic-focused interventions have been shown to increase CRC screening rates, reduce mortality, and minimize disparities by race/ethnicity.<sup>60-62</sup> Several randomized studies have provided evidence that offering different screening options to ensure testing characteristics are aligned with patient preferences may improve screening rates.<sup>57,63</sup> These evidence-based interventions may include mailed outreach, patient navigation, patient education and reminders, and clinician-directed feedback and alerts.<sup>62, 57,63</sup> Special attention should be given to certain patient characteristics (particularly to age <60 years, obesity, current smoking, and sedentary behavior) due to the association with non-participation in CRC screening programs as well as omitting doctor visits.<sup>64</sup>

### Screening Modalities (CSCR-A)

#### Structural Screening Tests

Structural screening tests detect adenomatous polyps and cancer using endoscopic or radiologic imaging. Endoscopic tests have several limitations, including their relative invasiveness, the need for dietary

preparation and bowel cleansing, and the time dedicated to the examination (typically a day). Endoscopic exams require informed consent and usually the need for sedation and have related risks including perforation and bleeding. A large cohort study of 53,220 Medicare patients between the ages of 66 to 95 years showed that the risks of adverse events after colonoscopy increase with age.<sup>65</sup>

#### Colonoscopy

Colonoscopy is the most complete screening procedure and is considered the current gold standard for assessing the sensitivity of detecting neoplasia for other screening modalities. The general consensus is that a 10-year interval is appropriate for most average-risk individuals who had a high-quality normal colonoscopy, defined as an exam complete to the cecum with bowel preparation adequate to detect polyps greater than 5 mm in size.<sup>66</sup> Although no RCTs directly demonstrate mortality reduction by colonoscopy, findings from case-control and cohort studies show significant impact of colonoscopy and polypectomy on decreasing CRC incidence and mortality.<sup>67-70</sup>

Interestingly, in a Canadian case-control study that matched each of the 10,292 individuals who died of CRC to five controls, colonoscopy was associated with lower mortality from distal CRC (adjusted conditional OR, 0.33; 95% CI, 0.28–0.39) but not proximal CRC (OR, 0.99; 95% CI, 0.86–1.14).<sup>71</sup> Additional studies have also demonstrated a reduced effectiveness in the right versus the left colon.<sup>72,73</sup> A population-based, case-control study in Germany demonstrated that colonoscopy in the preceding 10 years gave an overall 77% decrease in the risk for CRC.<sup>73</sup> However, while risk reduction was strongest for distal cancer, a 56% risk reduction was also seen for proximal disease. A case-control study using the SEER-Medicare database also found that colonoscopies are associated with a decrease in death from CRC, and the association was strongest for distal over proximal CRC.<sup>72,74</sup> Some of these findings of a





# NCCN Guidelines Version 1.2024

## Colorectal Cancer Screening

distal but not proximal risk reduction may be associated with variation in the quality of colonoscopy in alternative settings.

Analysis of two prospective cohorts (the Nurses' Health Study and the Health Professionals Follow-up Study) followed 88,902 participants for 22 years, comparing long-term outcomes in those who had screening colonoscopies, sigmoidoscopies, or no endoscopy.<sup>70</sup> Death from CRC was reduced after screening sigmoidoscopy (HR, 0.59; 95% CI, 0.45–0.76) and after screening colonoscopy (HR, 0.32; 95% CI, 0.24–0.45). However, mortality from proximal colon cancer was reduced after screening colonoscopy (HR, 0.47; 95% CI, 0.29–0.76) but not after sigmoidoscopy.

The impact of colonoscopy screening on CRC mortality has been investigated in studies that have evaluated the effects of colonoscopies with concurrent polypectomies. In the National Polyp Study, the mortality of 2602 patients with adenomas removed was compared to the incidence-based mortality from CRC in the SEER database.<sup>75</sup> With a median follow-up of 15.8 years, 12 deaths were attributed to CRC in the National Polyp Study group, compared with an expected 25.4 deaths in the general population, suggesting a 53% decrease in mortality.<sup>75</sup>

Another study estimated CRC mortality in 40,826 patients who underwent polypectomy in Norway.<sup>76</sup> Patients with high-risk adenomas were recommended for repeat colonoscopy in 10 years if they were <75 years of age or in 5 years if 3 or more adenomas were found. No further surveillance was recommended for patients with low-risk adenomas or those >74 years. As compared with expected CRC mortality rates in the general population, CRC mortality of patients with low-risk adenomas removed was lower (incidence-based standardized mortality ratio [SMR], 0.75; 95% CI, 0.63–0.88) after a mean follow-up of 7.7 years.<sup>76</sup> On the other hand, CRC mortality was increased in patients with high-risk adenomas removed (SMR, 1.16; 95% CI, 1.02–1.31), likely because these patients were predisposed to CRC and possibly because of the relatively

long 5-year screening interval recommended for these patients.<sup>76</sup> In addition to cancer prevention, colonoscopy screening is also expected to lead to earlier diagnosis. Supporting this supposition, a retrospective review of a prospective database compared 217 patients diagnosed with colon cancer through screening colonoscopy with 854 patients with colon cancer not diagnosed through screening.<sup>77</sup> Unscreened patients were at higher risk for more invasive tumors (RR, 1.96;  $P < .001$ ), nodal disease (RR, 1.92;  $P < .001$ ), and metastatic disease on presentation (RR, 3.37;  $P < .001$ ).<sup>77</sup> Furthermore, unscreened patients had higher rates of death and recurrence, shorter survival, and shorter disease-free intervals.

A meta-analysis of 14 RCTs and other controlled studies found that while endoscopic surveillance detected more advanced neoplasms than stool testing, its advantage was offset by a lower participation rate.<sup>78</sup> Interim results of the COLONPREV study, a randomized controlled study comparing one-time colonoscopy with biennial FIT (see discussion of FIT below) in asymptomatic adults aged 50 to 69 years, showed that the two tests identified similar numbers of cancers in initial screening, but colonoscopy identified significantly more advanced and non-advanced adenomas.<sup>79</sup> The data also showed that subjects were more likely to participate in FIT compared to colonoscopy screening (34.2% vs. 24.6%;  $P < .001$ ).<sup>79</sup> Subsequent analyses confirmed these observations.<sup>80</sup>

### Colorectal Cancer Screening Programs

An optimal screening program should have an interval during which there is a low likelihood of developing cancer, and it should be cost-effective based on the duration of risk reduction following an initial negative screen. The general consensus is that a 10-year interval is appropriate for most individuals (average risk) who had a complete colonoscopy procedure with an adequate bowel preparation, although a 1-year interval may be indicated depending on the completeness and quality of the



# NCCN Guidelines Version 1.2024

## Colorectal Cancer Screening

colonoscopy.<sup>66</sup> The panel emphasized the importance of family history in the screening scheme. Individual risk factors, the number or characteristics of polyps found, and physician judgment should also be included in the interval determination.

A 1996 study reported that 27% of individuals had adenomatous polyps identified on repeat colonoscopy a mean of 66 months after an initial negative colonoscopy, but none had colon cancer and only one of 154 individuals had a polyp greater than or equal to 1 cm.<sup>81</sup> These results suggest that an interval of repeat colonoscopy after an initial negative colonoscopy beyond 5 years is safe. Imperiale et al reported on 2436 individuals with no adenomatous polyps at baseline colonoscopy.<sup>82</sup> No cancers were found at rescreening at a mean of 5.3 years later. Adenomatous polyps were identified in 16% of individuals and only 1.3% had advanced adenomatous polyps. The authors recommended a rescreening interval of 5 years or longer. Lieberman and colleagues reported that advanced adenomatous polyps were found in only 2.4% of individuals on repeat colonoscopy within 5.5 years after a baseline normal colonoscopy.<sup>83</sup> In this study, individuals with 1 or 2 adenomatous polyps less than 1 cm at baseline also had a low rate of developing advanced neoplasia.

Singh et al also assessed the time that risk reduction persists after colonoscopy.<sup>84</sup> This study was a population-based retrospective analysis utilizing a physician billing claims database of individuals who had a negative screening colonoscopy. Patients in the surveillance cohort were compared to the general population regarding incidence of CRC. A negative colonoscopy was associated with a standardized incidence ratio (SIR) of 0.28 (95% CI, 0.09–0.65) at 10 years. A similar study calculated the adjusted RR for CRC among subjects with a previous negative colonoscopy.<sup>85</sup> The adjusted OR was 0.26 (95% CI, 0.16–0.40). The low risk was seen even if the colonoscopy had been performed up to 20 or

more years previously. The risk reduction seen following negative colonoscopy holds even for patients with a family history of CRC, but not for patients who currently smoke.<sup>86</sup>

In a population-based cohort study from a large community-based setting, Lee et al examined the risks of CRC and CRC-related death among colonoscopy patients with low- and high-risk adenomas, compared to patients with no adenoma.<sup>87</sup> With up to 14 years of follow-up, the high-risk adenoma group (n = 7563) had a higher risk of CRC (HR, 2.61; 95% CI, 1.87–3.63) and CRC-related death (HR, 3.94; 95% CI, 1.90–6.56) compared to the no-adenoma group (n = 45,881). However, the low-risk adenoma group (n = 10,978) did not have a significant increase in the risk of CRC (HR, 1.29; 95% CI, 0.89–1.88) or CRC-related death (HR, 0.65; 95% CI, 0.19–2.18).<sup>87</sup>

### *Colonoscopy Quality*

Recommendations made by the panel are based on the premise of complete, high-quality colonoscopies. The recommended priority quality indicators are: 1) the adenoma detection rate in asymptomatic individuals undergoing screening; 2) the frequency at which surveillance colonoscopies follow recommended post-polypectomy and post-cancer resection intervals; 3) the frequency with which 10-year intervals between screening colonoscopies are followed in average-risk patients with negative screens and adequate bowel preparation; and 4) the frequency with which visualization of the cecum is documented using notation and photodocumentation of landmarks.<sup>88</sup> Other suggested indicators include: 1) incidence of perforation; 2) management of post-polypectomy bleeding without surgery; 3) documentation of withdrawal time; 4) frequency of obtaining biopsies in individuals with diarrhea; 5) frequency of documentation of appropriate recommendation for interval colonoscopy; and 6) notification of the patient of this recommendation after review of histologic findings.<sup>88</sup> A European report on a screening program involving



# NCCN Guidelines Version 1.2024

## Colorectal Cancer Screening

more than 45,000 subjects confirmed that the endoscopist's rate of adenoma detection is an important predictor of the risk of interval CRC ( $P = .008$ ), highlighting the need for meticulous inspection of the large intestinal tract.<sup>89</sup> The study did not demonstrate statistical significance with cecal intubation rate, another widely recognized quality indicator. One explanation is that the importance of this factor is restricted to the ascending colon, which gives rise to a small number of cancer cases. Data analysis of almost 315,000 colonoscopies from an integrated health care delivery organization showed that higher adenoma detection rates were associated with lower rates of interval CRC (HR, 0.52; 95% CI, 0.39–0.69), advanced-stage interval CRC (HR, 0.43; 95% CI, 0.29–0.64), and fatal interval CRC (HR, 0.38; 95% CI, 0.22–0.65).<sup>90</sup> Furthermore, a recent meta-analysis reported that significantly higher colonoscopy volumes were associated with less adverse events and an increase in colonoscopy quality.<sup>91</sup> In an effort to enhance screening quality, the Quality Assurance Task Group of the National Colorectal Cancer Roundtable developed a standardized reporting system for colonoscopy.<sup>92</sup> These NCCN Guidelines list the common quality indicators of colonoscopy and minimum requirements of a colonoscopy report. Quality indicators, including withdrawal time and adenoma detection rate, are an important part of the fidelity of colonoscopy findings.<sup>90,93-95</sup> It should be noted that purposely seeking out polyps during colonoscopies may not significantly increase the polyp detection rate.<sup>96</sup> Several reports have shown that artificial intelligence assistance, if technologically feasible, may improve polyp and adenoma detection rates in colonoscopies.<sup>97-99</sup>

### *Bowel Preparation for Colonoscopy*

Split-dose preparation has been shown to be superior to the traditional regimen administered the day before colonoscopy and is therefore recommended.<sup>100-102</sup> The U.S. Multi-Society Task Force on Colorectal Cancer also recommends split preparation.<sup>66</sup>

The NCCN Panel and the U.S. Multi-Society Task Force agree that a same-day, morning-only regimen is an acceptable alternative, especially in patients undergoing afternoon procedures.<sup>103-105</sup>

### *Flexible Sigmoidoscopy*

Flexible sigmoidoscopy followed by colonoscopic polypectomy in patients with lesions greater than 1 cm significantly reduced mortality risk in early case-control studies.<sup>106,107</sup>

Evidence from RCTs has also demonstrated that flexible sigmoidoscopy reduces the incidence of and mortality from CRC.<sup>70,108-114</sup> The Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer screening group reported CRC mortality rates from its randomized, controlled flexible sigmoidoscopy screening trial, which screened more than 64,000 participants with flexible sigmoidoscopy and 59% of those participants a second time at 3 or 5 years.<sup>112-114</sup> A 26% reduction in deaths from CRC was seen in the screened group (RR, 0.74; 95% CI, 0.63–0.87;  $P < .001$ ), with a 50% reduction seen in mortality from distal disease and no effect on mortality from proximal disease.<sup>112</sup> This strong effect was seen despite an estimated 46% contamination rate of sigmoidoscopy or colonoscopy in the control arm, suggesting that the true benefit of screening is even greater.

The Norwegian Colorectal Cancer Prevention (NORCCAP) Study Group performed an RCT of one-time flexible sigmoidoscopy with or without a concurrent FOBT compared to a non-screened control group in more than 98,000 participants aged 55 to 64 years.<sup>109</sup> After 7 years of follow-up, the researchers reported no difference in the incidence of or mortality from CRC between screened and unscreened individuals. However, after 11 years of follow-up, the HR for death from CRC was 0.73 (95% CI, 0.56–0.94) in the screened groups.<sup>110</sup> Interestingly, the addition of FOBT did not affect the long-term outcomes of participants screened with sigmoidoscopy in this trial.



# NCCN Guidelines Version 1.2024

## Colorectal Cancer Screening

The SCORE trial randomized 34,272 subjects aged 55 to 64 years to one-time sigmoidoscopy or no screening and reported incidence and mortality results after greater than 10 years of median follow-up.<sup>111</sup> The intention-to-treat analysis demonstrated a 23% reduction in incidence and a 31% reduction in mortality. In addition, a randomized study examined the effect of flexible sigmoidoscopy offered once between age 55 and 64 years on CRC incidence and mortality.<sup>108</sup> Compared to the population that did not receive any screening, intention-to-treat analysis showed that intervention with flexible sigmoidoscopy decreased CRC incidence by 23% (HR, 0.77; 95% CI, 0.70–0.84) and CRC mortality by 31% (HR, 0.69; 95% CI, 0.59–0.82).<sup>108</sup> The benefit of one-time sigmoidoscopy demonstrating decreased CRC incidence and mortality was sustained after 17 years of follow-up.<sup>115</sup> Although more data are warranted to determine the implications of screening, it is worth noting that some studies suggest the long-term benefit of flexible sigmoidoscopy, in terms of decreased CRC incidence and mortality, may be more apparent in men and lower or undetectable in women.<sup>115,116</sup>

Meta-analyses of RCTs support the conclusion that screening by flexible sigmoidoscopy significantly reduces the incidence and mortality of CRC.<sup>117-120</sup> In addition, analysis of a 5% random Medicare sample of the SEER database found a similar reduction in distal CRC after both colonoscopy and sigmoidoscopy, with a reduction in proximal CRC after colonoscopy but not sigmoidoscopy.<sup>121</sup> A similar result was seen in a nested case-control study of four U.S. health plans in which the reduction of stage IIB or higher CRC was only seen in the distal colon.<sup>122</sup>

Compared to colonoscopy, sigmoidoscopy requires no sedation and less bowel preparation, but is limited to examination of the distal colon. An analysis of cancers not detected by flexible sigmoidoscopy in the PLCO trial showed that 37% of undetected lesions were beyond the reach of the sigmoidoscope.<sup>123</sup> The authors estimated that an additional 15% to 19% of

cancers may have been detected during screening had colonoscopy been used.

Flexible sigmoidoscopy should be performed using a scope 60 cm or longer. Polyps identified should be biopsied by trained personnel to determine if they are hyperplastic, adenomatous, or sessile serrated. Patients with lesions larger than 1 cm should be referred directly to colonoscopy, since these lesions are almost always adenomatous polyps or SSPs, which are associated with a risk of proximal colonic neoplasms.

### **Computed Tomographic Colonography**

CT colonography, also known as virtual colonoscopy or CTC, is evolving as a promising technique for CRC screening. CT colonography has the advantages of being noninvasive and not requiring sedation. The risk of test-related complications is also very low, and results of a systematic review suggest that CT colonography may be cost-effective when compared to colonoscopy.<sup>124</sup> However, a positive finding requires a colonoscopy, and extracolonic findings—which are present in up to 16% of patients—pose a dilemma.<sup>125,126</sup> These findings require further investigations and have a potential for both benefit and harm. At the present time, data to determine the clinical impact of these incidental findings are insufficient.

The accuracy of CT colonography in detecting polyps or cancers measuring 10 mm or more was assessed in the National CT Colonography Trial (ACRIN 6664) organized by the American College of Radiology (ACR) Imaging Network.<sup>127</sup> In this study, 2531 participants underwent CT colonography followed by traditional optical colonoscopy. Colonoscopy identified 128 large adenomatous polyps or carcinomas in 109 patients. CT colonography detected 90% of patients who had lesions measuring 10 mm or larger found by colonoscopy. There were also 30 lesions found on CT colonography, but not colonoscopy, for which 15 of 27 participants underwent a subsequent colonoscopy. Five of 18 lesions



# NCCN Guidelines Version 1.2024

## Colorectal Cancer Screening

were confirmed: 4 adenomatous polyps and 1 inflammatory polyp. The CT colonography performance in this study (sensitivity of 90% and specificity of 86%) was better than that reported from some earlier studies<sup>128,129</sup> and similar to what was reported by Pickhardt and colleagues in a prospective study with a design similar to the ACRIN trial.<sup>130</sup>

Kim et al also compared CT colonography with colonoscopy for the detection of advanced neoplasia.<sup>131</sup> Although this study was not randomized, the detection rates were comparable between the two groups of greater than 3100 patients each (3.2% for CT colonography and 3.4% for colonoscopy).

Furthermore, a small prospective study of 47 patients with pathologically proven lateral spreading tumors found that CT colonography may not be as sensitive as colonoscopy for detecting tumors with significant lateral spread.<sup>132</sup>

In 2005, two meta-analyses reviewed the performance of CT colonography in the detection of colorectal polyps.<sup>133,134</sup> In one of these studies, CT colonography showed high average sensitivity (93%) and specificity (97%) for polyps greater than or equal to 1 cm, both of which decreased to 86% when medium polyps (6–9 mm) were included in the analysis.<sup>133</sup> In the other meta-analysis, the sensitivity of CT colonography, although heterogeneous, improved as the polyp size increased (48% for polyps <6 mm, 70% for polyps 6–9 mm, and 85% for polyps >9 mm). The specificity was 92% to 97% for the detection of all the polyps.<sup>134</sup> Other studies have assessed growth rates of colorectal polyps (6–9 mm) using CT colonographic surveillance.<sup>135,136</sup> In a population-based CT colonography screening study, 93 individuals diagnosed with one or two polyps (6–9 mm) were examined with 3-year surveillance CT colonography to determine which polyps would progress to advanced adenomas.<sup>136</sup> Participants who had lesions greater than or equal to 6 mm were offered colonoscopy. With a mean surveillance interval of 3.3 years

(standard deviation [SD], 0.3; range, 3.0–4.6 years), 35% of the polyps progressed, 38% remained stable, and 27% regressed.<sup>136</sup> The study suggests that polyps that are 6 to 9 mm in size are unlikely to progress to advanced neoplasia within 3 years.<sup>136</sup> In a longitudinal study screening of 22,006 asymptomatic individuals, 243 adults (mean age, 57.4 years) had 306 colorectal polyps (6–9 mm).<sup>135</sup> With a mean surveillance interval of 2.3 years (SD, 1.4; range, 1–7 years), 22% of the polyps progressed, 50% remained stable, and 28% regressed.<sup>135</sup> Volumetric assessment determined that histology-established advanced adenomas grew faster than non-advanced adenomas, and only 6% of the 6- to 9-mm polyps exceeded 10 mm at follow-up.<sup>135</sup>

Two additional meta-analyses were published in 2011. An analysis of 49 studies found the sensitivities for detection of CRC by colonography and colonoscopy to be 96.1% and 94.7%, respectively, with overlapping CIs.<sup>137</sup> Another analysis focused only on studies of average-risk participants and found the sensitivity and specificity of CT colonography for the detection of adenomas greater than or equal to 1 cm to be 87.9% and 97.6%, respectively.<sup>138</sup> In a systematic evidence review of trials from the USPSTF in 2021 (7 trials, n = 5328), the sensitivity and specificity to detect adenomas 10 mm or larger were 89% (95% CI, 0.83–0.96) and 94% (95% CI, 0.89–1.0), respectively.<sup>59</sup> Similarly, the sensitivity and specificity to detect adenomas 6 mm or larger were 86% (95% CI, 0.78–0.95) and 88% (95% CI, 0.83–0.95), respectively.<sup>59</sup>

Importantly, CT colonography may be a more acceptable option to many individuals. A randomized study compared participation rates when members of the general population were offered CRC screening by either colonoscopy or CT colonography.<sup>139</sup> Significantly more people accepted the invitation for CT colonography (34% vs. 22%). While colonoscopy had a greater diagnostic yield in screened participants, the yields were similar when determined per the invited population. A prospective study has



# NCCN Guidelines Version 1.2024

## Colorectal Cancer Screening

shown good sensitivity and specificity of laxative-free CT colonography for detecting lesions greater than or equal to 1 cm.<sup>140</sup> This technique could present an alternative screening option to patients.

The technical aspects of CT colonography differ from study to study and have not been standardized. These details include the imaging, pre-procedure preparation, use of stool tagging, and expertise of the interpreter.<sup>141,142</sup> Long-term follow-up studies of patients who were screened by CT colonography are not yet available.

The issue of radiation exposure also requires consideration. The future risk related to undergoing a single CT colonography screening procedure is unknown but likely very low, and no empiric data have shown increased risk at levels below an exposure of 100 mSv.<sup>143</sup> Using the screening protocol for the ACRIN trial, Berrington de Gonzalez et al estimated the effective dose of low-dose CT colonography to be 9 mSv for women and 8 mSv for men, corresponding to 5 radiation-related cancer cases per 10,000 individuals undergoing one scan at 60 years of age.<sup>144</sup> Risks increase with repeated scanning. The 2014 ACR practice guidelines for the performance of CT colonography in adults recommend the use of a low-dose, non-enhanced CT technique on a multi-detector CT scanner to minimize radiation exposure to the patient.<sup>145</sup> Absorbed doses should not exceed 12.5 mGy total per scan.

Overall, available data indicate that CT colonography may be useful for the detection of larger polyps. Data on optimal frequency, polyp size leading to colonoscopy referral, and protocol for the evaluation of extracolonic lesions are evolving. If one or two lesions that are 6 to 9 mm are detected, CT colonography surveillance at year 3 or colonoscopy is recommended.<sup>135,136,146</sup> If more than three polyps that are 6 to 9 mm in size or lesions greater than or equal to 10 mm are detected, colonoscopy surveillance is recommended. The ACR has recommended that reporting of polyps less than or equal to 5 mm in size is not necessary.<sup>145</sup> However,

if polyps of this size are reported, the decision to refer for colonoscopy with polypectomy versus surveillance CT colonography should be individualized.

### Fecal-Based Screening Tests

Fecal-based tests are designed to detect signs of CRC in stool samples, specifically occult blood or alterations in exfoliated DNA in combination with occult blood. In contrast to structural tests, they are noninvasive and no bowel clearance is necessary. However, stool tests are less likely to detect polyps for cancer prevention on single application. Also, sensitivity can be limited by inadequate specimen collection or suboptimal processing and interpretation.

If a stool-based screening test is positive, colonoscopy is indicated. To ensure adequate follow-up, a health care professional should coordinate testing so that the patient who has a positive result completes colonoscopy evaluation.

### Fecal Occult Blood Test

Two types of FOBTs are currently available: guaiac-based and immunochemical. Annual FOBT should not be performed in combination with colonoscopy in an average-risk patient. Any positive result on FOBT, however, should be followed up with colonoscopy. It is important for FOBT alone to be performed annually, because the sensitivity in detecting advanced adenomas in a single test is fairly low.

FOBT of a single specimen obtained at digital rectal examination (DRE) is not recommended due to exceptionally low sensitivity.<sup>147,148</sup> Unfortunately, a survey of over 1000 primary care physicians revealed that inappropriate in-office testing is still widely used (25% used in-office testing only and 53% used both in-office and home testing), suggesting the need for strengthened education.<sup>149</sup>



# NCCN Guidelines Version 1.2024

## Colorectal Cancer Screening

### **Guaic FOBT**

Based on the pseudoperoxidase activity of heme in human blood, guaiac FOBT is the most common stool test in use for CRC screening. One major disadvantage of guaiac FOBT is that it may miss tumors that bleed in smaller amounts, intermittently, or not at all. Another limitation is the high false-positive rate resulting from reaction with non-human heme in food and blood from the upper gastrointestinal (GI) tract. To compensate for intermittent limitations, guaiac FOBT should be performed on three successive stool specimens obtained while the patient adheres to a prescribed diet.

There is direct evidence from RCTs that low-sensitivity guaiac FOBTs reduce mortality from CRC.<sup>150-152</sup> In the Minnesota Colon Cancer Control Study, greater than 46,000 participants were randomized to receive guaiac FOBT annually, biennially, or not at all. The 13-year cumulative mortality from CRC per 1000 was 5.88 and 8.83 in the annual and unscreened groups, respectively; this 33% difference was statistically significant.<sup>152</sup> After 30-year follow-up, a CRC mortality benefit was seen in both the annual and biennial screening groups (RR for annual FOBT, 0.68; 95% CI, 0.56–0.82; RR for biennial FOBT, 0.78; 95% CI, 0.65–0.93).<sup>153</sup> In addition, long-term follow-up of the Nottingham trial showed that individuals randomized to the biennial guaiac FOBT screening arm had a 13% reduction in CRC mortality at a median follow-up of 19.5 years (95% CI, 3%–22%), despite a 57% participation rate. Following adjustment for non-compliance, the reduction in CRC mortality was estimated to be 18%.<sup>154</sup> This reduction in CRC mortality using low-sensitivity guaiac FOBTs has been confirmed by systematic review and meta-analysis of multiple studies.<sup>119,155</sup>

A systematic review of four RCTs involving more than 320,000 participants showed a 16% reduction in RR for CRC death with guaiac FOBT screening (95% CI, 0.78–0.90).<sup>155</sup> Another meta-analysis came to a similar

conclusion, with guaiac FOBT screening reducing CRC mortality by 14% (RR, 0.86; 95% CI, 0.80–0.92).<sup>119</sup> The sensitivity of different guaiac FOBTs for cancer detection ranged from 37% to 79% in a study of about 8000 participants by Allison and colleagues.<sup>156</sup> In the UK National Health Service Bowel Cancer Screening Programme (BCSP), cancer was detected in 11.8% of individuals who had a colonoscopy following an abnormal or weak positive FOBT.<sup>157</sup> Adenomas were found in an additional 49.7% of participants.

The USPSTF defines high-sensitivity guaiac FOBT as a test with a sensitivity for cancer greater than 70% and a specificity greater than 90%.<sup>4</sup> Although high-sensitivity guaiac FOBTs that meet these criteria have not been tested in RCTs, some studies have shown that high-sensitivity guaiac FOBTs have higher CRC detection rates when compared to low-sensitivity guaiac FOBTs.<sup>156,158,159</sup> The NCCN CRC Screening Panel recommends that only high-sensitivity guaiac tests be used.

### **Fecal Immunochemical Test**

FIT, approved by the FDA in 2001, directly detects human globin within hemoglobin. Unlike guaiac FOBT, FIT does not require dietary restrictions, and a single testing sample is sufficient. In a systematic evidence review of trials from the USPSTF (14 trials, n = 45,403), the sensitivity and specificity of FIT to detect cancers was 74% and 94%, respectively.<sup>59</sup>

Comparative studies have shown that FIT is more sensitive than guaiac FOBT.<sup>159-164</sup> For example, one study demonstrated a higher sensitivity for cancer by FIT compared to a high-sensitivity guaiac FOBT (82% vs. 64%).<sup>159</sup> A Dutch randomized study also demonstrated higher detection rates of advanced neoplasia by FIT (2.4%) than guaiac FOBT (1.1%), although both were less sensitive for advanced neoplasia than flexible sigmoidoscopy (8.0%).<sup>161</sup> In addition, as seen in other trials, FIT had a significantly higher participation rate than guaiac FOBT in this trial. Following extensive literature analysis, an expert panel in Ontario



# NCCN Guidelines Version 1.2024

## Colorectal Cancer Screening

concluded that FIT is superior to guaiac FOBT in both participation rates and in detection of advanced adenomas and CRC.<sup>165</sup> Non-randomized studies have also shown that FIT screening reduces CRC mortality.<sup>166,167</sup> A large Taiwanese population-based study of 1,160,895 individuals aged 50 to 69 years were screened with 1 to 3 rounds of FIT and compared to an unscreened group. With a maximum follow-up of 6 years, there was a 10% decrease in CRC mortality in the FIT-screened population (RR, 0.90; 95% CI, 0.84–0.95).<sup>166</sup>

### ***FIT-DNA–Based or Multitarget Stool DNA Test***

One combined multitarget stool DNA (mt-sDNA) and occult blood test has emerged as an option for CRC screening. This test screens for the presence of known DNA alterations (*KRAS* mutations, aberrant *NDRG4* and *BMP3* methylation) during colorectal carcinogenesis in tumor cells sloughed into stool, as well as occult blood as measured by immunoassay. A study that included 9989 participants at average risk for CRC, each of whom underwent FIT, mt-sDNA testing, and a colonoscopy, found that the mt-sDNA test was more sensitive than FIT in the detection of CRC (92.3% vs. 73.8%;  $P = .002$ ), advanced precancerous lesions (42.4% vs. 23.8%;  $P < .001$ ), polyps with high-grade dysplasia (69.2% vs. 46.2%;  $P = .004$ ), and SSPs greater than 1 cm (42.4% vs. 5.1%;  $P < .001$ ).<sup>168</sup> However, FIT had significantly higher specificity than the mt-sDNA test (94.9% vs. 86.6% respectively, among participants with non-advanced or negative findings;  $P < .001$ ), and many more participants were excluded because of problems with mt-sDNA testing (689) than because of problems with FIT (34). The use of mt-sDNA testing is FDA approved for individuals of average risk only.

The NCCN CRC Screening Panel recommends the inclusion of mt-sDNA–based testing as a potential screening modality in average-risk individuals, but data to help determine adherence to/participation rates of screening and how mt-sDNA testing may fit into an overall screening program are

limited. A rescreening interval of every 3 years has been suggested and is approved by the FDA.<sup>3</sup> Using a clinical effectiveness model, one study showed that compared with a 10-year colonoscopy interval, annual mt-sDNA testing resulted in similar decreases in CRC incidence (65% vs. 63%) and mortality (73% vs. 72%).<sup>169</sup> At 3-year intervals, such testing was predicted to reduce CRC incidence and mortality by 57% and 67%, respectively. In addition, there are no or limited data in high-risk individuals who refuse colonoscopy or have limited access to conventional screening strategies;<sup>170</sup> therefore, the use of mt-sDNA–based testing should be individualized in these cases. If the colonoscopy is negative after a FIT or mt-sDNA and no additional symptoms are present, there is no need for further tests.

### ***Emerging Options***

Colon capsule endoscopy may be an alternative to currently approved modalities. A systematic review of 2485 patients in 13 studies reported that the CRC detection rate was 95% and no complications were described. The polyp detection rate was between 24% and 74%, with a sensitivity rate of 79% to 96% in polyps greater than 6 mm and 84% to 97% in polyps greater than or equal to 10 mm. Bowel preparation was adequate in 70% to 92% of examinations and completion rates were between 57% and 92%. Accuracy was reported to be comparable to colonoscopy and superior to CT colonography.<sup>171</sup>

Blood-based screening tests have also been evaluated. The methylation status of the septin9 (*SEPT9*) gene has been shown to distinguish CRC tissue from normal surrounding tissue, and circulating methylated *SEPT9* DNA in plasma is a biomarker for CRC.<sup>172-175</sup> A multicenter study compared the FIT test and a *SEPT9* DNA methylated blood test for CRC screening of 102 patients with identified CRC, and found that the specificity for CRC detection was higher for FIT (97.4% vs. 81.5%, respectively) but the sensitivity for CRC detection was not significantly different (68% vs.





# NCCN Guidelines Version 1.2024

## Colorectal Cancer Screening

73.3%, respectively).<sup>176</sup> Another clinical trial comparing the uptake of the methylated *SEPT9 DNA* blood-based test to FIT for CRC screening in 413 average-risk adults found that more participants took the blood test (99.5% vs. 88.1%;  $P < .001$ ).<sup>177</sup>

In 2016, a blood test that detects circulating methylated *SEPT9 DNA* was approved by the FDA and may provide an alternative for individuals who refuse other screening modalities. The sensitivity of the *SEPT9 DNA* test for the detection of CRC has been reported to be 68% with a specificity of 80%.<sup>178</sup> Factors that may potentially negatively impact the performance of the *SEPT9 DNA* test have been suggested, including early-stage disease, age >65 years, diabetes, arteriosclerosis, and arthritis.<sup>179</sup> Based on current data, the panel concludes that the interval for repeating testing is unclear; however, it will continue to review this strategy and monitor new, emerging data.

### Screening of Individuals at Average Risk (CSCR-3)

It is recommended that screening for persons at average risk begin at 45 years of age after available options have been discussed. Currently, recommended options include: colonoscopy every 10 years; annual high-sensitivity guaiac-based testing or FIT, or mt-sDNA–based testing (every 3 years); flexible sigmoidoscopy every 5 to 10 years; or CT colonography every 5 years.

If a colonoscopy is incomplete or preparation is suboptimal, consider either repeating colonoscopy within a year or screening with another modality.<sup>66</sup> Following a negative test, rescreening at the appropriate interval can be done with any accepted modality. Some data suggest that after one negative colonoscopy, following up with less invasive tests, such as annual fecal tests, provides approximately the same benefit with lower risks and costs than colonoscopy.<sup>180</sup>

Following a positive stool-based test, a colonoscopy within 6 to 12 months is recommended for additional evaluation. Although the data regarding an appropriate time frame for follow-up colonoscopy are limited, a large observational study evaluated whether time to colonoscopy after a positive FIT was associated with increased CRC risk.<sup>181</sup> The participants in this study included 70,124 CRC screening-eligible FIT-positive patients, aged 50 to 75 years, who had a follow-up colonoscopy. Compared to follow-up colonoscopy performed within 8 to 30 days, significantly higher risks for any CRC and advanced-stage disease were observed for examinations performed at 10 to 12 months and greater than 12 months.<sup>181</sup> A non-significant increase in any CRC risk and advanced-stage disease was observed beginning at 7 to 9 months.<sup>181</sup> The panel recommends that a negative colonoscopy after a FIT or mt-sDNA with no symptoms present warrants no further testing prior to the next recommended screening interval.

Alternative proposed strategies with flexible sigmoidoscopy include its use at an interval of every 10 years with an annual FIT, or flexible sigmoidoscopy at longer intervals without FIT.<sup>182</sup> Microsimulation modeling has found that flexible sigmoidoscopy every 5 years with an interval FOBT likely results in similar life-years gained as colonoscopy every 10 years.<sup>183</sup> A survival meta-analysis of four randomized trials<sup>108,110-112</sup> comparing screening with flexible sigmoidoscopy to no screening found that it takes up to 10 years after flexible sigmoidoscopy to attain an absolute reduction in mortality related to CRC.<sup>184</sup> Another microsimulation modeling study of a previously unscreened population undergoing CRC screening found that flexible sigmoidoscopy every 10 years with annual FIT offered similar life-years gained and comparable benefit as observed with colonoscopy every 10 years.<sup>182</sup>

The decision to screen between ages 76 to 85 years should be individualized, and include a discussion of the risks and benefits based on



# NCCN Guidelines Version 1.2024

## Colorectal Cancer Screening

comorbidity status and estimated life expectancy. Eligible individuals who have not been previously screened are most likely to benefit.

### Interpretation of Findings

Colonoscopy is indicated as follow-up of abnormal findings from other screening modalities—stool-based tests, flexible sigmoidoscopy (biopsy-proven adenoma), or CT colonography. During colonoscopy, any polyps found should be removed, and follow-up strategies should be based on the endoscopic and pathologic findings. Special attention should be paid to serrated polyps located in the ascending colon, as these tend to be associated with an increased rate of sporadic CRC with microsatellite instability (MSI)<sup>185</sup> and hence greater cancer risk that warrants additional surveillance. Ideally, all detected polyps should be removed, but this is not always possible. Removed polyps should be examined for degree of dysplasia, as well as for histologic features of SSPs.

### Adenoma/Adenomatous Polyps

Adenomas or adenomatous polyps (most often found to be tubular), the most common form of polyps, are associated with an increased risk for CRC, and patients with these polyps should be followed as described below (see *Screening of Individuals at Increased Risk*). Villous adenomatous polyps have a greater risk of harboring cancer and finding additional adenomatous polyps or cancer on follow-up.

### Sessile Serrated Polyps

According to the World Health Organization (WHO) criteria, there are three main subtypes of serrated polyps: SSPs, traditional serrated adenomas (TSAs), and hyperplastic polyps.<sup>186,187</sup> It is worth noting that the classification systems for serrated lesions are evolving, and a proposal by WHO suggests using the term sessile serrated lesions (SSLs).<sup>188</sup> SSPs, also known as sessile serrated adenomatous polyps, are a form of serrated polyps that have been associated with adenocarcinoma.<sup>189</sup> SSPs

are not dysplastic; however, they can develop foci of dysplasia and are then termed SSP with dysplasia (SSP-d). SSP-ds are thought to be the immediate precursors of high-frequency MSI sporadic CRC, and any dysplasia in an SSP is thought to be comparable to or more concerning than high-grade dysplasia in a conventional adenoma.<sup>187,190</sup> Thus, SSPs are managed like tubular adenomas, whereas SSP-ds are managed like high-risk adenomas.<sup>187,191-193</sup>

### Traditional Serrated Adenomas

An overall protuberant exophytic configuration, complex villous or tubulovillous growth pattern, and peculiar columnar cells with abundant eosinophilic cytoplasm characterize TSAs.<sup>187,194,195</sup> They are not as prevalent as SSPs in clinical studies,<sup>196-198</sup> and tend to be bulkier than SSPs.<sup>199</sup> Similar to SSPs, TSAs are associated with precancerous lesions.<sup>187</sup> Conventional adenoma-like and serrated dysplasia are observed in TSAs, and it is thought that TSAs increasingly acquire cytologic atypia before the development of CRC.<sup>187</sup> TSAs are managed like SSP-ds.

### Hyperplastic Polyps

Hyperplastic polyps are serrated polyps with normal crypt architecture and proliferative characteristics. A large body of literature indicates that hyperplastic polyps are not associated with a significantly increased risk for CRC, and supports the recommendation that persons with hyperplastic polyps be screened as average risk. Nevertheless, evidence suggests that some cancers with extensive DNA methylation and MSI might derive from hyperplastic polyps.<sup>200</sup> Furthermore, some studies suggest that a small subset of patients with multiple or large hyperplastic polyps have SPS, with a 26% to 70% risk for CRC (see *Serrated Polyposis Syndrome* in the [NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal](#)).<sup>201-203</sup> The majority of these patients had concomitant adenomatous polyps or SSP.<sup>204</sup> SPS is rarely reported to be inherited, and



# NCCN Guidelines Version 1.2024

## Colorectal Cancer Screening

the CRC risk for individuals with affected relatives remains unclear. Clinical criteria for serrated polyposis include: 1) 5 serrated lesions/polyps proximal to the rectum, all being 5 mm in size, with 2 being 10 mm in size; or 2) greater than 20 serrated lesions/polyps of any size distributed throughout the large bowel, with 5 being proximal to the rectum.<sup>188</sup>

There are conflicting data to suggest that hyperplastic polyp(s) (<1 cm) proximal to the sigmoid colon pose an increased risk and whether they should be managed differently.<sup>205,206</sup> An expert panel concluded that hyperplastic polyps greater than 5 mm occurring proximal to the sigmoid colon warrant a colonoscopy screening interval of 5 years.<sup>187</sup> In addition, when four or more hyperplastic polyps of any size are found proximal to the sigmoid colon, a 5-year colonoscopic screening interval is recommended.<sup>187</sup> Data to support these approaches are limited. There are conflicting and limited data to suggest whether individuals with hyperplastic polyps greater than 1 cm in size represent an increased risk group. Several analyses suggest that many of the larger polyps classified as hyperplastic in the past were re-classified as SSPs when reviewed by experts.<sup>206-210</sup> Therefore, it is reasonable to follow patients with hyperplastic polyps greater than or equal to 1 cm in size similarly to SSPs, especially if an expert GI pathologist has not reviewed them.

### Screening of Individuals at Increased Risk (CSCR-4)

#### Personal History of Polyps Found at Colonoscopy

Individuals with adenomatous polyps, SSPs, TSAs, or large hyperplastic polyps ( $\geq 1$  cm) are at increased risk for recurrent polyps and CRC. To minimize the risk of developing CRC, a surveillance program is recommended for these patients following colonoscopy and complete polypectomy.<sup>192</sup> The panel recommends surveillance colonoscopy in adults with a history of adenomas aged 45 to 75 years, who may have a life expectancy of 10 or more years. Surveillance of individuals between ages 76 and 85 years should be individualized and include a discussion of risks

and benefits of continued colonoscopy based on comorbidity status, estimated life expectancy, and finding on the last or most recent colonoscopy. For patients with completely resected adenomatous polyps, the surveillance schedule depends on the risk of recurrence, which in turn is related to the number, size, and histology of adenomatous polyps. Furthermore, when there is uncertainty about the completeness of removal in large and/or sessile polyps and when the colonic preparation was suboptimal, shorter surveillance intervals may be necessary.

Large cohort studies suggest that after removal of non-advanced adenomas and low-risk SSPs, there is not a significant increase in CRC risk and these patients may not require intensive surveillance.<sup>211,212</sup> Patients are considered to have low-risk adenomas when they have less than or equal to 2 tubular adenomas that are less than 1 cm. In this group, colonoscopy should be repeated between 7 to 10 years. Furthermore, patients are considered to have low-risk SSPs when they have less than or equal to 2 SSPs that are less than 1 cm without dysplasia. In this group, colonoscopy should be repeated in 5 years. In both cases, if this surveillance examination is normal, colonoscopy should be repeated every 10 years.<sup>192</sup> Any recommendations for a shorter interval should include a discussion with the individual based on an assessment of individual risk, including age, family history, comorbidities, and the results of previous colonoscopies.<sup>87,213-215</sup> If adenomas or SSPs are detected, a colonoscopy should be repeated according to clinical findings. Robertson et al reported on a study of 564 participants who had their first adenoma identified by colonoscopy and underwent two additional colonoscopies.<sup>216</sup> The study found that combining results of two prior colonoscopies can help predict the likelihood of high-risk findings (advanced adenomatous polyps or cancers) on the third screen. If no adenomas were found on the second exam, results of the first screening predicted results of the third. In this case, if the first colonoscopy showed only low-risk findings, then the chance of high-risk findings on the third colonoscopy was 4.9%, whereas



# NCCN Guidelines Version 1.2024

## Colorectal Cancer Screening

high-risk findings on the first colonoscopy gave a 12.3% risk of high-risk findings on the third colonoscopy ( $P = .015$ ).

The presence of a TSA, an adenoma with high-grade dysplasia or SSP-d, an adenoma/SSP greater than or equal to 1 cm, a polyp with villous or tubulovillous histology, or multiple (3–9) adenomatous polyps and/or SSPs or large ( $\geq 1$  cm) hyperplastic polyps have been associated with increased risk for CRC. High-grade dysplasia is defined as features of severe dysplasia (marked reduction of interglandular stromas with complex irregularity of glands, papillary infolding, and cytogenetic abnormalities) or severe architectural disturbance of glands along with cytologic features of dysplasia.<sup>217</sup> Carcinoma *in situ* is a term previously used by pathologists to describe colon polyps and cancer that has been replaced by the term *high-grade dysplasia*. A study by Golembeski and colleagues has shown that the identification of villous architecture and high-grade dysplasia is poorly reproducible among pathologists.<sup>218</sup> Studies reporting the association between polyp size and cancer risk have used 1 cm as the standard measure; data are lacking on the relative significance of intermediate-size adenomatous polyps (size 5–10 mm).

Individuals with high-risk polyps (advanced or multiple polyps) should have a repeat colonoscopy in 3 years, although some data suggest that intervals of 5 years may be appropriate. If the examination is normal, subsequent surveillance colonoscopies are recommended in 5 years. These intervals may be individualized based on the colonic preparation and completeness of polypectomy based on endoscopy, histology, and pathology reports.<sup>187,219</sup> It is appropriate to reassess risk, including contributing medical and personal factors, number and characteristics of adenomatous polyps, and family history at each interval prior to and following procedures.

In individuals with greater than 10 cumulative adenomatous polyps and/or SSPs, a polyposis syndrome should be considered (see *Assessment for*

*Hereditary CRC Syndrome* in the Discussion section of the [NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal](#)), although only a small fraction of those with no family history and low adenoma burden will have a defined hereditary syndrome. Genetic testing should be considered depending on patient age, the number of polyps, and family history. The cumulative presence of 10 polyps or fewer may occasionally be associated with an inherited polyposis syndrome, especially in patients <40 years of age or with a strong family history. Hence, a detailed family history is crucial in patients with multiple adenomatous polyps. Individual management is emphasized. A colonoscopy in one year is recommended. A repeat colonoscopy may be considered according to clinical findings.

In patients with greater than 20 cumulative adenomatous polyps and/or SSPs, individual management is emphasized and genetic testing should be considered for an inherited polyposis syndrome (see the [NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal](#)). Consider testing if 10 to 19 cumulative adenomas if other factors suggest the possibility of a polyposis/CRC syndrome such as age of onset or family or personal history of colorectal cancer. If the genetic testing result is negative or genetic testing is not done, the NCCN Panel recommends a repeat colonoscopy within 1 to 3 years. Frequency of surveillance may be modified based on factors such as age at which patient met cumulative adenoma threshold or total number of adenomas at most recent colonoscopy, with more frequent surveillance favored for younger age at meeting threshold or higher adenoma burden at last colonoscopy.

The [NCCN Guidelines for Colon Cancer](#) and the [NCCN Guidelines for Rectal Cancer](#) provide recommendations for management if a malignant polyp is found at colonoscopy.



# NCCN Guidelines Version 1.2024

## Colorectal Cancer Screening

### Management of Large Colorectal Polyps (CSCR-6)

The management of large polyps is challenging and may require surgical resection. For this reason, referral to a center with expertise in large polyp management or referral for surgical evaluation should be considered. Endoscopic resection, including polypectomy, endoscopic mucosal resection (EMR), and endoscopic submucosal dissection (ESD), is the preferred mode of intervention for large polyps.<sup>192,220</sup> However, one major limitation of endoscopic resection is its association with a high rate of recurrence, attributed to the presence of residual adenoma tissue at the time of resection.<sup>192,221</sup> Hence, frequent surveillance with colonoscopy is appropriate in this setting, particularly when the resection is suspected to be incomplete or was done in piecemeal fashion.<sup>192,222-224</sup> Also, because of this risk of recurrence and the not uncommon necessity of surgical resection, sessile polyps or large sessile lesions (LSLs) greater than or equal to 20 mm in size should have endoscopic tattoo placement next to the lesion.

For individuals with non-polypoid lesions or sessile colorectal polyps, evaluation for high-risk features of invasive cancer is necessary. A biopsy is recommended to determine if the cancer is invasive. For those with high-risk endoscopic features, but no invasive cancer, referral to a center of expertise for large polyp management or surgical evaluation should be considered. Those with invasive cancer should be followed according to the recommendations in the [NCCN Guidelines for Colon Cancer](#) and the [NCCN Guidelines for Rectal Cancer](#).

For patients with no high-risk features receiving complete resection, a follow-up colonoscopy is recommended in 1 to 3 years if no invasive cancer and no unfavorable risk factors for recurrence were found. Consider follow-up within 3 years when polyp(s) is greater than 2 cm or confidence of complete en bloc resection is low. Surveillance should be maintained in 3 years if no recurrence is found at the first surveillance

colonoscopy. If risk factors (LSL size  $\geq 40$  mm, intraprocedural bleeding requiring endoscopic control, high-risk dysplasia, or macroscopic tissue ablation performed)<sup>223</sup> for recurrence are associated with complete resection or a piecemeal resection is performed, follow-up with colonoscopy within 6 months is recommended. After complete resection and appropriate follow-up, if there is no disease recurrence, surveillance with colonoscopy within 1 year and subsequently in 3 years is appropriate. If the disease recurs, endoscopic therapy may be repeated. However, alternatively, and in the case of an incomplete resection, referral to a center with experience in endoscopic management of large colorectal polyps is recommended.

For individuals with pedunculated polyps, follow-up with colonoscopy in 3 years is recommended if there is no disease recurrence. If there is invasive cancer present, refer to the [NCCN Guidelines for Colon Cancer](#) and the [NCCN Guidelines for Rectal Cancer](#).

### Diagnosis of CRC (CSCR-7)

Individuals with a personal history of CRC should be followed according to the surveillance recommendations in the [NCCN Guidelines for Colon Cancer](#) and the [NCCN Guidelines for Rectal Cancer](#). These patients are at increased risk for recurrent adenomatous polyps and cancer. Studies have found a high recurrence rate in the 4 to 5 years following CRC resections.<sup>225-228</sup> In patients with rectal cancer, local recurrence at the rectal anastomosis has been reported to occur in 5% to 36% of patients.<sup>229-231</sup> Furthermore, an analysis of 3278 patients with resected stage II and III CRC in the Intergroup 0089 study found that the rate of second primary CRC is especially high in the immediate 5 years following surgery and adjuvant chemotherapy.<sup>232</sup> These results suggest that intense surveillance should be considered during that period, even though this analysis did not exclude patients with Lynch syndrome, who are at greater than 30% risk for synchronous and metachronous cancers.



# NCCN Guidelines Version 1.2024

## Colorectal Cancer Screening

The [NCCN Guidelines for Colon Cancer](#) and the [NCCN Guidelines for Rectal Cancer](#) recommend a complete colonoscopy preoperatively as well as at 1 year following surgery. If this examination is normal, colonoscopy should be repeated in 3 years, then every 5 years. Shorter intervals (1 year) are recommended if adenomatous polyps or SSPs are found. Subsequent colonoscopic intervals are individualized and generally should not exceed 5 years.

Advantages of more intensive follow-up of patients with stage II and/or stage III rectal cancer have been demonstrated prospectively in several studies<sup>226,233,234</sup> and in three meta-analyses of RCTs designed to compare low-intensity and high-intensity programs of surveillance.<sup>235-237</sup> Other studies impacting the issue of post-treatment CRC surveillance include results from an analysis of data from 20,898 patients enrolled in 18 large adjuvant colon cancer randomized trials.<sup>227</sup> The meta-analysis demonstrated that 80% of recurrences were in the first 3 years after surgical resection of the primary tumor. However, in the final analysis of Intergroup trial 0114, which compared bolus 5-FU to bolus 5-FU/LV in patients with surgically resectable rectal cancer, local recurrence rates continued to rise after 5 years.<sup>238</sup> Furthermore, a population-based report indicated that long-term survival is possible in patients treated for local recurrence of rectal cancer (overall 5-year relative survival rate of 15.6%), thereby providing support for more intensive post-treatment follow-up in these patients.<sup>239</sup> Nevertheless, controversies remain regarding selection of optimal strategies for following up patients after potentially curative CRC surgery.<sup>240,241</sup>

The NCCN Guidelines for Colorectal Cancer Screening recommend that patients with a personal history of CRC should routinely be tested for Lynch syndrome or mismatch repair (MMR) deficiency preferably at the time of diagnosis for all individuals with CRC (for the pros and cons of screening for Lynch syndrome using colonoscopy-based biopsies versus a

surgical resection specimen, see the [NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal](#)). The panel recommends universal screening of all CRC tumors to maximize sensitivity for identifying individuals with MMR deficiency and/or Lynch syndrome, and to inform prognosis and care processes in patients with and/or without Lynch syndrome. The panel recommends that tumor testing with immunohistochemistry (IHC) and/or MSI be used as the primary approach for pathology-lab-based universal screening and to guide treatment decisions. Testing for Lynch syndrome is discussed in more detail in the [NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal](#).

Based on a systematic review conducted by the USPSTF in 2022, the evidence on benefits of low-dose aspirin in reducing the risk of CRC incidence and mortality is limited.<sup>29</sup> Therefore, the USPSTF concluded that there is insufficient evidence that aspirin use reduces CRC incidence or mortality.<sup>30</sup> In contrast, there is some evidence suggesting the preventive benefit of aspirin on CRC in high-risk groups.<sup>242-245</sup> As new data emerge, consideration for recommending aspirin use for the primary prevention of CRC will need to be revisited.

### Personal History of Inflammatory Bowel Disease (CSCR-8)

It is well-recognized that individuals with a personal history of IBD (ie, ulcerative colitis, Crohn's colitis) are at an increased risk for CRC, because chronic inflammation can lead to dysplasia and subsequent malignant conversion.<sup>246-248</sup> Evidence shows that endoscopic surveillance can detect CRC at earlier stages in patients with extensive colitis, and that it may reduce the risk of death from CRC in these patients.<sup>249</sup> A retrospective review of 6823 patients with IBD found that the incidence of CRC in patients without a colonoscopy in the past 3 years was significantly higher than in those with a recent colonoscopy (2.7% vs. 1.6%; OR, 0.56; 95% CI, 0.39–0.80).<sup>250</sup> In addition, a colonoscopy within 6



# NCCN Guidelines Version 1.2024

## Colorectal Cancer Screening

to 36 months before CRC diagnosis was associated with reduced mortality (OR, 0.34; 95% CI, 0.12–0.95). Information regarding the value of endoscopic surveillance of long-standing Crohn's disease, on the other hand, is limited.

Risk factors for dysplasia in patients with IBD include ulcerative colitis, extensive colitis, colonic stricture, primary sclerosing cholangitis (PSC), family history of CRC (especially with diagnosis <50 years of age), personal history of dysplasia, and severe longstanding inflammation.<sup>246,251</sup> Confirmation of dysplasia by an expert GI pathologist is desirable. Patients with proctitis and proctosigmoiditis are likely at little or no increased risk of CRC compared with the general population and should be treated as having average risk.<sup>246,251</sup>

The NCCN Panel recommends colorectal surveillance by colonoscopy, initiated 8 years after the onset of symptoms in patients with a personal history of IBD involving the colon.<sup>252,253</sup> If PSC is present, annual surveillance colonoscopies should be started independent of the individual's time since symptom onset or colonoscopic findings and instead should be initiated at the time of PSC diagnosis. Family history of CRC is another important risk factor for developing CRC in patients with IBD, and such individuals may benefit from earlier initiation of colonoscopic surveillance.<sup>252,253</sup> A 2001 meta-analysis showed that patients with pancolitis have a higher risk of developing CRC than those with less extensive disease.<sup>254</sup>

Colonoscopic surveillance in patients with IBD should be performed during quiescent disease. Colonoscopic surveillance may be performed by chromoendoscopy with targeted biopsy.<sup>255-257</sup> Targeted biopsies have been found to improve detection of dysplasia and should be considered during surveillance chromoendoscopy where expertise is available.<sup>253,255-258</sup> With chromoendoscopy (dye spray or high-definition virtual) with targeted biopsies, consider taking two biopsies in every bowel segment, placed in

separate specimen jars, to document microscopic disease activity and extent of disease involvement.<sup>259,260</sup> Additional extensive sampling of strictures and masses is also recommended. Colonoscopic surveillance in IBD may also be performed with high-definition white light endoscopy (HD-WLE). Random four-quadrant biopsies every 10 cm with 32 or more samples should be taken for histologic examination. Linked color imaging (LCI) may be an alternative option to HD-WLE. A prospective trial reported no statistical difference in adenoma detection rate between LCI and HD-WLE.<sup>261</sup> If using standard-definition white light endoscopy (SD-WLE), performing the colonoscopy in conjunction with chromoendoscopy is recommended. If HD-WLE or chromoendoscopy is not available, the panel recommends referral to institutions with expertise in these modalities.

### Evaluation of Surveillance Findings in IBD (CSCR-9, 10)

Biopsies can be better targeted to abnormal-appearing mucosa using chromoendoscopy or confocal endomicroscopy, and several studies indicate increased sensitivity of chromoendoscopy in detecting dysplastic lesions; however, the natural history of these lesions is unclear.<sup>262</sup> Targeted biopsies should be performed of strictures and mass lesions. Lesions may be categorized using the Paris classification.<sup>255,263</sup> Dysplasia is classified as endoscopically visible and identified by resection or targeted biopsies or endoscopically invisible and detected by random biopsies.<sup>259</sup>

Patients with ulcerative colitis may develop sporadic colorectal adenomas at the same rate as the general population, and the appropriate management of adenomatous polyps in the setting of ulcerative colitis is dependent on various factors and should be based on individual risk factors such as duration of colitis, presence of dysplasia, and the number and size of adenomas. Lesions that appear endoscopically and histologically similar to a sporadic adenoma or SSP and without invasive carcinoma in the polyp may be managed by polypectomy. Some lesions



# NCCN Guidelines Version 1.2024

## Colorectal Cancer Screening

may require ESD or EMR techniques for complete resection. The confirmation of all polyp histology and dysplasia by an expert GI pathologist is desirable.

If invisible dysplasia (low- or high-grade) is detected or there are polypoid lesions or masses that are non-resectable, the patient should be referred to a surgeon with expertise in IBD to discuss potential surgical options. A surgical consultation may include a discussion about surveillance and colectomy based on multiple factors, including other visible dysplastic lesions in the same colon segment, histology, and a discussion with the patient about the risks and benefits of each approach. The presence of invisible dysplasia may be confirmed with chromoendoscopy, if this procedure has not already been performed. Given that invisible dysplasia is associated with increased risk for CRC,<sup>264,265</sup> if confirmed by an expert GI pathologist, a colectomy may be considered over intensified surveillance. When a single focus of low-grade dysplasia is found in patients with IBD, colectomy versus close colonoscopic surveillance may be discussed.

If dysplasia is detected, all endoscopically resectable lesions (eg, sessile/pedunculated polyp, nonpolypoid/flat lesion) should be removed.<sup>255,259</sup> Following endoscopic resection of visible lesions, consider taking a biopsy of surrounding mucosa to ensure complete removal. If chromoendoscopy is used, the yield of biopsies may be negligible. If complete endoscopic resection is feasible and patients present with low risk factors (ie, left-sided disease, hyperplastic or normal mucosa, no endoscopic or histologic active inflammation), surveillance colonoscopy should be performed in 2 to 3 years. During surveillance, if the patient has any high-risk factors (ie, PSC, extensive colitis, active inflammation, family history of CRC at <50 years of age, dysplasia), he or she should receive follow-up with colonoscopy 1 year after endoscopic resection.

Furthermore, if dysplastic lesions with high-grade dysplasia are detected

or if piecemeal resection was performed, follow-up with colonoscopy should be done within 3 to 6 months. If endoscopic resection is incomplete, the patient should be referred to either a center with expertise in IBD management or a surgeon with expertise in IBD. In addition, the patient may be further evaluated with chromoendoscopy assessment, if this procedure has not already been performed.

If no dysplasia is detected during surveillance (CSCR-10), and patients present with no endoscopic or histologic active inflammation, they can be considered to have low risk for CRC and undergo follow-up surveillance colonoscopy in 2 to 3 years.<sup>266,267</sup> Several GI societies' position statements recommend risk-stratified surveillance with an increased surveillance interval of 3 to 5 years in lowest risk patients.<sup>253</sup> However, if patients present with any of the following high-risk factors—PSC, active inflammation, or family history of CRC at <50 years of age—they may have increased risk for CRC and follow-up surveillance colonoscopy should be performed in 1 year.

Patients with traversable strictures should undergo follow-up surveillance colonoscopy in 1 year if surgery is not performed. In addition, referral to a center with expertise in IBD and consideration of chromoendoscopy assessment are recommended. Due to the risk of underlying CRC,<sup>268</sup> for patients with non-traversable or symptomatic strictures, especially in cases with long-standing IBD, the panel recommends referral to a surgeon with expertise in IBD to discuss potential surgical options.

### Increased Risk Based on Personal History of Cystic Fibrosis (CSCR-11)

Numerous reports show an increased risk of CRC in patients with CF,<sup>269-272</sup> and the increasing life expectancy of patients with CF is expected to increase the incidence of CRC in this population. The average age of onset of CRC in patients with CF is approximately 40 years, and the incidence of CRC in patients with CF aged 40 to 49 years is similar to that





# NCCN Guidelines Version 1.2024

## Colorectal Cancer Screening

of the general population aged 65 to 69 years.<sup>269,273</sup> The CRC risk stratification of a patient with CF is dependent on a history of solid organ transplant. A large population-based study involving the Cystic Fibrosis Foundation patient registry from 1990 to 1999 found that patients with CF who underwent transplant had a higher incidence of digestive tract tumors (SIR, 6.3; 95% CI, 3.4–10.8).

The NCCN Panel recommends that, in patients with a history of solid organ transplant, surveillance should be initiated at  $\geq 30$  years of age or within 2 years of the transplantation. In patients with no history of solid organ transplant, initiation of surveillance should begin at  $\geq 40$  years of age. Surveillance methodology involves colonoscopies with intensive bowel preparation specific for patients with CF, because standard colonoscopy bowel preparation is often inadequate.<sup>274</sup> If the colonoscopy returns no findings, a colonoscopy should be repeated every 5 years. If the colonoscopy reports adenomatous polyps, a colonoscopy should be repeated every 3 years.

### Increased Risk Based on Positive Family History (CSCR-12)

Patients not meeting criteria for consideration of a hereditary cancer syndrome or if appropriate testing for a hereditary cancer syndrome rules it out or is not done should have their individualized risk based on family history. It is recommended that risk assessment be individualized and include a careful family history to determine whether a familial clustering of cancers is present in the extended family. Family history is one of the most important risk factors for CRC. It is essential to obtain a detailed family history including first-degree relatives (parents, siblings, and offspring), second-degree relatives (aunts, uncles, grandparents, and half-siblings), and additional relatives (cousins, great-grandparents, nieces, and nephews). Grandchildren are often not old enough to manifest any of the clinical phenotypes of cancer syndromes.

For each of the relatives, current age and age at diagnosis of any cancer as well as a date, age, cause of death, and availability of a tumor sample are very important for discerning whether relatives were at risk for developing cancer, how long they were at risk, and what type of cancer they had. It is particularly important to note the occurrence of multiple primary tumors. Other inherited conditions and birth defects should be included in this family history. Ethnicity and country of origin are also important. The ASCO Cancer Genetics Subcommittee has provided guidance for taking and interpreting a family history that discusses barriers to accuracy in the process.<sup>275</sup> For further details and guidance, also see the [NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal](#).

### Positive Family History

If a patient meets the criteria for an inherited colorectal syndrome (see the [NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal](#)), further risk evaluation and counseling, as outlined in the guidelines, is required. When any one of the revised Bethesda criteria<sup>276</sup> are met (listed in the [NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal](#)), the possibility of Lynch syndrome is suggested, and IHC staining of the four MMR proteins and/or MSI testing of the colon tumor of the youngest affected family member is warranted.

Other individuals with a family history of CRC have an increased risk for the disease themselves and should therefore undergo earlier and/or more frequent screenings.<sup>277-279</sup> If multiple distant relatives are affected, an evaluation for an inherited colorectal syndrome should be considered.<sup>280</sup> In cases in which testing for a hereditary syndrome is non-diagnostic or may not have been done, the panel's recommendations are as follows:

For patients with at least one affected first-degree relative with CRC at any age, colonoscopy is recommended every 5 years, beginning 10 years prior to the earliest diagnosis in the family, or by age 40 years at the latest.<sup>281</sup> If



# NCCN Guidelines Version 1.2024

## Colorectal Cancer Screening

colonoscopy is positive, follow-up colonoscopy should be based on findings.

Individuals with second- or third-degree relatives with CRC at any age are recommended to undergo colonoscopy every 10 years, beginning by age 45.<sup>282</sup> If colonoscopy is positive, follow-up should be based on colonoscopy findings.

Individuals with a first-degree relative with a confirmed history of advanced adenoma(s) (ie, high-grade dysplasia,  $\geq 1$  cm, villous or tubulovillous histology, TSA) or advanced SSPs (ie,  $\geq 1$  cm, any dysplasia) at any age should undergo colonoscopy at the relative's age of onset of adenoma or by age 40 years (whichever is earliest) with repeat colonoscopy every 5 to 10 years or based on findings. Endoscopists should add specific recommendations to reports for sharing of information with first-degree relatives when applicable.

Multiple ( $\geq 2$ ) negative colonoscopies may support stepwise lengthening of the colonoscopy interval in these individuals. Data suggesting an increased risk for CRC in this population are limited.<sup>283,284</sup> Colonoscopy intervals may be further modified based on personal and family history as well as on individual preferences. A population-based study analyzed more than 2 million individuals to determine RRs for the development of CRC depending on family history of CRC.<sup>277</sup> Results showed that some combinations of affected first-, second-, and third-degree relatives may increase risk sufficiently to alter screening guidelines from the recommendations listed above.

Factors that modify age to begin screening and colonoscopy intervals include: 1) age of individual undergoing screening; and 2) specifics of the family history, including number and age of onset of all affected relatives and/or whether relatives had an inciting cause such as IBD. A retrospective, population-based, case-control study showed that of 18,208

index patients diagnosed with CRC, the highest familial risk was found in first-degree relatives of index patients with CRC who were diagnosed prior to age 40 years (HR, 2.53; 95% CI, 1.7–3.79).<sup>285</sup> However, familial risk for CRC was increased in first-degree relatives regardless of the age of diagnosis of the index patient.<sup>285</sup> The PLCO trial evaluated the effect of family history on CRC risk after 55 years of age, when risk of early-onset cancer has passed, and found that subjects with 1 first-degree relative had a modest increase in risk for CRC incidence and mortality.<sup>286</sup> Individuals with greater than or equal to two first-degree relatives with CRC had continued increased risk in older age.<sup>286</sup>

Other factors that modify colonoscopy intervals include the size of the family, completeness of the family history, participation of family members in screening, and colonoscopy findings in family members.

### Increased Risk Based on Personal History of Childhood, Adolescent, and Young Adult Cancer (CSCR-13)

Therapy-associated polyposis is an acquired phenotype that presents years after exposure to chemotherapy and/or RT. If an individual has a cumulative incidence of greater than or equal to 10 GI polyps of any type (including adenoma, SSLs, or hamartomas) in the entire GI tract, has a history of systemic therapy and/or RT for a childhood or young adult cancer (specifically abdominopelvic RT and/or alkylating chemotherapy), and has completed multi-gene testing without an identified pathogenic variant, then a baseline upper endoscopy is indicated if polyposis is identified. Multi-gene testing should include all hereditary polyposis and CRC genes.<sup>287</sup> Pathogenic variants associated with adenomatous polyposis include, but are not limited to monoallelic pathogenic variants in *APC*, *GREM1*, *POLE*, *POLD1*, and *AXIN2*, and biallelic pathogenic variants in *MUTYH*, *NTHL1*, and *MSH3*. Additional surveillance recommendations on colonic adenomatous polyposis of unknown



# NCCN Guidelines Version 1.2024 Colorectal Cancer Screening

etiology can be found in the [NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal](#) on CPUE-1.

Individuals who received chemotherapy, RT (particularly to the abdominopelvic field [ie, abdomen, pelvis, spine]), or total body irradiation (regardless of dose, with or without chemotherapy) are at an increased risk for CRC. For patients with a history of chemotherapy only, a colonoscopy starting at 35 years of age or 10 years after chemotherapy (whichever occurs first) is recommended.<sup>288</sup> For patients that have a history of RT that included the abdominopelvic field or total body irradiation with or without chemotherapy, a colonoscopy starting at 30 years of age or 5 years after treatment (whichever occurs last) and repeating every 5 years is recommended.<sup>289</sup> For patients who have no history of chemotherapy or RT that included the abdominopelvic field, it is recommended to follow the average-risk screening guidelines, which entail receiving a colonoscopy starting at age 45 years and repeating every 10 years.<sup>289</sup>

Discussion  
update in  
progress



# NCCN Guidelines Version 1.2024

## Colorectal Cancer Screening

### References

1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. *CA Cancer J Clin* 2022;72:7-33. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/35020204>.
2. Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. *CA Cancer J Clin* 2008;58:130-160. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18322143>.
3. Rex DK, Johnson DA, Anderson JC, et al. American College of Gastroenterology guidelines for colorectal cancer screening 2009 [corrected]. *Am J Gastroenterol* 2009;104:739-750. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19240699>.
4. USPSTF. Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med* 2008;149:627-637. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18838716>.
5. Siegel RL, Miller KD, Goding Sauer A, et al. Colorectal cancer statistics, 2020. *CA Cancer J Clin* 2020. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32133645>.
6. Cheng L, Eng C, Nieman LZ, et al. Trends in colorectal cancer incidence by anatomic site and disease stage in the United States from 1976 to 2005. *Am J Clin Oncol* 2011;34:573-580. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21217399>.
7. Ansa BE, Coughlin SS, Alema-Mensah E, Smith SA. Evaluation of colorectal cancer incidence trends in the United States (2000-2014). *J Clin Med* 2018;7. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29385768>.
8. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. *CA Cancer J Clin* 2011;61:212-236. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21685461>.
9. Meester RG, Doubeni CA, Lansdorp-Vogelaar I, et al. Colorectal cancer deaths attributable to nonuse of screening in the United States. *Ann Epidemiol* 2015;25:208-213 e201. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25721748>.
10. Cancer screening - United States, 2010. *MMWR Morb Mortal Wkly Rep* 2012;61:41-45. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22278157>.
11. Sabatino SA, Thompson TD, White MC, et al. Cancer Screening Test Use-U.S., 2019. *Am J Prev Med* 2022;63:431-439. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/35469700>.
12. Meester RG, Doubeni CA, Zauber AG, et al. Public health impact of achieving 80% colorectal cancer screening rates in the United States by 2018. *Cancer* 2015. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25763558>.
13. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. *CA Cancer J Clin* 2017;67:7-30. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28055103>.
14. Levine O, Zbuk K. Colorectal cancer in adolescents and young adults: Defining a growing threat. *Pediatr Blood Cancer* 2019;66:e27941. Available at: <https://pubmed.ncbi.nlm.nih.gov/31348592/>.
15. U.S. National Library of Medicine-Key MEDLINE® Indicators. Available at: [http://www.nlm.nih.gov/bsd/bsd\\_key.html](http://www.nlm.nih.gov/bsd/bsd_key.html). Accessed July 24, 2014.
16. Giovannucci E. Modifiable risk factors for colon cancer. *Gastroenterol Clin North Am* 2002;31:925-943. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/12489270>.
17. World Cancer Research Fund/American Institute for Cancer Research. Diet, Nutrition, Physical Activity and Cancer: a Global Perspective.



# NCCN Guidelines Version 1.2024

## Colorectal Cancer Screening

Continuous Update Project Expert Report. 2018. Available at: <https://www.wcrf.org/dietandcancer>. Accessed March 19, 2020.

18. Kohler LN, Harris RB, Oren E, et al. Adherence to nutrition and physical activity cancer prevention guidelines and development of colorectal adenoma. *Nutrients* 2018;10. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30115827>.

19. Solans M, Chan DSM, Mitrou P, et al. A systematic review and meta-analysis of the 2007 WCRF/AICR score in relation to cancer-related health outcomes. *Ann Oncol* 2020;31:352-368. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32067678>.

20. Rezende LFM, Lee DH, Keum N, et al. Physical activity during adolescence and risk of colorectal adenoma later in life: results from the Nurses' Health Study II. *Br J Cancer* 2019;121:86-94. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31114018>.

21. IARC. Vitamin D and Cancer. IARC Working Group Report Volume 5, International Agency for research on Cancer. Lyon: 2008. Available at: <https://publications.iarc.fr/Book-And-Report-Series/Iarc-Working-Group-Reports/Vitamin-D-And-Cancer-2008>. Accessed March 24, 2020.

22. Koushik A, Hunter DJ, Spiegelman D, et al. Fruits, vegetables, and colon cancer risk in a pooled analysis of 14 cohort studies. *J Natl Cancer Inst* 2007;99:1471-1483. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/17895473>.

23. Michels KB, Edward G, Joshipura KJ, et al. Prospective study of fruit and vegetable consumption and incidence of colon and rectal cancers. *J Natl Cancer Inst* 2000;92:1740-1752. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/11058617>.

24. Karahalios A, English DR, Simpson JA. Weight change and risk of colorectal cancer: a systematic review and meta-analysis. *Am J Epidemiol* 2015;181:832-845. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25888582>.

25. Lauby-Secretan B, Scoccianti C, Loomis D, et al. Body fatness and cancer--Viewpoint of the IARC Working Group. *N Engl J Med* 2016;375:794-798. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27557308>.

26. Ligibel JA, Alfano CM, Courneya KS, et al. American Society of Clinical Oncology position statement on obesity and cancer. *J Clin Oncol* 2014;32:3568-3574. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25273035>.

27. Bouvard V, Loomis D, Guyton KZ, et al. Carcinogenicity of consumption of red and processed meat. *Lancet Oncol* 2015;16:1599-1600. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26514947>.

28. Johnston BC, Zeraatkar D, Han MA, et al. Unprocessed red meat and processed meat consumption: Dietary guideline recommendations from the Nutritional Recommendations (NutriRECS) Consortium. *Ann Intern Med* 2019;171:756-764. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31569235>.

29. Guirguis-Blake JM, Evans CV, Perdue LA, et al. Aspirin use to prevent cardiovascular disease and colorectal cancer: Updated evidence report and systematic review for the US Preventive Services Task Force. *JAMA* 2022;327:1585-1597. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/35471507>.

30. Force USPST, Davidson KW, Barry MJ, et al. Aspirin use to prevent cardiovascular disease: US Preventive Services Task Force recommendation statement. *JAMA* 2022;327:1577-1584. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/35471505>.

31. Bains SJ, Mahic M, Myklebust TA, et al. Aspirin as secondary prevention in patients with colorectal cancer: an unselected population-based study. *J Clin Oncol* 2016;34:2501-2508. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27247217>.

32. Ghaddaf AA, Aziz M, Alomari MS, et al. Influence of aspirin on prevention of colorectal cancer: an updated systematic review and meta-



# NCCN Guidelines Version 1.2024

## Colorectal Cancer Screening

analysis of randomized controlled trials. *Int J Colorectal Dis* 2021;36:1711-1722. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33682036>.

33. Ma S, Han T, Sun C, et al. Does aspirin reduce the incidence, recurrence, and mortality of colorectal cancer? A meta-analysis of randomized clinical trials. *Int J Colorectal Dis* 2021;36:1653-1666. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33594505>.

34. Veettil SK, Kew ST, Lim KG, et al. Very-low-dose aspirin and surveillance colonoscopy is cost-effective in secondary prevention of colorectal cancer in individuals with advanced adenomas: network meta-analysis and cost-effectiveness analysis. *BMC Gastroenterol* 2021;21:130. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33743605>.

35. McNeil JJ, Nelson MR, Woods RL, et al. Effect of aspirin on all-cause mortality in the healthy elderly. *N Engl J Med* 2018;379:1519-1528. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30221595>.

36. U.S. Department of Health and Human Services. *The Health Consequences of Smoking: 50 Years of Progress. A report of the Surgeon General*. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health. 2014. Available at: [https://www.cdc.gov/tobacco/data\\_statistics/sgr/50th-anniversary/index.htm](https://www.cdc.gov/tobacco/data_statistics/sgr/50th-anniversary/index.htm). Accessed March 20, 2020.

37. Chao A, Thun MJ, Jacobs EJ, et al. Cigarette smoking and colorectal cancer mortality in the cancer prevention study II. *J Natl Cancer Inst* 2000;92:1888-1896. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/11106680>.

38. Hannan LM, Jacobs EJ, Thun MJ. The association between cigarette smoking and risk of colorectal cancer in a large prospective cohort from the United States. *Cancer Epidemiol Biomarkers Prev* 2009;18:3362-3367. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/19959683>.

39. LoConte NK, Brewster AM, Kaur JS, et al. Alcohol and cancer: A statement of the American Society of Clinical Oncology. *J Clin Oncol*

2018;36:83-93. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29112463>.

40. LoConte NK, Gershenwald JE, Thomson CA, et al. Lifestyle modifications and policy implications for primary and secondary cancer prevention: Diet, exercise, sun safety, and alcohol reduction. *Am Soc Clin Oncol Educ Book* 2018;38:88-100. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30231343>.

41. Fedirko V, Tramacere I, Bagnardi V, et al. Alcohol drinking and colorectal cancer risk: an overall and dose-response meta-analysis of published studies. *Ann Oncol* 2011;22:1958-1972. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/21307158>.

42. Stoffel EM, Murphy CC. Epidemiology and mechanisms of the increasing incidence of colon and rectal cancers in young adults. *Gastroenterology* 2020;158:341-353. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31394082>.

43. Siegel RL, Miller KD, Fedewa SA, et al. Colorectal cancer statistics, 2017. *CA Cancer J Clin* 2017;67:177-193. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28248415>.

44. Ansa BE, Coughlin SS, Alema-Mensah E, Smith SA. Evaluation of colorectal cancer incidence trends in the United States (2000-2014). *J Clin Med* 2018;7:22. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29385768>.

45. Meester RGS, Peterse EFP, Knudsen AB, et al. Optimizing colorectal cancer screening by race and sex: Microsimulation analysis II to inform the American Cancer Society colorectal cancer screening guideline. *Cancer* 2018. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29846942>.

46. Peterse EFP, Meester RGS, Siegel RL, et al. The impact of the rising colorectal cancer incidence in young adults on the optimal age to start screening: Microsimulation analysis I to inform the American Cancer Society colorectal cancer screening guideline. *Cancer* 2018. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29846933>.



# NCCN Guidelines Version 1.2024

## Colorectal Cancer Screening

47. Wolf AMD, Fontham ETH, Church TR, et al. Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. *CA Cancer J Clin* 2018. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29846947>.

48. Kitahara CM, Berndt SI, de Gonzalez AB, et al. Prospective investigation of body mass index, colorectal adenoma, and colorectal cancer in the prostate, lung, colorectal, and ovarian cancer screening trial. *J Clin Oncol* 2013;31:2450-2459. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23715565>.

49. Luo W, Cao Y, Liao C, Gao F. Diabetes mellitus and the incidence and mortality of colorectal cancer: a meta-analysis of 24 cohort studies. *Colorectal Dis* 2012;14:1307-1312. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23046351>.

50. Lieberman DA, Williams JL, Holub JL, et al. Race, ethnicity, and sex affect risk for polyps >9 mm in average-risk individuals. *Gastroenterology* 2014;147:351-358; quiz e314-355. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24786894>.

51. Agrawal S, Bhupinderjit A, Bhutani MS, et al. Colorectal cancer in African Americans. *Am J Gastroenterol* 2005;100:515-523; discussion 514. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15743345>.

52. Lansdorp-Vogelaar I, Kuntz KM, Knudsen AB, et al. Contribution of screening and survival differences to racial disparities in colorectal cancer rates. *Cancer Epidemiol Biomarkers Prev* 2012;21:728-736. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22514249>.

53. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. *CA Cancer J Clin* 2012;62:10-29. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22237781>.

54. Montminy EM, Zhou M, Maniscalco L, et al. Trends in the incidence of early-onset colorectal adenocarcinoma among Black and White US residents aged 40 to 49 years, 2000-2017. *JAMA Netw Open* 2021;4:e2130433. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/34751760>.

55. Rogers CR, Matthews P, Xu L, et al. Interventions for increasing colorectal cancer screening uptake among African-American men: A systematic review and meta-analysis. *PLoS One* 2020;15:e0238354. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32936812>.

56. Burt RW. Colorectal cancer screening. *Curr Opin Gastroenterol* 2010;26:466-470. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20664346>.

57. Inadomi JM, Vijan S, Janz NK, et al. Adherence to colorectal cancer screening: a randomized clinical trial of competing strategies. *Arch Intern Med* 2012;172:575-582. Available at: <https://pubmed.ncbi.nlm.nih.gov/22493463/>.

58. Steffen A, Weber MF, Roder DM, Banks E. Colorectal cancer screening and subsequent incidence of colorectal cancer: results from the 45 and Up Study. *Med J Aust* 2014;201:523-527. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25358576>.

59. Lin JS, Perdue LA, Henrikson NB, et al. Screening for colorectal cancer: Updated evidence report and systematic review for the US Preventive Services Task Force. *JAMA* 2021;325:1978-1998. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/34003220>.

60. Levin TR, Corley DA, Jensen CD, et al. Effects of Organized Colorectal Cancer Screening on Cancer Incidence and Mortality in a Large Community-Based Population. *Gastroenterology* 2018;155:1383-1391.e1385. Available at: <https://pubmed.ncbi.nlm.nih.gov/30031768/>.

61. Mehta SJ, Jensen CD, Quinn VP, et al. Race/ethnicity and adoption of a population health management approach to colorectal cancer screening in a community-based healthcare system. *J Gen Intern Med* 2016;31:1323-1330. Available at: <https://pubmed.ncbi.nlm.nih.gov/27412426/>.

62. Shah SK, Nakagawa M, Lieblong BJ. Examining aspects of successful community-based programs promoting cancer screening uptake to reduce cancer health disparity: A systematic review. *Prev Med* 2020;141:106242. Available at: <https://pubmed.ncbi.nlm.nih.gov/32882299/>.



# NCCN Guidelines Version 1.2024

## Colorectal Cancer Screening

63. Mehta SJ, Induru V, Santos D, et al. Effect of sequential or active choice for colorectal cancer screening outreach: A randomized clinical trial. *JAMA Netw Open* 2019;2:e1910305. Available at: <https://pubmed.ncbi.nlm.nih.gov/31469393/>.

64. Unanue-Arza S, Solis-Ibinagaitia M, Diaz-Seoane M, et al. Inequalities and risk factors related to non-participation in colorectal cancer screening programmes: a systematic review. *Eur J Public Health* 2021;31:346-355. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33313657>.

65. Warren JL, Klabunde CN, Mariotto AB, et al. Adverse events after outpatient colonoscopy in the Medicare population. *Ann Intern Med* 2009;150:849-857, W152. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19528563>.

66. Johnson DA, Barkun AN, Cohen LB, et al. Optimizing adequacy of bowel cleansing for colonoscopy: recommendations from the US multi-society task force on colorectal cancer. *Gastroenterology* 2014;147:903-924. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25239068>.

67. Brenner H, Chang-Claude J, Jansen L, et al. Reduced risk of colorectal cancer up to 10 years after screening, surveillance, or diagnostic colonoscopy. *Gastroenterology* 2014;146:709-717. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24012982>.

68. Jacob BJ, Moineddin R, Sutradhar R, et al. Effect of colonoscopy on colorectal cancer incidence and mortality: an instrumental variable analysis. *Gastrointest Endosc* 2012;76:355-364 e351. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22658386>.

69. Kahi CJ, Imperiale TF, Juliar BE, Rex DK. Effect of screening colonoscopy on colorectal cancer incidence and mortality. *Clin Gastroenterol Hepatol* 2009;7:770-775; quiz 711. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19268269>.

70. Nishihara R, Wu K, Lochhead P, et al. Long-term colorectal-cancer incidence and mortality after lower endoscopy. *N Engl J Med*

2013;369:1095-1105. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24047059>.

71. Baxter NN, Goldwasser MA, Paszat LF, et al. Association of colonoscopy and death from colorectal cancer. *Ann Intern Med* 2009;150:1-8. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19075198>.

72. Baxter NN, Warren JL, Barrett MJ, et al. Association between colonoscopy and colorectal cancer mortality in a US cohort according to site of cancer and colonoscopist specialty. *J Clin Oncol* 2012;30:2664-2669. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22689809>.

73. Brenner H, Chang-Claude J, Seiler CM, et al. Protection from colorectal cancer after colonoscopy: a population-based, case-control study. *Ann Intern Med* 2011;154:22-30. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21200035>.

74. Kahi CJ, Pohl H, Myers LJ, et al. Colonoscopy and colorectal cancer mortality in the Veterans Affairs health care system: A case-control study. *Ann Intern Med* 2018;168:481-488. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29532085>.

75. Zauber AG, Winawer SJ, O'Brien MJ, et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. *N Engl J Med* 2012;366:687-696. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22356322>.

76. Loberg M, Kalager M, Holme O, et al. Long-term colorectal-cancer mortality after adenoma removal. *N Engl J Med* 2014;371:799-807. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25162886>.

77. Amri R, Bordeianou LG, Sylla P, Berger DL. Impact of screening colonoscopy on outcomes in colon cancer surgery. *JAMA Surg* 2013;148:747-754. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23784448>.

78. Hassan C, Giorgi Rossi P, Camilloni L, et al. Meta-analysis: adherence to colorectal cancer screening and the detection rate for advanced





# NCCN Guidelines Version 1.2024

## Colorectal Cancer Screening

neoplasia, according to the type of screening test. Aliment Pharmacol Ther 2012;36:929-940. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/23035890>.

79. Quintero E, Castells A, Bujanda L, et al. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N Engl J Med 2012;366:697-706. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/22356323>.

80. Salas D, Vanaclocha M, Ibanez J, et al. Participation and detection rates by age and sex for colonoscopy versus fecal immunochemical testing in colorectal cancer screening. Cancer Causes Control 2014;25:985-997. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/24859111>.

81. Rex DK, Cummings OW, Helper DJ, et al. 5-year incidence of adenomas after negative colonoscopy in asymptomatic average-risk persons [see comment]. Gastroenterology 1996;111:1178-1181. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8898630>.

82. Imperiale TF, Glowinski EA, Lin-Cooper C, et al. Five-year risk of colorectal neoplasia after negative screening colonoscopy. N Engl J Med 2008;359:1218-1224. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/18799558>.

83. Lieberman DA, Weiss DG, Harford WV, et al. Five-year colon surveillance after screening colonoscopy. Gastroenterology 2007;133:1077-1085. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/17698067>.

84. Singh H, Turner D, Xue L, et al. Risk of developing colorectal cancer following a negative colonoscopy examination: evidence for a 10-year interval between colonoscopies. JAMA 2006;295:2366-2373. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/16720822>.

85. Brenner H, Chang-Claude J, Seiler CM, et al. Does a negative screening colonoscopy ever need to be repeated? Gut 2006;55:1145-1150. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16469791>.

86. Brenner H, Chang-Claude J, Seiler CM, Hoffmeister M. Long-term risk of colorectal cancer after negative colonoscopy. J Clin Oncol 2011;29:3761-3767. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/21876077>.

87. Lee JK, Jensen CD, Levin TR, et al. Long-term risk of colorectal cancer and related death after adenoma removal in a large, community-based population. Gastroenterology 2020;158:884-894 e885. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/31589872>.

88. Rex DK, Schoenfeld PS, Cohen J, et al. Quality indicators for colonoscopy. Am J Gastroenterol 2015;110:72-90. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/25448873>.

89. Kaminski MF, Regula J, Kraszewska E, et al. Quality indicators for colonoscopy and the risk of interval cancer. N Engl J Med 2010;362:1795-1803. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20463339>.

90. Corley DA, Jensen CD, Marks AR, et al. Adenoma detection rate and risk of colorectal cancer and death. N Engl J Med 2014;370:1298-1306. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24693890>.

91. Forbes N, Boyne DJ, Mazurek MS, et al. Association between endoscopist annual procedure volume and colonoscopy quality: Systematic review and meta-analysis. Clin Gastroenterol Hepatol 2020;18:2192-2208.e2112. Available at:

<https://pubmed.ncbi.nlm.nih.gov/32240836/>.

92. Lieberman D, Nadel M, Smith RA, et al. Standardized colonoscopy reporting and data system: report of the Quality Assurance Task Group of the National Colorectal Cancer Roundtable. Gastrointest Endosc 2007;65:757-766. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/17466195>.

93. Butterly L, Robinson CM, Anderson JC, et al. Serrated and adenomatous polyp detection increases with longer withdrawal time: results from the New Hampshire Colonoscopy Registry. Am J Gastroenterol 2014;109:417-426. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/24394752>.



# NCCN Guidelines Version 1.2024

## Colorectal Cancer Screening

94. Fayad NF, Kahi CJ. Quality measures for colonoscopy: a critical evaluation. *Clin Gastroenterol Hepatol* 2014;12:1973-1980. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24095973>.
95. Lee TJ, Blanks RG, Rees CJ, et al. Longer mean colonoscopy withdrawal time is associated with increased adenoma detection: evidence from the Bowel Cancer Screening Programme in England. *Endoscopy* 2013;45:20-26. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23254403>.
96. Chu Y, Zhang J, Wang P, et al. Will purposely seeking detect more colorectal polyps than routine performing during colonoscopy? *Medicine (Baltimore)* 2020;99:e22738. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33080734>.
97. Li J, Lu J, Yan J, et al. Artificial intelligence can increase the detection rate of colorectal polyps and adenomas: a systematic review and meta-analysis. *Eur J Gastroenterol Hepatol* 2021;33:1041-1048. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32804846>.
98. Luo Y, Zhang Y, Liu M, et al. Artificial intelligence-assisted colonoscopy for detection of colon polyps: A prospective, randomized cohort study. *J Gastrointest Surg* 2021;25:2011-2018. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32968933>.
99. Spadaccini M, Iannone A, Maselli R, et al. Computer-aided detection versus advanced imaging for detection of colorectal neoplasia: a systematic review and network meta-analysis. *Lancet Gastroenterol Hepatol* 2021;6:793-802. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/34363763>.
100. Enestvedt BK, Tofani C, Laine LA, et al. 4-Liter split-dose polyethylene glycol is superior to other bowel preparations, based on systematic review and meta-analysis. *Clin Gastroenterol Hepatol* 2012;10:1225-1231. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22940741>.
101. Gurudu SR, Ramirez FC, Harrison ME, et al. Increased adenoma detection rate with system-wide implementation of a split-dose preparation for colonoscopy. *Gastrointest Endosc* 2012;76:603-608 e601. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22732876>.
102. Kilgore TW, Abdinoor AA, Szary NM, et al. Bowel preparation with split-dose polyethylene glycol before colonoscopy: a meta-analysis of randomized controlled trials. *Gastrointest Endosc* 2011;73:1240-1245. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21628016>.
103. Longcroft-Wheaton G, Bhandari P. Same-day bowel cleansing regimen is superior to a split-dose regimen over 2 days for afternoon colonoscopy: results from a large prospective series. *J Clin Gastroenterol* 2012;46:57-61. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22064553>.
104. Matro R, Shnitser A, Spodik M, et al. Efficacy of morning-only compared with split-dose polyethylene glycol electrolyte solution for afternoon colonoscopy: a randomized controlled single-blind study. *Am J Gastroenterol* 2010;105:1954-1961. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20407434>.
105. Varughese S, Kumar AR, George A, Castro FJ. Morning-only one-gallon polyethylene glycol improves bowel cleansing for afternoon colonoscopies: a randomized endoscopist-blinded prospective study. *Am J Gastroenterol* 2010;105:2368-2374. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20606677>.
106. Newcomb PA, Norfleet RG, Storer BE, et al. Screening sigmoidoscopy and colorectal cancer mortality. *J Natl Cancer Inst* 1992;84:1572-1575. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1404450>.
107. Muller AD, Sonnenberg A. Prevention of colorectal cancer by flexible endoscopy and polypectomy. A case-control study of 32,702 veterans. *Ann Intern Med* 1995;123:904-910. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/7486484>.
108. Atkin WS, Edwards R, Kralj-Hans I, et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre



# NCCN Guidelines Version 1.2024

## Colorectal Cancer Screening

randomised controlled trial. *Lancet* 2010;375:1624-1633. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20430429>.

109. Hoff G, Grotmol T, Skovlund E, Bretthauer M. Risk of colorectal cancer seven years after flexible sigmoidoscopy screening: randomised controlled trial. *BMJ* 2009;338:b1846. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19483252>.

110. Holme O, Loberg M, Kalager M, et al. Effect of flexible sigmoidoscopy screening on colorectal cancer incidence and mortality: a randomized clinical trial. *JAMA* 2014;312:606-615. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25117129>.

111. Segnan N, Armaroli P, Bonelli L, et al. Once-only sigmoidoscopy in colorectal cancer screening: follow-up findings of the Italian Randomized Controlled Trial--SCORE. *J Natl Cancer Inst* 2011;103:1310-1322. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21852264>.

112. Schoen RE, Pinsky PF, Weissfeld JL, et al. Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. *N Engl J Med* 2012;366:2345-2357. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22612596>.

113. Weissfeld JL, Schoen RE, Pinsky PF, et al. Flexible sigmoidoscopy in the PLCO cancer screening trial: results from the baseline screening examination of a randomized trial. *J Natl Cancer Inst* 2005;97:989-997. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15998952>.

114. Weissfeld JL, Schoen RE, Pinsky PF, et al. Flexible sigmoidoscopy in the randomized prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial: added yield from a second screening examination. *J Natl Cancer Inst* 2012;104:280-289. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22298838>.

115. Atkin W, Wooldrage K, Parkin DM, et al. Long term effects of once-only flexible sigmoidoscopy screening after 17 years of follow-up: the UK Flexible Sigmoidoscopy Screening randomised controlled trial. *Lancet* 2017;389:1299-1311. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28236467>.

116. Holme O, Loberg M, Kalager M, et al. Long-term effectiveness of sigmoidoscopy screening on colorectal cancer incidence and mortality in women and men: A randomized trial. *Ann Intern Med* 2018;168:775-782. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29710125>.

117. Brenner H, Stock C, Hoffmeister M. Effect of screening sigmoidoscopy and screening colonoscopy on colorectal cancer incidence and mortality: systematic review and meta-analysis of randomised controlled trials and observational studies. *BMJ* 2014;348:g2467. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24922745>.

118. Elmunzer BJ, Hayward RA, Schoenfeld PS, et al. Effect of flexible sigmoidoscopy-based screening on incidence and mortality of colorectal cancer: a systematic review and meta-analysis of randomized controlled trials. *PLoS Med* 2012;9:e1001352. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23226108>.

119. Holme O, Bretthauer M, Fretheim A, et al. Flexible sigmoidoscopy versus faecal occult blood testing for colorectal cancer screening in asymptomatic individuals. *Cochrane Database Syst Rev* 2013;9:CD009259. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24085634>.

120. Shroff J, Thosani N, Batra S, et al. Reduced incidence and mortality from colorectal cancer with flexible-sigmoidoscopy screening: a meta-analysis. *World J Gastroenterol* 2014;20:18466-18476. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25561818>.

121. Wang YR, Cangemi JR, Loftus EV, Jr., Picco MF. Risk of colorectal cancer after colonoscopy compared with flexible sigmoidoscopy or no lower endoscopy among older patients in the United States, 1998-2005. *Mayo Clin Proc* 2013;88:464-470. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23522751>.

122. Doubeni CA, Weinmann S, Adams K, et al. Screening colonoscopy and risk for incident late-stage colorectal cancer diagnosis in average-risk adults: a nested case-control study. *Ann Intern Med* 2013;158:312-320. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23460054>.



# NCCN Guidelines Version 1.2024

## Colorectal Cancer Screening

123. Schoen RE, Pinsky PF, Weissfeld JL, et al. Colorectal cancers not detected by screening flexible sigmoidoscopy in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. *Gastrointest Endosc* 2012;75:612-620. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/22341106>.

124. Kriza C, Emmert M, Wahlster P, et al. An international review of the main cost-effectiveness drivers of virtual colonography versus conventional colonoscopy for colorectal cancer screening: is the tide changing due to adherence? *Eur J Radiol* 2013;82:e629-636. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/23938237>.

125. Kim DH, Pickhardt PJ, Taylor AJ, Menias CO. Imaging evaluation of complications at optical colonoscopy. *Curr Probl Diagn Radiol* 2008;37:165-177. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/18502324>.

126. Whitlock EP, Lin JS, Liles E, et al. Screening for colorectal cancer: a targeted, updated systematic review for the U.S. Preventive Services Task Force. *Ann Intern Med* 2008;149:638-658. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/18838718>.

127. Johnson CD, Chen MH, Toledano AY, et al. Accuracy of CT colonography for detection of large adenomas and cancers. *N Engl J Med* 2008;359:1207-1217. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/18799557>.

128. Johnson CD, Toledano AY, Herman BA, et al. Computerized tomographic colonography: performance evaluation in a retrospective multicenter setting. *Gastroenterology* 2003;125:688-695. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/12949715>.

129. Rockey DC, Paulson E, Niedzwiecki D, et al. Analysis of air contrast barium enema, computed tomographic colonography, and colonoscopy: prospective comparison. *Lancet* 2005;365:305-311. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/15664225>.

130. Pickhardt PJ, Choi JR, Hwang I, et al. Computed tomographic virtual colonoscopy to screen for colorectal neoplasia in asymptomatic adults. *N*

*Engl J Med* 2003;349:2191-2200. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/14657426>.

131. Kim DH, Pickhardt PJ, Taylor AJ, et al. CT colonography versus colonoscopy for the detection of advanced neoplasia. *N Engl J Med* 2007;357:1403-1412. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/17914041>.

132. Togashi K, Utano K, Kijima S, et al. Laterally spreading tumors: limitations of computed tomography colonography. *World J Gastroenterol* 2014;20:17552-17557. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/25516670>.

133. Halligan S, Altman DG, Taylor SA, et al. CT colonography in the detection of colorectal polyps and cancer: systematic review, meta-analysis, and proposed minimum data set for study level reporting. *Radiology* 2005;237:893-904. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/16304111>.

134. Mulhall BP, Veerappan GR, Jackson JL. Meta-analysis: computed tomographic colonography. *Ann Intern Med* 2005;142:635-650. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/15838071>.

135. Pickhardt PJ, Kim DH, Pooler BD, et al. Assessment of volumetric growth rates of small colorectal polyps with CT colonography: a longitudinal study of natural history. *Lancet Oncol* 2013;14:711-720. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/23746988>.

136. Tutein Nolthenius CJ, Boellaard TN, de Haan MC, et al. Evolution of screen-detected small (6-9 mm) polyps after a 3-year surveillance interval: Assessment of growth with CT colonography compared With histopathology. *Am J Gastroenterol* 2015;110:1682-1690. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/26482858>.

137. Pickhardt PJ, Hassan C, Halligan S, Marmo R. Colorectal cancer: CT colonography and colonoscopy for detection--systematic review and meta-analysis. *Radiology* 2011;259:393-405. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/21415247>.



# NCCN Guidelines Version 1.2024

## Colorectal Cancer Screening

138. de Haan MC, van Gelder RE, Graser A, et al. Diagnostic value of CT-colonography as compared to colonoscopy in an asymptomatic screening population: a meta-analysis. *Eur Radiol* 2011;21:1747-1763. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21455818>.

139. Stoop EM, de Haan MC, de Wijkerslooth TR, et al. Participation and yield of colonoscopy versus non-cathartic CT colonography in population-based screening for colorectal cancer: a randomised controlled trial. *Lancet Oncol* 2012;13:55-64. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22088831>.

140. Zalis ME, Blake MA, Cai W, et al. Diagnostic accuracy of laxative-free computed tomographic colonography for detection of adenomatous polyps in asymptomatic adults: a prospective evaluation. *Ann Intern Med* 2012;156:692-702. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22586008>.

141. Fletcher JG, Chen MH, Herman BA, et al. Can radiologist training and testing ensure high performance in CT colonography? Lessons from the National CT Colonography Trial. *AJR Am J Roentgenol* 2010;195:117-125. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20566804>.

142. Lin OS. Computed tomographic colonography: hope or hype? *World J Gastroenterol* 2010;16:915-920. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20180228>.

143. Society HP. Radiation Risk in Perspective: Position Statement of the Health Physics Society. 2019. Available at: <http://hps.org/documents/radiationrisk.pdf>.

144. Berrington de Gonzalez A, Kim KP, Yee J. CT colonography: perforation rates and potential radiation risks. *Gastrointest Endosc Clin N Am* 2010;20:279-291. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20451817>.

145. ACR-SAR-SCBT-MR Practice Parameter for the Performance of Computed Tomography (CT) Colonography in Adults. 2014. Available at: [http://www.acr.org/~media/ACR/Documents/PGTS/guidelines/CT\\_Colonography.pdf](http://www.acr.org/~media/ACR/Documents/PGTS/guidelines/CT_Colonography.pdf). Accessed September, 2016.

146. Zalis ME, Barish MA, Choi JR, et al. CT colonography reporting and data system: a consensus proposal. *Radiology* 2005;236:3-9. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/15987959>.

147. Sox HC. Office-based testing for fecal occult blood: do only in case of emergency. *Ann Intern Med* 2005;142:146-148. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15657163>.

148. Collins JF, Lieberman DA, Durbin TE, Weiss DG. Accuracy of screening for fecal occult blood on a single stool sample obtained by digital rectal examination: a comparison with recommended sampling practice. *Ann Intern Med* 2005;142:81-85. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15657155>.

149. Nadel MR, Berkowitz Z, Klabunde CN, et al. Fecal occult blood testing beliefs and practices of U.S. primary care physicians: serious deviations from evidence-based recommendations. *J Gen Intern Med* 2010;25:833-839. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20383599>.

150. Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. *Lancet* 1996;348:1472-1477. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8942775>.

151. Kronborg O, Fenger C, Olsen J, et al. Randomised study of screening for colorectal cancer with faecal-occult-blood test. *Lancet* 1996;348:1467-1471. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8942774>.

152. Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. *N Engl J Med* 1993;328:1365-1371. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8474513>.

153. Shaikat A, Mongin SJ, Geisser MS, et al. Long-term mortality after screening for colorectal cancer. *N Engl J Med* 2013;369:1106-1114. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24047060>.



# NCCN Guidelines Version 1.2024

## Colorectal Cancer Screening

154. Scholefield JH, Moss SM, Mangham CM, et al. Nottingham trial of faecal occult blood testing for colorectal cancer: a 20-year follow-up. *Gut* 2012;61:1036-1040. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/22052062>.

155. Hewitson P, Glasziou P, Watson E, et al. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. *Am J Gastroenterol* 2008;103:1541-1549.

Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18479499>.

156. Allison JE, Tekawa IS, Ransom LJ, Adrain AL. A comparison of fecal occult-blood tests for colorectal-cancer screening. *N Engl J Med* 1996;334:155-159. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/8531970>.

157. Lee TJ, Clifford GM, Rajasekhar P, et al. High yield of colorectal neoplasia detected by colonoscopy following a positive faecal occult blood test in the NHS Bowel Cancer Screening Programme. *J Med Screen* 2011;18:82-86. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/21852700>.

158. Ahlquist DA, Sargent DJ, Loprinzi CL, et al. Stool DNA and occult blood testing for screen detection of colorectal neoplasia. *Ann Intern Med* 2008;149:441-450, W481. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/18838724>.

159. Allison JE, Sakoda LC, Levin TR, et al. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. *J Natl Cancer Inst* 2007;99:1462-1470. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/17895475>.

160. Faivre J, Dancourt V, Denis B, et al. Comparison between a guaiac and three immunochemical faecal occult blood tests in screening for colorectal cancer. *Eur J Cancer* 2012;48:2969-2976. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/22572481>.

161. Hol L, van Leerdam ME, van Ballegooijen M, et al. Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy.

*Gut* 2010;59:62-68. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/19671542>.

162. Park DI, Ryu S, Kim YH, et al. Comparison of guaiac-based and quantitative immunochemical fecal occult blood testing in a population at average risk undergoing colorectal cancer screening. *Am J Gastroenterol* 2010;105:2017-2025. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/20502450>.

163. Parra-Blanco A, Gimeno-Garcia AZ, Quintero E, et al. Diagnostic accuracy of immunochemical versus guaiac faecal occult blood tests for colorectal cancer screening. *J Gastroenterol* 2010;45:703-712. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/20157748>.

164. van Rossum LG, van Rijn AF, Laheij RJ, et al. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. *Gastroenterology* 2008;135:82-90.

Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18482589>.

165. Rabeneck L, Rumble RB, Thompson F, et al. Fecal immunochemical tests compared with guaiac fecal occult blood tests for population-based colorectal cancer screening. *Can J Gastroenterol* 2012;26:131-147.

Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22408764>.

166. Chiu HM, Chen SL, Yen AM, et al. Effectiveness of fecal immunochemical testing in reducing colorectal cancer mortality from the One Million Taiwanese Screening Program. *Cancer* 2015;121:3221-3229.

Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25995082>.

167. Giorgi Rossi P, Vicentini M, Sacchetti C, et al. Impact of screening program on incidence of colorectal cancer: A cohort study in Italy. *Am J Gastroenterol* 2015;110:1359-1366. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/26303133>.

168. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. *N Engl J Med* 2014;370:1287-1297. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/24645800>.



# NCCN Guidelines Version 1.2024

## Colorectal Cancer Screening

169. Berger BM, Schroy PC, 3rd, Dinh TA. Screening for colorectal cancer using a multitarget stool DNA test: modeling the effect of the intertest interval on clinical effectiveness. *Clin Colorectal Cancer* 2016;15:e65-74. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26792032>.

170. Redwood DG, Asay ED, Blake ID, et al. Stool DNA testing for screening detection of colorectal neoplasia in Alaska Native people. *Mayo Clin Proc* 2016;91:61-70. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26520415>.

171. Vuik FER, Nieuwenburg SAV, Moen S, et al. Colon capsule endoscopy in colorectal cancer screening: a systematic review. *Endoscopy* 2021;53:815-824. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33440442>.

172. Ahmed D, Danielsen SA, Aagesen TH, et al. A tissue-based comparative effectiveness analysis of biomarkers for early detection of colorectal tumors. *Clin Transl Gastroenterol* 2012;3:e27. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23324654>.

173. deVos T, Tetzner R, Model F, et al. Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. *Clin Chem* 2009;55:1337-1346. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/19406918>.

174. Lofton-Day C, Model F, Devos T, et al. DNA methylation biomarkers for blood-based colorectal cancer screening. *Clin Chem* 2008;54:414-423. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/18089654>.

175. Wasserkort R, Kalmar A, Valcz G, et al. Aberrant septin 9 DNA methylation in colorectal cancer is restricted to a single CpG island. *BMC Cancer* 2013;13:398. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23988185>.

176. Johnson DA, Barclay RL, Mergener K, et al. Plasma Septin9 versus fecal immunochemical testing for colorectal cancer screening: a prospective multicenter study. *PLoS One* 2014;9:e98238. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24901436>.

177. Liles EG, Coronado GD, Perrin N, et al. Uptake of a colorectal cancer screening blood test is higher than of a fecal test offered in clinic: A randomized trial. *Cancer Treatment and Research Communications* 2017;10:27-31. Available at: <http://www.sciencedirect.com/science/article/pii/S2468294216300181>.

178. Potter NT, Hurban P, White MN, et al. Validation of a real-time PCR-based qualitative assay for the detection of methylated SEPT9 DNA in human plasma. *Clin Chem* 2014;60:1183-1191. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24938752>.

179. Orntoft MB, Nielsen HJ, Orntoft TF, et al. Performance of the colorectal cancer screening marker Sept9 is influenced by age, diabetes and arthritis: a nested case-control study. *BMC Cancer* 2015;15:819. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26514170>.

180. Knudsen AB, Hur C, Gazelle GS, et al. Rescreening of persons with a negative colonoscopy result: results from a microsimulation model. *Ann Intern Med* 2012;157:611-620. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23128861>.

181. Corley DA, Jensen CD, Quinn VP, et al. Association between time to colonoscopy after a positive fecal test result and risk of colorectal cancer and cancer stage at diagnosis. *JAMA* 2017;317:1631-1641. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28444278>.

182. Knudsen AB, Zauber AG, Rutter CM, et al. Estimation of benefits, burden, and harms of colorectal cancer screening strategies: Modeling study for the US Preventive Services Task Force. *JAMA* 2016;315:2595-2609. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27305518>.

183. Zauber AG, Lansdorp-Vogelaar I, Knudsen AB, et al. Evaluating test strategies for colorectal cancer screening: a decision analysis for the U.S. Preventive Services Task Force. *Ann Intern Med* 2008;149:659-669. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18838717>.

184. Tang V, Boscardin WJ, Stijacic-Cenzer I, Lee SJ. Time to benefit for colorectal cancer screening: survival meta-analysis of flexible



# NCCN Guidelines Version 1.2024

## Colorectal Cancer Screening

sigmoidoscopy trials. *BMJ* 2015;350:h1662. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25881903>.

185. Hawkins NJ, Ward RL. Sporadic colorectal cancers with microsatellite instability and their possible origin in hyperplastic polyps and serrated adenomas. *J Natl Cancer Inst* 2001;93:1307-1313. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/11535705>.

186. Rosty C, Hewett DG, Brown IS, et al. Serrated polyps of the large intestine: current understanding of diagnosis, pathogenesis, and clinical management. *J Gastroenterol* 2013;48:287-302. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23208018>.

187. Rex DK, Ahnen DJ, Baron JA, et al. Serrated lesions of the colorectum: review and recommendations from an expert panel. *Am J Gastroenterol* 2012;107:1315-1329; quiz 1314, 1330. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/22710576>.

188. WHO Classification of Tumors Editorial Board. Digestive System Tumours: IARC Lyon, France; 2019:162-169.

189. Kalady MF. Sessile serrated polyps: an important route to colorectal cancer. *J Natl Compr Canc Netw* 2013;11:1585-1594. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24335690>.

190. Sheridan TB, Fenton H, Lewin MR, et al. Sessile serrated adenomas with low- and high-grade dysplasia and early carcinomas: an immunohistochemical study of serrated lesions "caught in the act". *Am J Clin Pathol* 2006;126:564-571. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16938659>.

191. Alvarez C, Andreu M, Castells A, et al. Relationship of colonoscopy-detected serrated polyps with synchronous advanced neoplasia in average-risk individuals. *Gastrointest Endosc* 2013;78:333-341 e331. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23623039>.

192. Lieberman DA, Rex DK, Winawer SJ, et al. Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer.

*Gastroenterology* 2012;143:844-857. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22763141>.

193. Salaria SN, Streppel MM, Lee LA, et al. Sessile serrated adenomas: high-risk lesions? *Hum Pathol* 2012;43:1808-1814. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22784922>.

194. Kim MJ, Lee EJ, Suh JP, et al. Traditional serrated adenoma of the colorectum: clinicopathologic implications and endoscopic findings of the precursor lesions. *Am J Clin Pathol* 2013;140:898-911. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24225759>.

195. Torlakovic EE, Gomez JD, Driman DK, et al. Sessile serrated adenoma (SSA) vs. traditional serrated adenoma (TSA). *Am J Surg Pathol* 2008;32:21-29. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/18162766>.

196. Gurudu SR, Heigh RI, De Petris G, et al. Sessile serrated adenomas: demographic, endoscopic and pathological characteristics. *World J Gastroenterol* 2010;16:3402-3405. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/20632442>.

197. Hetzel JT, Huang CS, Coukos JA, et al. Variation in the detection of serrated polyps in an average risk colorectal cancer screening cohort. *Am J Gastroenterol* 2010;105:2656-2664. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/20717107>.

198. Spring KJ, Zhao ZZ, Karamatic R, et al. High prevalence of sessile serrated adenomas with BRAF mutations: a prospective study of patients undergoing colonoscopy. *Gastroenterology* 2006;131:1400-1407. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/17101316>.

199. Hasegawa S, Mitsuyama K, Kawano H, et al. Endoscopic discrimination of sessile serrated adenomas from other serrated lesions. *Oncol Lett* 2011;2:785-789. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/22866127>.





# NCCN Guidelines Version 1.2024

## Colorectal Cancer Screening

200. Leggett BA, Devereaux B, Biden K, et al. Hyperplastic polyposis: association with colorectal cancer. *Am J Surg Pathol* 2001;25:177-184. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11176066>.

201. Chow E, Lipton L, Lynch E, et al. Hyperplastic polyposis syndrome: phenotypic presentations and the role of MBD4 and MYH. *Gastroenterology* 2006;131:30-39. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16831587>.

202. Rubio CA, Stemme S, Jaramillo E, Lindblom A. Hyperplastic polyposis coli syndrome and colorectal carcinoma. *Endoscopy* 2006;38:266-270. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16528654>.

203. Yeoman A, Young J, Arnold J, et al. Hyperplastic polyposis in the New Zealand population: a condition associated with increased colorectal cancer risk and European ancestry. *N Z Med J* 2007;120:U2827. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18264196>.

204. Ferrandez A, Samowitz W, DiSario JA, Burt RW. Phenotypic characteristics and risk of cancer development in hyperplastic polyposis: case series and literature review. *Am J Gastroenterol* 2004;99:2012-2018. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15447765>.

205. Li D, Liu L, Fevrier HB, et al. Increased risk of colorectal cancer in individuals with a history of serrated polyps. *Gastroenterology* 2020;159:502-511 e502. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32277950>.

206. Anderson JC, Robinson CM, Butterly LF. Increased risk of metachronous large serrated polyps in individuals with 5- to 9-mm proximal hyperplastic polyps: data from the New Hampshire Colonoscopy Registry. *Gastrointest Endosc* 2020;92:387-393. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32348745>.

207. Anderson JC, Lisovsky M, Greene MA, et al. Factors associated with classification of hyperplastic polyps as sessile serrated adenomas/polyps on morphologic review. *J Clin Gastroenterol* 2018;52:524-529. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28723863>.

208. Kim SW, Cha JM, Lee JI, et al. A significant number of sessile serrated adenomas might not be accurately diagnosed in daily practice. *Gut Liver* 2010;4:498-502. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/21253298>.

209. Obuch JC, Pigott CM, Ahnen DJ. Sessile serrated polyps: detection, eradication, and prevention of the evil twin. *Curr Treat Options Gastroenterol* 2015;13:156-170. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25623474>.

210. Singh H, Bay D, Ip S, et al. Pathological reassessment of hyperplastic colon polyps in a city-wide pathology practice: implications for polyp surveillance recommendations. *Gastrointest Endosc* 2012;76:1003-1008. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23078924>.

211. Cottet V, Jooste V, Fournel I, et al. Long-term risk of colorectal cancer after adenoma removal: a population-based cohort study. *Gut* 2012;61:1180-1186. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/22110052>.

212. He X, Hang D, Wu K, et al. Long-term risk of colorectal cancer after removal of conventional adenomas and serrated polyps. *Gastroenterology* 2020;158:852-861 e854. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31302144>.

213. Dube C, Yakubu M, McCurdy BR, et al. Risk of advanced adenoma, colorectal cancer, and colorectal cancer mortality in people with low-risk adenomas at baseline colonoscopy: A systematic review and meta-analysis. *Am J Gastroenterol* 2017;112:1790-1801. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29087393>.

214. Click B, Pinsky PF, Hickey T, et al. Association of colonoscopy adenoma findings with long-term colorectal cancer incidence. *JAMA* 2018;319:2021-2031. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29800214>.

215. Lieberman D, Sullivan BA, Hauser ER, et al. Baseline colonoscopy findings associated with 10-year outcomes in a screening cohort



# NCCN Guidelines Version 1.2024

## Colorectal Cancer Screening

undergoing colonoscopy surveillance. *Gastroenterology* 2020;158:862-874 e868. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31376388>.

216. Robertson DJ, Burke CA, Welch HG, et al. Using the results of a baseline and a surveillance colonoscopy to predict recurrent adenomas with high-risk characteristics. *Ann Intern Med* 2009;151:103-109. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19620162>.

217. O'Brien MJ, Winawer SJ, Zauber AG, et al. The National Polyp Study. Patient and polyp characteristics associated with high-grade dysplasia in colorectal adenomas. *Gastroenterology* 1990;98:371-379. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/2403953>.

218. Golembeski C, McKenna B, Appelman HD. Advanced adenomas: Pathologists don't agree [abstract]. *Modern Pathology* 2007;20:115A. Available at: <http://www.nature.com/modpathol/journal/v20/n2s/pdf/3800805a.pdf>.

219. Brenner H, Chang-Claude J, Rickert A, et al. Risk of colorectal cancer after detection and removal of adenomas at colonoscopy: population-based case-control study. *J Clin Oncol* 2012;30:2969-2976. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22826281>.

220. Hassan C, Repici A, Sharma P, et al. Efficacy and safety of endoscopic resection of large colorectal polyps: a systematic review and meta-analysis. *Gut* 2016;65:806-820. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25681402>.

221. Walsh RM, Ackroyd FW, Shellito PC. Endoscopic resection of large sessile colorectal polyps. *Gastrointest Endosc* 1992;38:303-309. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1607080>.

222. Seo GJ, Sohn DK, Han KS, et al. Recurrence after endoscopic piecemeal mucosal resection for large sessile colorectal polyps. *World J Gastroenterol* 2010;16:2806-2811. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/20533602>.

223. Tate DJ, Desomer L, Klein A, et al. Adenoma recurrence after piecemeal colonic EMR is predictable: the Sydney EMR recurrence tool.

*Gastrointest Endosc* 2017;85:647-656 e646. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27908600>.

224. Moss A, Williams SJ, Hourigan LF, et al. Long-term adenoma recurrence following wide-field endoscopic mucosal resection (WF-EMR) for advanced colonic mucosal neoplasia is infrequent: results and risk factors in 1000 cases from the Australian Colonic EMR (ACE) study. *Gut* 2015;64:57-65. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24986245>.

225. Rex DK, Kahi CJ, Levin B, et al. Guidelines for colonoscopy surveillance after cancer resection: a consensus update by the American Cancer Society and US Multi-Society Task Force on Colorectal Cancer. *CA Cancer J Clin* 2006;56:160-167; quiz 185-166. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16737948>.

226. Rodriguez-Moranta F, Salo J, Arcusa A, et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. *J Clin Oncol* 2006;24:386-393. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16365182>.

227. Sargent DJ, Wieand HS, Haller DG, et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. *J Clin Oncol* 2005;23:8664-8670. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16260700>.

228. Shureiqi I, Cooksley CD, Morris J, et al. Effect of age on risk of second primary colorectal cancer. *J Natl Cancer Inst* 2001;93:1264-1266. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11504772>.

229. Hoffman JP, Riley L, Carp NZ, Litwin S. Isolated locally recurrent rectal cancer: a review of incidence, presentation, and management. *Semin Oncol* 1993;20:506-519. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8211198>.

230. Lowy AM, Rich TA, Skibber JM, et al. Preoperative infusional chemoradiation, selective intraoperative radiation, and resection for locally



# NCCN Guidelines Version 1.2024

## Colorectal Cancer Screening

advanced pelvic recurrence of colorectal adenocarcinoma. *Ann Surg* 1996;223:177-185. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/8597512>.

231. Yu TK, Bhosale PR, Crane CH, et al. Patterns of locoregional recurrence after surgery and radiotherapy or chemoradiation for rectal cancer. *Int J Radiat Oncol Biol Phys* 2008;71:1175-1180. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/18207667>.

232. Green RJ, Metlay JP, Propert K, et al. Surveillance for second primary colorectal cancer after adjuvant chemotherapy: an analysis of Intergroup 0089. *Ann Intern Med* 2002;136:261-269. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/11848723>.

233. Pietra N, Sarli L, Costi R, et al. Role of follow-up in management of local recurrences of colorectal cancer: a prospective, randomized study. *Dis Colon Rectum* 1998;41:1127-1133. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/9749496>.

234. Secco GB, Fardelli R, Gianquinto D, et al. Efficacy and cost of risk-adapted follow-up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. *Eur J Surg Oncol* 2002;28:418-423. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/12099653>.

235. Desch CE, Benson AB, Somerfield MR, et al. Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. *J Clin Oncol* 2005;23:8512-8519. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/16260687>.

236. Jeffery M, Hickey BE, Hider PN. Follow-up strategies for patients treated for non-metastatic colorectal cancer. *Cochrane Database Syst Rev* 2007:CD002200. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/17253476>.

237. Renehan AG, Egger M, Saunders MP, O'Dwyer ST. Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials. *BMJ*

2002;324:813-813. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/11934773>.

238. Tepper JE, O'Connell M, Niedzwiecki D, et al. Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control--final report of intergroup 0114. *J Clin Oncol* 2002;20:1744-1750. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/11919230>.

239. Guyot F, Faivre J, Manfredi S, et al. Time trends in the treatment and survival of recurrences from colorectal cancer. *Ann Oncol* 2005;16:756-761. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15790673>.

240. Li Destri G, Di Cataldo A, Puleo S. Colorectal cancer follow-up: useful or useless? *Surg Oncol* 2006;15:1-12. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/16891116>.

241. Pfister DG, Benson AB, 3rd, Somerfield MR. Clinical practice. Surveillance strategies after curative treatment of colorectal cancer. *N Engl J Med* 2004;350:2375-2382. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/15175439>.

242. Ait Ouakrim D, Dashti SG, Chau R, et al. Aspirin, ibuprofen, and the risk of colorectal cancer in Lynch syndrome. *J Natl Cancer Inst* 2015;107. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26109217>.

243. Burn J, Gerdes AM, Macrae F, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. *Lancet* 2011;378:2081-2087. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/22036019>.

244. Movahedi M, Bishop DT, Macrae F, et al. Obesity, aspirin, and risk of colorectal cancer in carriers of hereditary colorectal cancer: A prospective investigation in the CAPP2 study. *J Clin Oncol* 2015;33:3591-3597. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26282643>.

245. Rothwell PM, Fowkes FG, Belch JF, et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. *Lancet* 2011;377:31-41. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/21144578>.



# NCCN Guidelines Version 1.2024

## Colorectal Cancer Screening

246. Beaugerie L, Svrcek M, Seksik P, et al. Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease. *Gastroenterology* 2013;145:166-175 e168. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23541909>.

247. Herszenyi L, Barabas L, Miheller P, Tulassay Z. Colorectal cancer in patients with inflammatory bowel disease: the true impact of the risk. *Dig Dis* 2015;33:52-57. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25531497>.

248. Lutgens MW, van Oijen MG, van der Heijden GJ, et al. Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies. *Inflamm Bowel Dis* 2013;19:789-799. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23448792>.

249. Collins PD, Mpofu C, Watson AJ, Rhodes JM. Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease. *Cochrane Database Syst Rev* 2006:CD000279. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16625534>.

250. Ananthakrishnan AN, Cagan A, Cai T, et al. Colonoscopy is associated with a reduced risk for colon cancer and mortality in patients with inflammatory bowel diseases. *Clin Gastroenterol Hepatol* 2014. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25041865>.

251. Lutgens M, Vermeire S, Van Oijen M, et al. A rule for determining risk of colorectal cancer in patients with inflammatory bowel disease. *Clin Gastroenterol Hepatol* 2015;13:148-154 e141. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25041864>.

252. Samadder NJ, Valentine JF, Guthery S, et al. Family history associates with increased risk of colorectal cancer in patients with inflammatory bowel diseases. *Clin Gastroenterol Hepatol* 2018. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30267862>.

253. Shergill AK, Farraye FA. Toward a consensus on endoscopic surveillance of patients with colonic inflammatory bowel disease.

*Gastrointest Endosc Clin N Am* 2014;24:469-481. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24975537>.

254. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. *Gut* 2001;48:526-535. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11247898>.

255. Laine L, Kaltenbach T, Barkun A, et al. SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease. *Gastroenterology* 2015;148:639-651 e628. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25702852>.

256. Murthy SK, Kiesslich R. Evolving endoscopic strategies for detection and treatment of neoplastic lesions in inflammatory bowel disease. *Gastrointest Endosc* 2013;77:351-359. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23317581>.

257. Picco MF, Pasha S, Leighton JA, et al. Procedure time and the determination of polypoid abnormalities with experience: implementation of a chromoendoscopy program for surveillance colonoscopy for ulcerative colitis. *Inflamm Bowel Dis* 2013;19:1913-1920. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23811635>.

258. Neumann H, Vieth M, Langner C, et al. Cancer risk in IBD: how to diagnose and how to manage DALM and ALM. *World J Gastroenterol* 2011;17:3184-3191. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/21912466>.

259. American Society for Gastrointestinal Endoscopy Standards of Practice C, Shergill AK, Lightdale JR, et al. The role of endoscopy in inflammatory bowel disease. *Gastrointest Endosc* 2015;81:1101-1121 e1101-1113. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25800660>.

260. Mowat C, Cole A, Windsor A, et al. Guidelines for the management of inflammatory bowel disease in adults. *Gut* 2011;60:571-607. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/21464096>.



# NCCN Guidelines Version 1.2024

## Colorectal Cancer Screening

261. Hasegawa I, Yamamura T, Suzuki H, et al. Detection of colorectal neoplasms using linked color imaging: A prospective, randomized, tandem colonoscopy trial. *Clin Gastroenterol Hepatol* 2021;19:1708-1716 e1704. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33839277>.

262. Marion JF, Sands BE. The SCENIC consensus statement on surveillance and management of dysplasia in inflammatory bowel disease: praise and words of caution. *Gastroenterology* 2015;148:462-467. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/25702851>.

263. The Paris endoscopic classification of superficial neoplastic lesions: esophagus, stomach, and colon: November 30 to December 1, 2002. *Gastrointest Endosc* 2003;58:S3-43. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/14652541>.

264. Annese V, Daperno M, Rutter MD, et al. European evidence based consensus for endoscopy in inflammatory bowel disease. *J Crohns Colitis* 2013;7:982-1018. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24184171>.

265. Zisman TL, Bronner MP, Rulyak S, et al. Prospective study of the progression of low-grade dysplasia in ulcerative colitis using current cancer surveillance guidelines. *Inflamm Bowel Dis* 2012;18:2240-2246. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/22508402>.

266. Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. *Gut* 2019;68:s1-s106. Available at: <https://pubmed.ncbi.nlm.nih.gov/31562236/>.

267. Magro F, Gionchetti P, Eliakim R, et al. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. *J Crohns Colitis* 2017;11:649-670. Available at: <https://pubmed.ncbi.nlm.nih.gov/28158501/>.

268. Rutter MD, Saunders BP, Wilkinson KH, et al. Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict

cancer risk. *Gut* 2004;53:1813-1816. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/15542520>.

269. Maisonneuve P, FitzSimmons SC, Neglia JP, et al. Cancer risk in nontransplanted and transplanted cystic fibrosis patients: a 10-year study. *J Natl Cancer Inst* 2003;95:381-387. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/12618503>.

270. Maisonneuve P, Marshall BC, Knapp EA, Lowenfels AB. Cancer risk in cystic fibrosis: a 20-year nationwide study from the United States. *J Natl Cancer Inst* 2013;105:122-129. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23178438>.

271. Fink AK, Yanik EL, Marshall BC, et al. Cancer risk among lung transplant recipients with cystic fibrosis. *J Cyst Fibros* 2017;16:91-97. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27539828>.

272. Neglia JP, FitzSimmons SC, Maisonneuve P, et al. The risk of cancer among patients with cystic fibrosis. *Cystic Fibrosis and Cancer Study Group. N Engl J Med* 1995;332:494-499. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/7830730>.

273. Hadjiliadis D, Khoruts A, Zauber AG, et al. Cystic fibrosis colorectal cancer screening consensus recommendations. *Gastroenterology* 2018;154:736-745 e714. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29289528>.

274. Matson AG, Bunting JP, Kaul A, et al. A non-randomised single centre cohort study, comparing standard and modified bowel preparations, in adults with cystic fibrosis requiring colonoscopy. *BMC Gastroenterol* 2019;19:89. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31195989>.

275. Lu KH, Wood ME, Daniels M, et al. American Society of Clinical Oncology Expert Statement: collection and use of a cancer family history for oncology providers. *J Clin Oncol* 2014;32:833-840. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24493721>.

276. Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch



# NCCN Guidelines Version 1.2024

## Colorectal Cancer Screening

syndrome) and microsatellite instability. *J Natl Cancer Inst* 2004;96:261-268. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14970275>.

277. Taylor DP, Burt RW, Williams MS, et al. Population-based family history-specific risks for colorectal cancer: a constellation approach. *Gastroenterology* 2010;138:877-885. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/19932107>.

278. Taylor DP, Stoddard GJ, Burt RW, et al. How well does family history predict who will get colorectal cancer? Implications for cancer screening and counseling. *Genet Med* 2011;13:385-391. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21270638>.

279. Samadder NJ, Curtin K, Tuohy TM, et al. Increased risk of colorectal neoplasia among family members of patients with colorectal cancer: a population-based study in Utah. *Gastroenterology* 2014;147:814-821 e815; quiz e815-816. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25042087>.

280. Tian Y, Kharazmi E, Sundquist K, et al. Familial colorectal cancer risk in half siblings and siblings: nationwide cohort study. *BMJ* 2019;364:l803. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30872356>.

281. Samadder NJ, Pappas L, Boucherr KM, et al. Long-term colorectal cancer incidence after negative colonoscopy in the state of Utah: The effect of family history. *Am J Gastroenterol* 2017;112:1439-1447. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28695908>.

282. Ochs-Balcom HM, Kanth P, Cannon-Albright LA. Early-onset colorectal cancer risk extends to second- and third-degree relatives. *Cancer Epidemiol* 2021;73:101973. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/34198235>.

283. Imperiale TF, Ransohoff DF. Risk for colorectal cancer in persons with a family history of adenomatous polyps: a systematic review. *Ann Intern Med* 2012;156:703-709. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22586009>.

284. Tuohy TM, Rowe KG, Mineau GP, et al. Risk of colorectal cancer and adenomas in the families of patients with adenomas: a population-based study in Utah. *Cancer* 2014;120:35-42. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24150925>.

285. Samadder NJ, Smith KR, Hanson H, et al. Increased risk of colorectal cancer among family members of all ages, regardless of age of index case at diagnosis. *Clin Gastroenterol Hepatol* 2015;13:2305-2311 e2301-2302. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26188136>.

286. Schoen RE, Razzak A, Yu KJ, et al. Incidence and mortality of colorectal cancer in individuals with a family history of colorectal cancer. *Gastroenterology* 2015;149:1438-1445 e1431. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26255045>.

287. Stanich PP, Pearlman R, Hinton A, et al. Prevalence of germline mutations in polyposis and colorectal cancer-associated genes in patients with multiple colorectal polyps. *Clin Gastroenterol Hepatol* 2019;17:2008-2015 e2003. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30557735>.

288. Biller LH, Ukaegbu C, Dhingra TG, et al. A multi-institutional cohort of therapy-associated polyposis in childhood and young adulthood cancer survivors. *Cancer Prev Res (Phila)* 2020;13:291-298. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32051178>.

289. Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent and Young Adult Cancers (ed 5.0). Monrovia, CA: Children's Oncology Group; 2018.